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Abstract 
 
Microglial responses critically underpin pathological processes associated with 
progressive neurodegenerative diseases including Alzheimer’s disease (AD) and 
Parkinson’s disease. Regulated inflammation is essential in the healthy brain for the 
removal of debris and apoptotic cells. However, prolonged inflammation, often 
attributed to dysregulated microglial activation, is neurotoxic and implicated in the 
pathogenesis of multiple neurodegenerative diseases. GWAS have identified mutations 
in the genes for triggering receptor expressed on myeloid cells (TREM2) and 
Complement Receptor 1 (CR1) as putative risk factors for late-onset Alzheimer’s 
disease (LOAD) (Guerreiro et al. 2013a; Jonsson et al. 2013; Lambert et al. 
2013).TREM2 is a major microglia-specific gene and may act as a lock to repress 
microglial pro-inflammatory activity, whilst promoting protective responses such as 
chemotaxis and phagocytosis. CR1 is a member of the regulators of the complement 
activation family and is reported to be expressed on rodent microglia, although there is 
a lack of clear evidence of human microglial expression. CR1 acts to clear opsonised 
immune complexes from the blood as well as acting as a complement activation 
regulator. 
CRISPR/Cas9-generated TREM2 knockdown and knockout mouse microglia cell lines 
have been characterised and utilised for functional experiments in order to further 
appreciate the role of TREM2 in microglia, alongside iPSC-derived microglia-like cells 
(iPSC-MGLC) generated from patients carrying TREM2 mutations linked to AD and 
Nasu Hakola Disease. TREM2 knockout lines have altered actin structures and 
demonstrate defective responses to stimuli compared with WT cells. Both TREM2 
knockout cell lines and human iPSC-MGLC display altered cytokine responses and 
phagocytosis compared to control cells. Human tissues, including AD brain samples 
and blood derived cells, have been used to confirm a lack of CR1 in unstimulated 
human microglia and iPSC-MGLC were utilised to investigate the effect of TREM2 
mutations on the expression of other AD-linked complement factors, including C1q and 
CR3.  
 
 4 
 
Acknowledgements 
 
Firstly I would like to thank my supervisors Dr Jennifer Pocock, Professor John Hardy 
and Professor Simon Lovestone for their guidance during my PhD. Particularly thank 
you to Jenny for giving me the opportunity to undertake my PhD in her lab and for 
supporting and encouraging me up the steep PhD learning curve. I would also like to 
acknowledge Complement UK and Alexion for funding my PhD. 
I would like to thank all those who have been members of the Pocock lab during my 
PhD. In particular Claudio Villegas-Llerena for the BV2s and for being my partner in 
crime throughout the last 4 years, Dr Pablo Garcia Reitbӧck for introducing the iPSCs 
and inspiring me to eat an unhealthy amount of Franco Manca, Dr Katharina Cosker for 
all the advice, the girl power and for training me in the art of being a western blot ninja, 
and Dr Thomas Piers for his keen eye for formatting errors, willingness to discuss new 
results and experiments with me, and for always making the tea. Thank you also to 
Dimitra Schiza for her expert training on confocal microscopy, Professor Ken Smith for 
allowing me to use his group’s confocal, and to Michael Clark for his supervision of my 
immunohistochemistry. I am also grateful to Charlotte Burt for all of her administrative 
help and, more importantly, for supplying the office with a constant supply of biscuits. 
I could not have finished this thesis without my work wife, Dimitra. Thank you for 
always being there during the weekends in the lab, the long boring days of writing up, 
and the horrible early mornings in the gym. Thank you for helping me to overcome the 
many challenges faced both inside and outside of the lab, and for always keeping us 
going with feta, frappes and protein shakes.  
Special love and thanks go to those who kept the benches outside The Harrison warm 
all through the winters I was forced to endure outside: Dimitra, Kim, Alina, Mario, Tom, 
Kat, Mikey and, of course, Jack. I have spent some of the best years of my life and the 
vast majority of my stipend on those benches, and I can’t think of better people to have 
shared it with.  
Away from the lab, I would like to thank my amazing Sutton High girls and the ladies of 
Number 46 for always being there to remind me that there is life beyond the bench and 
my desk. You have all been terrible, but extremely welcome, distractions and I can’t 
wait to have my freedom back to celebrate properly with you all.  
Finally, and most importantly, I want to thank Mum, Dad, Laura and Grandma for all of 
their love, encouragement and advice. Your support for me has been unfaltering 
through all of the highs and lows, but your understanding and reassurance during the 
final stressful few months of experiments and writing up gave me the strength to 
complete this thesis. 
 
 5 
 
Table of Contents 
 
Declaration ............................................................................................................................................ 2 
Abstract .................................................................................................................................................. 3 
Acknowledgements .............................................................................................................................. 4 
Table of Contents ................................................................................................................................. 5 
List of Figures ....................................................................................................................................... 8 
List of Tables ....................................................................................................................................... 10 
Abbreviations ...................................................................................................................................... 11 
1. Introduction ..................................................................................................................................... 13 
1.1 Microglia..................................................................................................................... 13 
1.1.1 Microglial Ontogeny ............................................................................................... 13 
1.1.2 Microglia in Surveillance........................................................................................ 15 
1.1.3 Microglia in Homeostasis ...................................................................................... 16 
1.1.4 Microglia in Neurogenesis ..................................................................................... 18 
1.1.5 Microglia in Synaptic Connectivity ....................................................................... 20 
1.1.6 Microglial Activation ............................................................................................... 21 
1.1.7 Microglia and Neurodegenerative Disease ........................................................ 22 
1.2 Models of Microglia ....................................................................................................... 23 
1.2.1 Primary Microglia .................................................................................................... 24 
1.2.2 Immortalised Microglial Cell Lines ....................................................................... 25 
1.2.3 Induced pluripotent stem cell (iPSC) models ..................................................... 26 
1.2.4 CRISPR-Cas9 Genome Editing of Microglia ...................................................... 30 
1.3 Alzheimer’s Disease ...................................................................................................... 32 
1.3.1 The Role of Microglia in Alzheimer’s disease .................................................... 34 
1.4 TREM2 ............................................................................................................................ 36 
1.4.1 TREM2 in Alzheimer’s Disease ............................................................................ 43 
1.5 The Complement System ............................................................................................. 45 
1.5.1 Complement in the Brain ....................................................................................... 47 
1.5.2 Complement in Alzheimer’s Disease .................................................................. 50 
1.5.3 CR1........................................................................................................................... 52 
1.5.4 CR1 in Alzheimer’s Disease ................................................................................. 54 
1.5.5 C1q ........................................................................................................................... 56 
 
 6 
 
1.5.6 Complement Receptor 3 ....................................................................................... 57 
1.6 Aims ................................................................................................................................. 60 
2. Materials and Methods .................................................................................................................. 61 
2.1 Materials .......................................................................................................................... 61 
2.2 BV2 Cell Culture & Maintenance ................................................................................. 62 
2.3 Primary Cell Culture ...................................................................................................... 63 
2.3.1 Human Neutrophil Isolation .................................................................................. 63 
2.3.2 Human Blood-derived Monocyte Isolation .......................................................... 63 
2.3.3 Human Monocyte-Derived Macrophages ........................................................... 64 
2.4 Generation of human induced Pluripotent Stem Cell-derived Microglia-like Cells 
(iPSC-MGLC) ........................................................................................................................ 64 
2.5 CRISPR/Cas9 Mediated Generation of TREM2 Knockdown and TREM2 
Knockout BV2 Cell Lines ..................................................................................................... 67 
2.6 Cell Treatments .............................................................................................................. 68 
2.7 Microscopy ...................................................................................................................... 68 
2.7.1 Immunocytochemistry ............................................................................................ 68 
2.7.2 Phalloidin labelling of F-actin ................................................................................ 70 
2.7.3 Immunohistochemistry ........................................................................................... 71 
2.8 Western Blotting ............................................................................................................. 71 
2.9 Enzyme-linked Immunosorbent Assay (ELISA) ........................................................ 73 
2.9.1 ELISA analysis of soluble TREM2 in mouse BV2 cell cultures ....................... 74 
2.9.2 ELISA analysis of soluble TREM2 in human iPSC-MGLC cultures ............... 74 
2.9.3 Mouse TNFα Cytokine Quantification ................................................................. 75 
2.9.4 Human TNFα & IL-6 Cytokine Quantification ..................................................... 75 
2.9.5 Human C1q ELISA ................................................................................................. 75 
2.9.6 Mouse Cytokine Array ........................................................................................... 76 
2.10 Quantitative Polymerase Chain Reaction (qPCR) for evaluation of mRNA 
expression levels .................................................................................................................. 76 
2.11 Analysis of phagocytic activity by flow cytometry ................................................... 78 
2.12 Statistical Analysis ....................................................................................................... 78 
3. Characterisation of CRISPR/Cas9 TREM2 gene editing in mouse BV2 microglial cell 
line ........................................................................................................................................................ 79 
3.1 The generation of TREM2 knockdown and knockout cell lines .............................. 79 
3.2 TREM2 knockdown alters LPS-induced TNFα gene transcription......................... 84 
 
 7 
 
3.3 TREM2 knockdown and knockout microglia have altered actin cytoskeletal 
structures ............................................................................................................................... 88 
3.4 TREM2 knockdown affects the ability of microglia to alter morphology in 
response to stimuli ............................................................................................................... 91 
3.5 TREM2 knockdown and knockout affects the expression of Iba1 ......................... 96 
3.6 Pre-treatment with sTREM2 does not rescue the morphological defects in the 
MCSF response found in TREM2 knockout cells ............................................................ 98 
3.7 TREM2 knockout cells are less able to phagocytose E.coli particles ................... 99 
3.8 The effect of TREM2 knockdown and knockout expression of chemokines ...... 100 
3.9 Discussion..................................................................................................................... 103 
4. TREM2 mutations in human iPSC-derived microglia-like cells ............................................. 112 
4.1 The generation of human iPSC-derived microglia-like cells ................................. 113 
4.2 iPSC-MGLC express microglial genes including TREM2 ..................................... 116 
4.3 The generation of iPSC-MGLC harbouring TREM2 mutations ............................ 118 
4.4 iPSC-MGLC harbouring mutations in TREM2 still express microglial markers . 120 
4.5 Reduced TREM2 expression in TREM2 mutant iPSC-MGLC .............................. 122 
4.6 The expression of TREM2 T66M homozygous mutations affects phagocytosis by 
iPSC-MGLC......................................................................................................................... 128 
4.7 Homozygous TREM2 mutant iPSC-MGLC secrete more TNFα in response to 
LPS than controls ............................................................................................................... 130 
4.8 iPSC-MGLC express other dementia-associated microglial genes ..................... 132 
4.9 The expression of TREM2 T66M and W50C mutations affect/do not affect the 
expression of dementia-associated microglial genes ................................................... 133 
4.10 Discussion .................................................................................................................. 135 
5. CR1 and Complement in Human Microglia ............................................................................. 149 
5.1 CR1 mRNA is undetectable in control human temporal lobe ............................... 150 
5.2 RNA expression databases indicate that CR1 expression is undetectable in 
human brain ........................................................................................................................ 151 
5.3 Protein expression database suggests that CR1 protein is not detectable in 
human brain ........................................................................................................................ 152 
5.4 CR1 mRNA is almost undetectable in microglia and iPSC-derived microglia-like 
cells ...................................................................................................................................... 153 
5.5 RNA expression database concurs with very low levels of CR1 mRNA in 
microglia .............................................................................................................................. 154 
5.6 CR1 mRNA expression is upregulated in pre-AD temporal lobe ......................... 155 
5.7 Preliminary immunohistochemical analysis of CR1 expression indicates 
upregulation with AD progression .................................................................................... 158 
 
 8 
 
5.8 Microglia and iPSC-MGLC express other complement factors linked to 
Alzheimer’s disease ........................................................................................................... 161 
5.9 Mutations in TREM2 alter the mRNA expression levels of AD-linked complement 
factors .................................................................................................................................. 163 
5.10 TREM2 R47H mutations affect the secretion of C1q by iPSC-MGLC .............. 165 
6. Conclusions .................................................................................................................................. 179 
7. References .................................................................................................................................... 182 
 
List of Figures 
 
Figure 1.1 Summary of proposed TREM2 ligands, signalling and function .................. 38 
Figure 1.2: Diagram showing the convergence of the three pathways of complement 
activation .................................................................................................................... 46 
Figure 1.3: Schematic of CR1 A and B allele structures .............................................. 53 
Figure 3.1 CRISPR/Cas9 nickase modification of the Trem2 gene in BV2 cells .......... 80 
Figure 3.2 Characterisation of TREM2 knockdown and knockout clones generated 
using CRISPR/Cas9 modification ............................................................................... 81 
Figure 3.3 Characterisation of TREM2 cellular localisation by immunocytochemistry in 
WT, knockdown and knockout BV2 clones ................................................................. 83 
Figure 3.4 Quantification of soluble TREM2 release from WT, TREM2 knockdown and 
TREM2 knockout BV2 cells by ELISA ......................................................................... 84 
Figure 3.5 Expression of Tnf mRNA by WT, TREM2 knockdown and TREM2 knockout 
cells following 2hr and 6hr of LPS treatment ............................................................... 85 
Figure 3.6 ELISA quantification of TNFα secretion by WT, TREM2 knockdown and 
TREM2 knockout BV2 cells ........................................................................................ 86 
Figure 3.7 Expression of Tnf mRNA in untreated WT, TREM2 knockdown and TREM2 
knockout cells ............................................................................................................. 86 
Figure 3.8 ELISA analysis of LPS-induced TNFα secretion after depletion of existing 
stores .......................................................................................................................... 88 
Figure 3.9 The effect of TREM2 knockdown and knockout on the morphology of BV2 
cells ............................................................................................................................ 89 
Figure 3.10 The effect of TREM2 knockdown and knockout on filopodia formation by 
BV2 cells .................................................................................................................... 91 
Figure 3.11 Expression of Actb mRNA in WT, TREM2 knockdown and TREM2 
knockout BV2 cells ..................................................................................................... 91 
 
 9 
 
Figure 3.12 The effect of TREM2 knockdown and knockout on cytoskeletal 
reorganisation in response to LPS treatment in BV2 cells ........................................... 93 
Figure 3.13 Definition of membrane ruffles in BV2 microglial cells .............................. 94 
Figure 3.14 The effect of TREM2 knockdown and knockout on membrane ruffling by 
BV2 cells in response to ATP or MCSF treatment ....................................................... 96 
Figure 3.15 The effect of TREM2 knockdown and knockout on the expression of Iba1 in 
BV2 cells .................................................................................................................... 97 
Figure 3.16 Pretreatment with soluble TREM2 does not restore deficits in 
morphological responses to MCSF ............................................................................. 98 
Figure 3.17 The effect of TREM2 knockdown and knockout on the phagocytosis of 
E.coli particles by BV2 cells ........................................................................................ 99 
Figure 3.18 Membrane-based proteome array of cytokines and chemokines secreted 
by  untreated and LPS-stimulated BV2 cell lines ....................................................... 101 
Figure 3.19 Heatmap analysis of cytokines and chemokines secreted by BV2 cells . 102 
Figure 4.1 The generation and characterisation of iPSC-MGLC ................................ 116 
Figure 4.2 Expression of microglial markers by monocytes, macrophages and iPSC-
MGLC ....................................................................................................................... 117 
Figure 4.3 Expression of TREM2 mRNA in iPSC-MGLC ........................................... 118 
Figure 4.4 Expression of microglial markers in iPSC-MGLC harbouring TREM2 
mutations .................................................................................................................. 121 
Figure 4.5 The expression of TREM2 and its signalling partner TYROBP in control and 
TREM2 mutant iPSC-MGLC ..................................................................................... 122 
Figure 4.6 Expression of TREM2 protein in control and TREM2 mutant iPSC-MGLC 124 
Figure 4.7 Soluble TREM2 release from control and TREM2 mutant iPSC-MGLC .... 125 
Figure 4.8 Immunocytochemical analysis of TREM2 expression ............................... 127 
Figure 4.9 The effect of TREM2 mutations on the phagocytosis of pHrodo fluorescent 
E.coli particles by iPSC-MGLC ................................................................................. 129 
Figure 4.10 Expression of MERTK and AXL in iPSC-MGLC ..................................... 130 
Figure 4.11 ELISA quantification of TNFα secretion by iPSC-MGLC ........................ 131 
Figure 4.12 ELISA quantification of IL-6 secretion by iPSC-MGLC ........................... 131 
Figure 4.13 Expression of neurodegenerative disease risk factors in iPSC-MGLC ... 133 
Figure 4.14 Expression of neurodegenerative disease risk factors in TREM2 mutant 
iPSC-MGLC .............................................................................................................. 134 
Figure 4.15 Summary of findings in T66M homozygous iPSC-MGLC and potential 
effects on pathogenesis ............................................................................................ 144 
Figure 5.1 mRNA expression of CR1 and microglial makers in control human temporal 
lobe........................................................................................................................... 150 
 
 10 
 
Figure 5.2 Expression of CR1 in human brain according to RNA-seq databases ...... 152 
Figure 5.3 Expression of CR1 in human brain according to Protein Atlas expression 
database ................................................................................................................... 153 
Figure 5.4 Expression of CR1 mRNA in CNS and immune cells ............................... 154 
Figure 5.5 Expression of CR1 in CNS cells according to Barres Brain RNA seq 
database ................................................................................................................... 155 
Figure 5.6 Expression of CR1 and P2YR12 in temporal and occipital lobes of control 
and pre-AD cases ..................................................................................................... 157 
Figure 5.7 Testing of CR1 antibody in human kidney tissue ...................................... 158 
Figure 5.8 Expression of CR1 in control, pre-AD and AD temporal lobes .................. 160 
Figure 5.9 Varied morphology of CR1-positive staining ............................................ 161 
Figure 5.10 Expression of AD-linked complement factors by iPSC-MGLC and microglia
 ................................................................................................................................. 162 
Figure 5.11 TREM2 mutations alter complement factor expression in iPSC-MGLC .. 164 
Figure 5.12 ELISA analysis of C1q secretion by control and R47H TREM2 iPSC-MGLC
 ................................................................................................................................. 165 
Figure 5.13 Analysis of C1q mRNA expression and secretion by control, Bion control 
and Bion R47H iPSC-MGLC ..................................................................................... 166 
 
List of Tables 
 
Table 1.1 Frequencies and molecular weights of CR1 allotypes ................................. 54 
Table 2.1 Table of iPSC lines used ............................................................................. 66 
Table 2.2 Cell culture treatments ................................................................................ 68 
Table.2.3 Antibodies used for immunocytochemistry .................................................. 69 
Table 2.4 Antibodies used for western blotting ............................................................ 73 
Table 2.5 Primer IDs for TaqMan qPCR probes (Thermo Fisher Scientific) ................ 78 
Table 4.1 Characteristics of TREM2 mutant and control iPSC lines used in this study
 ................................................................................................................................. 119 
Table 5.1 Pathological details of human control, pre-AD and AD samples ................ 156 
 
  
 
 11 
 
Abbreviations 
 
A: Aβ (amyloid-β), AD (Alzheimer’s disease), ALS (amyotrophic lateral sclerosis), 
ApoE (apolipoprotein E), ANOVA (analysis of variance), APP (amyloid precursor 
protein), ATP (adenosine triphosphate) 
B: BBB (blood brain barrier), BMP-4 (bone morphogenetic factor 4), BDNF (brain-
derived neurotrophic factor), bp (base pair), BSA (bovine serum albumin) 
C: C5a (complement component 5a), Cas9 (CRISPR-associated protein 9), CNV (copy 
number variation), CNS (central nervous system), CR1 (complement receptor 1), CR3 
(complement receptor 3), CREG (regulators of complement), CRISPR (clustered 
regularly interspaced short palindromic repeats), Crry (complement receptor 1-related 
gene/protein Y), CSF (cerebrospinal fluid), Ct (cycle threshold), CTF (C-terminal 
fragment), CytoD (cytochalasinD) 
D: DAB (3,3'-diaminobenzidine), DAMP (damage-associated molecular pattern), 
DAP12 (DNAX-activating protein of 12kDa), DAPI (4',6-diamidino-2-phenylindole), 
ddH2O (double-distilled water), DNA (deoxyribose nucleic acid) 
E: EAE (experimental autoimmune encephalitis), EB (embryoid body), EDTA 
(ethylenediaminetetraacetic acid), ELISA (enzyme-linked immunosorbent assay), 
EOAD (early onset Alzheimer’s disease), ER (endoplasmic reticulum), ESC (embryonic 
stem cell) 
F: FBS (foetal bovine serum), FGF (fibroblast growth factor), FTD (fronto-temporal 
dementia) 
G: GFP (green fluorescent protein), GWAS (genome-wide association study) 
H: HBSS (Hanks’ balanced saline solution), HRP (horseradish peroxidase) 
I: Iba1 (ionized calcium binding adaptor molecule 1), IGF-1 (insulin-like growth factor 
1), IFNγ (interferon-γ), IL-1β (interleukin-1β), IL-3 (interleukin-3), IL-6 (interleukin-6), IL-
10 (interleukin-10), IL-12 (interleukin-12), IL-34 (interleukin-34), iPSC (induced 
pluripotent stem cell), iPSC-MGLC (induced pluripotent stem cell-derived microglia-like 
cell), iNOS (inducible nitric oxide synthase), ITAM (immunoreceptor tyrosine-based 
activation motif) 
K: KD (knockdown), KO (knockout) 
 
 12 
 
L: LHR (long homologous repeat), LOAD (late onset Alzheimer’s disease), LPS 
(lipopolysaccharide), LTP (long term potentiation) 
M: MAC (membrane attack complex), MCSF (macrophage colony-stimulating factor), 
MGCM (microglia conditioned medium), MHC (major histocompatibility complex), MS 
(multiple sclerosis) 
N: NGF (nerve growth factor), NHD (Nasu Hakola Disease), NO (nitric oxide) 
O: OR (odds ratio) 
P: PAMP (pathogen-associated molecular pattern), PBMC (peripheral blood 
mononuclear cell), PBS (phosphate-buffered saline), PBS-T (1x PBS/0.1% Tween-20 ), 
(PCR (polymerase chain reaction), PD (Parkinson’s disease), PFA (paraformaldehyde), 
PLOSL (polycystic lipomembranous osteodysplasia with sclerosing 
leukoencephalopathy), PNGase (peptide:N-gycosidase), PRR (pattern recognition 
receptor), PS (phosphatidylserine), PSEN1 & 2 (presenilin 1 & 2) 
Q: qPCR (quantitative polymerase chain reaction) 
R: RNA (ribonucleic acid), ROS (reactive oxygen species), RPKM (reads per kilobase 
per million mapped reads), RPMI (Roswell Park Memorial Institute medium 1640), RT-
PCR (reverse transcription polymerase chain reaction) 
S: SCF (stem cell factor), SCR (short consensus repeats), SDS-PAGE (sodium 
dodecyl polyacrylamide gel electrophoresis), SEM (standard error of the mean), SNP 
(small nuclear polymorphism), sTREM2 (soluble TREM2) 
T: T66Mhet (iPSC-derived microglia-like cell line carrying heterozygous T66M mutation 
in TREM2 gene), T66Mhom (iPSC-derived microglia-like cell line carrying homozygous 
T66M mutation in TREM2 gene), TALENs (transcription activator-like effector 
nucleases), TLR (toll-like receptor), TMB (3,3',5,5'-tetramethylbenzidine), TNFα 
(tumour necrosis factor α), TPM (transcripts per million), TREM2 (triggering receptor 
expressed in myeloid cells-2), TYROBP (tyrosine kinase binding protein) 
U: UCL (University College London) 
V: VEGF (vascular endothelial growth factor) 
W: W50Chom (iPSC-derived microglia-like cell line carrying homozygous W50C 
mutation in TREM2 gene), WT (wildtype) 
Z: ZFN (zinc finger nucleases) 
 
 13 
 
1. Introduction 
 
1.1 Microglia 
 
The mammalian central nervous system (CNS) is comprised of the brain and the spinal 
cord, and, in humans, is populated by an estimated 86 billion neurons and a further 84 
billion non-neuronal glial cells (Azevedo et al., 2009). Despite the overall 1:1 ratio in the 
brain of glia to neurons, the ratio varies across brain regions, with glia outnumbering 
neurons by as much as 17:1 in the thalamus (Pakkenberg and Gundersen, 1997). 
There are three main cell types defined as glia: astrocytes, oligodendrocytes and 
microglia. Glia were traditionally viewed as merely neuronal support cells, hence the 
derivation of the name from the Greek word for ‘glue’. However this opinion has 
gradually been found to be outdated, as key functions performed by glia during CNS 
development, homeostasis and disease continue to be identified (reviewed by Barres 
et al. 2008; Reemst et al. 2016; Colonna & Butovsky 2017). The importance of 
understanding the interactions between neurons and glia is becoming increasingly 
relevant for both the study of the human brain and also for understanding and treating 
neurodegenerative diseases. 
Microglia are the resident phagocytes of the CNS and make up approximately 15% of 
the glial cells in the adult CNS, where their primary functions are to provide an innate 
immune response and to ensure clearance of debris resulting from cell death, infection 
or insult. They are found in all regions of the brain, at densities in the adult mouse brain 
ranging from 5% in the corpus callosum to 12% in the substantia nigra (Lawson et al., 
1990). The first description of microglia was made by Franz Nissl in 1899, who 
described ‘Stabchenzellen’, or rod cells, with migratory, phagocytic and proliferative 
potential. The term ‘microglial cell’ was introduced in 1939 by Del Rio-Hortega to 
distinguish microglia from oligodendrocytes within the non-neuronal, non-astrocytic 
group of cells found in the CNS.  
1.1.1 Microglial Ontogeny 
 
For decades microglia were believed to share a neuro-ectodermal origin with other glial 
cells, however it has now been established that they originate from yolk sac-derived 
primitive macrophages (reviewed by Ginhoux et al. 2013) that share the same myeloid-
origins as blood monocytes and monocyte-derived macrophages but differ in their 
dependence on the transcription factor Myb. The myeloid origin of microglia was 
demonstrated in a mouse model with disrupted expression of the gene encoding for 
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PU.1, an essential transcription factor for myeloid cells including macrophages, in 
which microglia failed to develop in the CNS (McKercher et al., 1996). Similarly, 
disruptions in the formation of other cells, including macrophages, neutrophils and 
monocytes were reported in this model confirming their common myeloid origin. 
Yolk sac blood island derived-primitive macrophages, which eventually differentiate into 
microglia, populate the mouse neuroepithelium from embryonic day 9.5 (Ginhoux et al., 
2010). As the yolk sac is the only source of haematopoiesis at this stage of 
development (Alliot, Godin and Pessac, 1999), with fetal liver haematopoiesis not 
occurring until after the initiation of  blood brain barrier closure from E13.5 (Daneman, 
2012), the microglial progenitors present in the CNS must therefore be yolk sac-
derived. A clear distinction between the yolk sac-derived primitive macrophages and 
the haematopoietic stem cell-derived monocytes and macrophages can be made 
based upon their dependence on Myb. Schulz et al demonstrated using Myb-/- mice that 
tissue resident macrophages with yolk sac origins, such as CNS microglia, liver Kupffer 
cells and epidermal Langerhans cells, do not require the Myb transcription factor for 
development, unlike monocytes and monocyte-derived cells (Schulz et al., 2012). 
The brain resident population of microglia that are present since embryonic 
development proliferate slowly but at a rate that is sufficient to maintain microglial 
numbers throughout adulthood, at least during homeostasis. However, monocytes 
have been shown to be recruited to the adult brain under certain conditions, including 
inflammation (Priller et al., 2001), although whether these cells differentiate into fully 
functional microglia is not yet known. During CNS inflammation and 
neurodegeneration, reactive microgliosis occurs resulting in microglial population 
increases although definitive evidence of the origin of these microglia are lacking; are 
numbers increased by proliferation of existing brain resident microglia or are 
monocytes recruited from the periphery? In models deficient in embryonic microglia, 
bone marrow-derived myeloid cells are capable of populating the CNS and adopting 
the morphology and activity of microglia following bone marrow transplantation (Beers 
et al., 2006). Furthermore, ablation of microglia by irradiation resulted in recruitment of 
bone marrow-derived monocytes to the CNS (Mildner et al., 2007), likely due to 
inflammation induced by the irradiation procedure. Long term study of microglial 
population maintenance through the use of parabiosis studies in mice have shown that 
bone marrow derived cells from control mice were not identified in the CNS of 
irradiated mice (Ginhoux et al., 2010), demonstrating that local self-renewal  is 
sufficient for maintaining the microglial population, even following denervation and 
amytotrophic lateral sclerosis (ALS) models of neurodegeneration (Ajami et al., 2007). 
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It is has been demonstrated that monocytes are recruited to the CNS during 
inflammatory disease and, although they do not persist and differentiate into microglia, 
can contribute to pathogenesis (Ajami et al., 2011). Therefore, in  the healthy brain, 
existing microglia self-renew in order to maintain the necessary cell population 
numbers but peripheral monocytes are occasionally found in the parenchyma, 
particularly following priming due to inflammation or injury where they can alter disease 
severity despite their transient presence.  
1.1.2 Microglia in Surveillance 
 
Microglia play a role in a wide range of biological functions in both the developing and 
the adult brain, responding to a multitude of stimuli in physiological and pathological 
conditions. They are responsible for mounting immunological responses in the immune 
privileged CNS and the ability of these cells to release a vast array of cytokines, 
chemokines and growth factors allows microglia to orchestrate the responses of both 
CNS resident cells and infiltrating immune cells. Microglia also regulate neuron number 
and synapse strength to ensure proper signalling in the neuronal network of the adult 
brain. This assortment of functions means that any dysregulation of microglial activity 
could have widespread effects throughout the CNS. 
In vivo analysis of so called ‘resting’ microglia in the adult brain demonstrated that 
these cells display surprisingly high levels of motility, even in physiological conditions 
(Nimmerjahn, Kirchhoff and Helmchen, 2005). Microglia exist in non-overlapping 
domains which they constantly monitor through random outgrowth and retraction of 
their ramified processes (Davalos et al., 2005; Nimmerjahn, Kirchhoff and Helmchen, 
2005), ensuring continuous surveillance of their environment. The CNS has an immune 
privileged existence due to the lack of lymphatic system, absence of adaptive immune 
responses and protection from free diffusion of molecular and cellular components 
thanks to the blood brain barrier (Ousman and Kubes, 2012). Therefore microglia act 
as sentinels to monitor and protect the CNS from any potential mediators of infection or 
insult, ensuring that any pathogens or tissue damage are rapidly identified and 
resolved.  
Microglia express a wide range of pattern-recognition receptors (PRRs) for the 
detection of pathogen- or damage-associated molecular patterns (PAMPs and DAMPs) 
including the toll like receptors 4 and 1/2 (TLR4 and TLR1/2) and their co-receptors 
CD14, CD36 and CD47 (Lehnardt, 2010). Detection of microbes and pathogen 
associated signals through TLRs results in a phagocytic response associated with 
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release of pro-inflammatory mediators, including TNFα and nitric oxide (NO), to 
encourage further pathogen removal. However, this response can have off target 
neurotoxic effects if inflammatory conditions are prolonged. In addition to this innate 
immune response, activated microglia are capable of upregulating the necessary 
machinery for inducing an adaptive immune responses through antigen presentation 
including MHC I and II (Mack et al., 2003; Malone et al., 2008). 
1.1.3 Microglia in Homeostasis 
 
Microglial phagocytosis is essential for maintaining homeostasis in the developing and 
adult brain as it is required for tackling infections, the removal of surplus neurons 
during development and the clearance of protein aggregates and apoptotic cells 
induced by neurodegeneration or aging (Tremblay et al., 2011). Phagocytosis is the 
process by which phagocytes recognise, bind and engulf a range of solid particulates 
including cellular debris, pathogens and apoptotic cells, into membrane protrusions 
called phagosomes, which fuse with acidic lysomes for degradation. The word derives 
from the Greek words ‘phagein’ (to devour), ‘kytos’ (cell) and ‘-osis’ (process). 
The uptake of dead and apoptotic cells prior to complete cellular disintegration is 
important to minimise inflammation, as they are a source of self-antigens and 
intracellular contents that may be toxic to surrounding cells (Neumann, Kotter and 
Franklin, 2009). Furthermore, clearance of apoptotic cells has been shown to 
downregulate microglial expression of pro-inflammatory cytokines (Magnus et al., 
2001), which are excitotoxic to neurons (Pickering, Cumiskey and O’Connor, 2005). It 
is hypothesised that microglia utilise ‘eat me’ signals found on the surface of apoptotic 
cells to direct their selection of cells for clearance. Similarly, ‘don’t eat me’ signals are 
recognised on healthy, ‘self’ cells to ensure that inappropriate phagocytosis does not 
occur.  
Examples of ‘eat me’ signals include calreticulin, a lack of sialylation on cell surface 
and phosphatidylserine (PS). PS is usually expressed on the inner layer of the cell 
membrane, however, during apoptosis or cell stress this is flipped out and is either 
recognised directly by multiple microglial receptors or is tagged for clearance by 
opsonins (Tyurina et al., 2007; Segawa et al., 2014). These PS recognising receptors 
include milk fat globule epidermal growth factor 8 (MFG-E8) (Hanayama et al., 2002), 
BAI1, TIM4 (Mazaheri et al., 2014), scavenger receptors CD36 and SR1 (Areschoug 
and Gordon, 2009), and the TAM receptor tyrosine kinases (Tyro3, Axl and Mertk) 
which recognise PS via the opsonins growth arrest-specific 6 (GAS6) and protein-S 
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(Lemke, 2013). Similarly, cell stress induces the cell surface exposure of calreticulin 
(Panaretakis et al., 2009), typically found within the endoplasmic reticulum (ER), which 
upon recognition by low density lipoprotein receptor related protein (LRP), induces 
phagocytosis of the cell by microglia (Gardai et al., 2005). Thus, microglia are capable 
of efficiently identifying and clearing dying cells before significant degradation occurs 
that they might cause an inflammatory insult. 
In addition to cell-cell communications initiating phagocytosis of apoptotic cells, 
microglia are also recruited to areas of injury and neuronal death by long distance 
soluble factors acting as ‘find me’ signals such as the nucleotides ATP and UDP, 
chemokines and fractalkine. Microglia express purinergic receptors allowing them to 
detect ATP released from intracellular stores of lysed, necrotic cells or from apoptotic 
cells, in which ATP is generated in a caspase-dependent manner (Elliott et al., 2009). 
ATP has been shown to induce rapid migration of microglial processes towards sites of 
damage in a model of traumatic brain injury (Davalos et al., 2005). Expression of the 
receptor for the chemokine CXCL10, another ‘find me’ signal, is essential for microglial 
migration to the site of injury and for microglial clearance of denervated dendrites in a 
model of brain lesions (Rappert et al., 2004).  
Fractalkine exists either tethered to neuronal membranes, where it is thought to play a 
role in adhesion, or as a soluble factor released by ADAM17 cleavage (Garton et al., 
2001), which acts as a microglial chemokine (Sokolowski et al., 2014). In the CNS, 
fractalkine is primarily expressed by neurons and microglia are the only CNS cell type 
to express the fractalkine receptor, CX3CR1. Knockout of CX3CR1 results in reduced 
microglial process motility and impaired migration to sites of neuronal injury (Liang et 
al., 2009). In addition to acting as a long distance chemokine for the recruitment of 
microglia, fractalkine has also been reported to downregulate microglial activation 
(Cardona et al., 2015; Ślusarczyk et al., 2016).  
Phagocytic clearance by microglia following injury may be fundamental for 
reorganisation of neural circuits and triggering repair. Declines in this clearance, which 
are often associated with aging, or insufficient clearance during disease may prevent 
the formation of adequate repair responses (Neumann, Kotter and Franklin, 2009). The 
presence of uncleared myelin may actively block regrowth following injury as it 
prevents the differentiation of oligodendrocyte precursors (Kotter et al., 2005). 
Furthermore myelin contains molecules such as Nogo A which inhibit axonal 
regeneration (Schwab, 2004). Therefore the phagocytic activity of microglia is essential 
for myelin regeneration and repair following periods of demyelination. In models of 
demyelination, IL-1β and TNFα have also been shown to be necessary for the initiation 
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of efficient remyelination responses (Arnett et al., 2001; Mason et al., 2001), indicating 
that these microglial-secreted factors that typically associated with pro-inflammatory, 
damaging responses are necessary in certain contexts for protective and regenerative 
effects.  
Glutamate is the primary excitatory neurotransmitter and dysregulation of extracellular 
levels of glutamate can cause neuronal excitotoxicity, due to excessive cation influxes  
causing osmotic and mitochondrial stress (Barger et al., 2007). Although astrocytes 
take up the majority of excess glutamate, this function is also performed by microglia 
(Nakajima et al., 2001). Microglia both express glutamatergic receptors (Pocock and 
Kettenmann, 2007), allowing them to detect and respond to this neurotransmitter, as 
well as act as a source of glutamate generation, particularly following activation (Barger 
et al., 2007). Neuronal NMDA receptor activation has been shown to result in ATP 
release, which is detected by microglial purinergic receptors, inducing microglial 
process outgrowth (Dissing-Olesen et al., 2014) and TNFα release (Masuch et al., 
2016). Interestingly, microglial release of TNFα, a well-known pro-inflammatory 
cytokine, has been found to play both protective and detrimental roles in the response 
to disproportionate neurotransmitter release. TNFα can augment glutamate-induced 
excitotoxicity by activating microglia in an autocrine manner, which upregulates 
glutaminase activity (Takeuchi et al., 2006). Conversely, TNFα release has also been 
shown to protect neurons against AMPA and NMDA-induced excitotoxicity (Bernardino 
et al., 2005; Masuch et al., 2016). The ability of microglia to detect both excessive 
neurotransmitter and ATP release, which is often associated with the presence of 
apoptotic neurons, allows them to generate neuroprotective responses to maintain 
homeostasis and ensure proper neuronal network signalling. 
1.1.4 Microglia in Neurogenesis 
 
In addition to their role immune surveillance and clearing any stimuli that could initiate 
inflammation, microglia play an important role in neurogenesis. Microglia exert both 
positive and negative regulatory effects on neurogenesis and neuronal cell numbers 
during CNS development. Microglia secrete growth and trophic factors that encourage 
neural precursor survival and differentiation, as well as concurrently contributing to the 
programmed cell death and pruning of supernumerary neurons and synapses. 
Migration to the brain by the primitive macrophages that become the resident microglial 
population occurs early on in CNS development, at approximately embryonic day  9.5 
(Ginhoux et al. 2010, see 1.1.1 Microglial Ontogeny).  
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It is well documented that neurons are produced in excess in the developing brain and 
up to half of cells in certain regions are removed during the process of network 
remodelling during pre and postnatal development (Oppenheim, 1991; de la Rosa and 
de Pablo, 2000). This process of network refinement during development results in the 
generation of large amounts of apoptotic cells, which if not cleared appropriately, as 
discussed previously, can damage surrounding cells (Neumann, Kotter and Franklin, 
2009).  As the resident phagocytes of the brain, microglia play a key role in the 
clearance of these neurons that fail to become established in networks, but more 
recently have also been identified as active contributors to the elimination of neuronal 
numbers.  
Several mechanisms have been hypothesised to be involved in microglial elimination of 
excessive neurons including initiation of apoptosis via superoxide ion generation and 
subsequent phagocytosis of viable cells, known as primary phagocytosis or 
phagoptosis (Brown and Neher, 2014) and the targeting of neural precursors to limit 
further neuron generation (Cunningham, Martínez-Cerdeño and Noctor, 2013). In the 
cerebral cortex of pre- and post-natal rats and monkeys, microglia have been shown to 
phagocytose neural precursor cells in order to control the formation of cortical neurons 
(Cunningham, Martínez-Cerdeño and Noctor, 2013). This regulation of neural 
precursor cell number was found to be dependent upon microglial activation state as 
maternal immune activation in utero resulted in augmented removal of these viable 
neural precursor cells.   
Microglia selectively remove Purkinje cells in the cerebellum (Marín-Teva et al., 2004) 
and neurons in the hippocampus (Wakselman et al., 2008) through the generation of 
reactive oxygen species. Reactive oxygen species, such as superoxide anions, induce 
the exposure of PS on viable neurons, providing the ‘eat me’ signal for clearance by 
microglia (Neher et al., 2011). Ablation of microglia or knockout of the CR3 receptor 
responsible for phagocytosis of the targeted neurons resulted in increases in surviving 
neurons (Marín-Teva et al., 2004; Wakselman et al., 2008), demonstrating that 
microglial phagocytosis contributes to removal of neurons during development through 
apoptosis and cell death. 
Microglia continue to alter neurogenesis in the adult brain. The subgranular zone of the 
hippocampus continues to give rise to neuroblasts throughout adulthood, however very 
few of these cells are maintained and integrated into the neuronal circuitry. Excess 
newborn cells that are undergoing apoptosis have been shown to be cleared by rapid 
and highly efficient microglial phagocytosis, with 90% of apoptotic cells engulfed within 
1.5 hours (Sierra et al., 2010).  
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Conversely, fractalkine signalling has been shown to be important for microglial 
neurotrophic support during postnatal neuronal network refinement. In CX3CR1-/- mice, 
increased levels of apoptosis were identified in the layer V cortical neurons (Ueno et 
al., 2013) in addition to cognitive function deficits and LTP impairment (Rogers et al., 
2011). It was demonstrated that the increase in apoptosis identified in CX3CR1-/- mice 
was due to an increase in the expression of inhibitors of the trophic factor insulin-like 
growth factor 1 (IGF-1). Furthermore, both inhibition of microglial activation and 
selective ablation of microglia, resulted in significant increases in layer V neuron cell 
death (Ueno et al., 2013), demonstrating the importance of the trophic factors released 
by activated microglia for neuronal survival during early postnatal development.  
1.1.5 Microglia in Synaptic Connectivity 
 
In addition to their role in regulating neuronal cell number, microglia play a role in 
monitoring synapses and altering synaptic density and connectivity. In the adult brain, 
microglia have been observed to have frequent, brief interactions with synapses, 
occurring approximately once per hour and lasting 5 minutes (Wake et al., 2009). 
Therefore, as the synaptic interactions were found to be activity dependent, this could 
be a mechanism through which microglia contribute to synaptic plasticity. In the 
CX3CR1-/- model, which is associated with reduced microglial density, increased 
dendritic spines and immature synapses were found in the developing hippocampus 
(Paolicelli et al., 2011), indicating that microglial synapse surveillance and 
phagocytosis contributes to regulation of synapse and dendritic spine numbers.  
It has been observed that microglia are capable of sensing synaptic activity and 
detecting weaker synapses, which are then preferentially phagocytosed (Schafer et al., 
2012). Schafer et al. demonstrated, using transgenic models deficient in various 
complement cascade components, that early postnatal synaptic activity modulates 
complement-mediated phagocytosis of synapses by microglia. Deficiencies in any of 
these essential complement components, C1q, C3 or CR3, which will be described in 
more detail at a later point (1.5.1 Complement in the Brain), resulted in aberrant 
synaptic connectivity and a reduction in eye-specific segregation in the dorsal lateral 
geniculate nucleus (Schafer et al., 2012). The importance of complement-mediated 
synaptic pruning by microglia has been further demonstrated by the development of 
epileptic symptoms in C1q deficient models, due to the maintenance of inappropriate 
connections in the sensorimotor cortical regions (Chu et al., 2010). Manipulation of 
visual experience alters the strength of synapses in the visual cortex of juvenile mice, 
such as the reduction in synaptic strength induced by a light deprivation paradigm 
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(Maffei et al., 2006). Following light deprivation, microglial processes were found to 
make more contacts with smaller, weak synapses and microglia contained more 
structures associated with phagocytosis (Tremblay, Lowery and Majewska, 2010), 
suggesting that synapse strength and experience may alter microglial remodelling of 
synaptic structures. 
Microglial activity has been shown to alter synaptic plasticity through the release of pro-
inflammatory cytokines, reactive oxygen species (ROS) and neurotrophic factors 
(Vezzani and Viviani, 2015). Synaptic plasticity is the process by which synaptic activity 
modifies the strength or efficacy of existing synapses, affecting both the pre and post 
synaptic regions, contributing to learning and memory formation (Citri and Malenka, 
2008).  
Microglial brain-derived neurotrophic factor (BDNF) has been shown to promote the 
expression of glutamatergic receptor subunits at synapses in a learning-dependent 
manner in the developing mouse hippocampus and cortex (Parkhurst et al., 2013). 
Depletion of microglia in this model, thus removing the BDNF source, reduced the 
number of learning-dependent glutamatergic excitatory synapses and resulted in a 
lower score in learning tasks. Glutamate-induced generation of ROS by microglia 
modulates synaptic plasticity by altering the expression of serine/threonine protein 
phosphatase 2A (PP2A) in neurons, which promotes the internalisation of AMPA 
receptors, weakening AMPA receptor mediated signalling (Collingridge and Peineau, 
2014). Therefore microglia can contribute to glutamate-induced LTD, which could 
precede microglial pruning of these weakened synapses. 
1.1.6 Microglial Activation  
 
The M1/M2 paradigm of macrophage activation states (Mills et al., 2000) is often also 
applied to microglia, in which activation is classified as classical, pro-inflammatory, 
neurotoxic M1 activation or alternative, anti-inflammatory, reparative M2 activation 
(Colton, 2009). M1 activation can be achieved in vitro through LPS and interferon-γ 
stimulation and results in the secretion of pro-inflammatory cytokines, including TNFα, 
IL-6 and IL-12, in addition to NADPH oxidase-mediated superoxide and reactive 
oxygen species (ROS) generation. Anti-inflammatory M2 activation is promoted by IL-4 
and IL-13 signalling and induces IL-10 and TGF-β release, resulting in arginase 1 
expression and the release of multiple growth and neurotrophic factors that are 
neuroprotective and encourage tissue repair, including insulin growth factor I (IGF-I), 
fibroblast growth factor (FGF), nerve growth factor (NGF) and BDNF.  
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This nomenclature has primarily been used to define the activity and the nature of 
microglia in vitro, however it has since been argued that advances in our abilities to 
study and model microglia, as well as the macrophages which were first defined as 
being either M1/M2, in vivo have rendered this bipolar framework redundant as ever 
increasing activation states and associated functions are identified (Martinez and 
Gordon, 2014; Ransohoff, 2016). Transcriptomic evidence has shown that microglial 
activation states are highly varied and, particularly in the context of neurodegenerative 
disease, are capable of expressing both M1 and M2 associated factors (Wes et al., 
2016). Therefore, it is difficult to justify the use a paradigm that restricts the activity of 
cells as plastic and varied as microglia into just two states. It is likely that microglial 
activity is more accurately represented as a spectrum of activation states that are 
heavily influenced by environmental and context-dependent signalling. 
1.1.7 Microglia and Neurodegenerative Disease 
 
Inflammation is widely recognised as a pathological component of most 
neurodegenerative diseases and, as microglia are the primary contributors of pro-
inflammatory cytokines in the CNS, they are likely to be playing an active role in 
pathogenesis (Wolf, Boddeke and Kettenmann, 2017). Furthermore, due to the 
extensive influence of microglial activity on the developing and adult brain, it is not 
surprising that microglial dysfunction has been identified in a range of CNS diseases 
including Alzheimer’s disease, Parkinson’s disease, multiple sclerosis and amyotrophic 
lateral sclerosis (ALS). Expression in microglia of several risk alleles associated with 
progressive neurodegenerative diseases further supports a link between the innate 
immune response and pathogenesis (Gosselin et al., 2017). 
Microglia express a range of pattern recognition receptors PRRs that are capable of 
detecting DAMPs associated with neurodegenerative diseases, including misfolded 
and aggregated proteins, nucleic acids and apoptotic cells. It is postulated that in the 
early stages of disease, microglial phagocytic activity is neuroprotective, ensuring the 
clearance of apoptotic cells and pathological protein aggregates such as amyloid-β 
(Aβ) (Lee and Landreth, 2010). Indeed, knockout of the microglia-expressed 
chemokine receptor CCR2, which is thought to be important for microglial recruitment 
to areas of high pathology, resulted in increased pathology and mortality (El Khoury et 
al., 2007). Furthermore, C3-/- mice, which are deficient in one of the key components 
required for complement mediated phagocytosis, had greater plaque loads and 
neuronal loss compared to C3 expressing mice in a model of Alzheimer’s disease 
(Maier et al., 2008), suggesting that microglial activity is neuroprotective in this context. 
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Ligation of PRRs by DAMPs is associated with continual release of pro-inflammatory 
mediators by microglia (Wolf, Boddeke and Kettenmann, 2017) that can lead to an 
augmented generation of pathological proteins, pro-inflammatory cytokines and 
apoptosis, thereby contributing to disease progression. In agreement with this, in a 
model of ALS, minimising microglial activation via inhibition of NF-κB signalling  
protected motor neurons from microglia-mediated neurotoxicity and improved 
transgenic mouse survival (Frakes et al., 2014). Microglial processes essential for the 
development of neural networks or for defence from pathogens can become 
dysregulated following inflammatory or degenerative disease-associated priming of 
microglia, resulting in neurotoxicity and aberrant removal of viable neurons and 
synapses. Following LPS-induced inflammation or Aβ exposure, microglia have been 
shown to target viable cells rather than clearing apoptotic neurons, resulting in 
inappropriate phagoptosis and neuronal loss (Neniskyte, Neher and Brown, 2011; 
Fricker et al., 2012). C1q, which plays a role in refining synaptic connectivity during 
CNS development, has been shown to be necessary for the toxic effects of Aβ on 
synapses, and C1q or C3 inhibition are protective against Aβ-induced microglial 
dysfunction in an AD model (Hong et al., 2016). Furthermore, C1q has been shown to 
be associated with Aβ plaques in patient samples (Afagh et al., 1996). 
The net effect of microglia, in particular microglial activation, in neurodegenerative 
disease is contentious. It appears to be context dependent, as exemplified by 
conflicting results regarding the neuroprotective nature of C3 and complement 
mediated phagocytosis (Maier et al., 2008; Hong et al., 2016). As microglial activity is 
implicated in so many neurodegenerative diseases, greater understanding of how to 
appropriately control the activity of these cells in disease-specific contexts could prove 
to be significant for the development of therapies. 
1.2 Models of Microglia 
 
Microglial function has been studied in vitro for decades however, increasing evidence 
associating microglia-expressed genes with neurodegenerative diseases, including 
Alzheimer’s disease, has recently been identified (reviewed by Villegas-Llerena et al. 
2016),  igniting the microglia field. Here the classic models for studying microglial 
function and also the emergence of iSPC models that have allowed the investigation of 
microglia in neurodegenerative diseases will be reviewed. 
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1.2.1 Primary Microglia 
 
Despite making up approximately 15% of the cells in the CNS, microglia contribute to 
less than 0.1% of the protein and RNA, therefore, in order to obtain information on the 
expression and function of these rare cells, it is usual to study them in isolation. 
Studying cells in vitro allows the modification of conditions in isolation to establish the 
effects of individual factors, providing information on aspects such as activation, 
secretion and motility, which are difficult to monitor in vivo. Various methods for the 
extraction and culture of microglia from brain tissue samples have been developed and 
rely upon density gradient separation of glia from the rest of the CNS cell types. Mixed 
glial cultures can be generated from which microglia ‘bud off’ into the cell supernatant 
or magnetic bead separation based on cell-specific antibodies can be used to generate 
pure microglia cultures. Primary cell cultures are frequently used as they are thought to 
bear many similarities in phenotype and function to cells found in vivo. However, 
particularly in the case of human microglia, a lack of tissue availability represents a 
significant obstacle to performing these experiments. Human microglia have been 
isolated from biopsy and autopsy samples, however due to the scarcity of samples for 
immediate isolation post mortem it is difficult to get sufficient numbers for statistical 
analysis and yields from small pieces of biopsy tissue are too low for high throughput 
assays. 
Monocyte derived macrophages are often used as a model of microglia due to 
similarities in function with the benefit of providing higher cell yields for study. Methods 
for the isolation of monocytes from blood samples are well established and easily 
performed and the collection of blood is non-invasive relative to brain biopsies. 
Monocytes are cultured for 7 days with macrophage colony stimulating factor (MSCF) 
to induce differentiation into macrophages, providing a source of human cells of the 
same myeloid origin as microglia. However, recent developments in the understanding 
of the ontogeny of microglia in the developing CNS have shown that microglia are 
derived from the yolk sac and migrate to the CNS prior to the closure of the blood brain 
barrier (BBB) (Ginhoux et al., 2010, 2013) whereas blood monocytes are renewed by 
hematopoietic stem cells that populate the bone marrow after the closure of the BBB 
(Ginhoux et al., 2010; Hoeffel et al., 2015). Therefore, monocyte derived macrophages 
do not recapitulate the ontogeny of microglia and may not act as a suitable model of 
the yolk sac-derived microglia.  
The majority of primary microglia cultures are derived from neonatal and adult rat and 
mouse brain tissue. Mammalian genomes are highly evolutionarily conserved so the 
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use of mouse and rat models has been extremely valuable for not only modelling 
development and disease in vivo but also providing tissue for the extraction of primary 
cells for studying microglia in isolation. Furthermore the development of transgenic 
animals in which specific genes have been modified in order to mimic previously 
identified disease-associated mutations or to facilitate observations of specific cell 
types, such as GFP-tagged CX3CR1 for microglia (Jung et al., 2000), have provided 
vast amounts of data that would not be attainable through the study of post-mortem 
human tissue alone.  
There are disadvantages associated with the use of primary cells for the study of 
microglia including the ethical implications of using embryonic human and animal tissue 
as well as the use of animal tissue of any kind. Despite most human and mouse genes 
being orthologous, approximately 20% do not have a clear orthologue and 1% are 
without a homologue (Chinwalla et al., 2002), therefore posing the question of whether 
animals should be sacrificed in order to provide cells that may not accurately express 
the genes of interest. Furthermore, analysis of human and mouse microglia showed 
that human microglia highly expressed 400 genes that were not in mouse microglia 
(Gosselin et al., 2017), indicating that differences exist in the transcriptional 
mechanisms between these species. Other disadvantages to primary culture is that 
once isolated, microglia do not replicate so, in addition to being scarce in difficult to 
acquire tissue, the numbers of cells available to use for experiments are finite. 
1.2.2 Immortalised Microglial Cell Lines 
 
The use of immortalised cell lines overcomes several of the difficulties associated with 
primary microglia. Primarily, due to the immortalised nature of the lines, they are 
proliferative and provide large numbers of cells for high throughput assays, whilst also 
being derived from a single donor which minimises the number of embryos and animals 
that need to be sacrificed to derive the cell line from. The increased yield of cells allows 
more complex experiments such as genome editing, which can have very low 
efficiency rates so requires large numbers of cells for successful clones to be 
generated.  
Several microglial cell lines of mouse and human origin have been generated by 
genetically immortalising primary microglia through the use of retroviruses. Two of the 
most frequently used are the murine BV2 and N9 microglial cell lines, which were both 
generated through transfection of mouse primary microglia with a retrovirus expressing 
the v-myc oncogene to induce immortalisation (Righi et al., 1989; Blasi et al., 1990). In 
a comparable manner to primary microglia, these cells have been shown to express 
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microglial markers, respond similarly to pro-inflammatory activation and perform 
phagocytic functions (Righi et al., 1989; Blasi et al., 1990; Kopec and Carroll, 1998; 
Fleisher-Berkovich et al., 2010; Fu et al., 2012).  
The HM06 human microglia cell line was generated by transfection of primary human 
embryonic microglia cultures with a v-myc oncogene-expressing retroviral vector. This 
cell line has been shown to have similar gene expression responses to Aβ and LPS as 
found in primary cells as well as behaving as predicted in regards to cytokine release 
(Nagai et al., 2001).  
Despite their usefulness, all immortalised cell lines carry similar disadvantages that, as 
the technology for the generation of iPSC-derived cells improves, may render these 
cells no longer suitable as models for the study of microglia. Due to the immortalisation 
process, genetic footprints in the form of retroviral insertions into the genome are left 
behind. This insertional mutagenesis can alter the karyotype, phenotype, proliferation 
and gene expression of the cells, significantly altering them from the primary cells from 
which they were derived. Indeed, increased proliferation, altered adhesion and variable 
morphologies have been reported in mouse microglial cell lines (Horvath et al., 2008) 
compared with primary microglia. Microglia in physiological conditions typically 
proliferate very slowly so these highly proliferative, immortalised cell lines do not 
accurately mimic the behaviour of the microglia in vivo. 
1.2.3 Induced pluripotent stem cell (iPSC) models 
 
In 2006, the method for the generation of induced pluripotent stem cells (iPSC) was 
first published  (Takahashi and Yamanaka, 2006). These cells resembled embryonic 
stem cells (ESCs) and were generated from mouse embryonic and adult fibroblasts 
(Takahashi and Yamanaka, 2006). Protocols for the differentiation of iPSCs into 
virtually all somatic cell types, including microglia, are being developed, providing an 
extremely useful tool for modelling human cells and disease. In their ground-breaking 
paper, Takahashi and Yamanaka demonstrated that the ectopic expression of a few 
key transcription factors in somatic cells was sufficient to reprogram the cells to a 
pluripotent state.  In order to develop their protocol, information was pooled from the 
past four decades of research into somatic cell nuclear transfer and ESC culture 
techniques (Yamanaka et al., 2012).  
ESCs had previously been the only source of pluripotent cells but are associated with a 
range of ethical issues and have extremely limited availability. Once methods had been 
developed for the isolation of both human and mouse ESCs (Evans and Kaufman, 
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1981; Martin, 1981; Thomson et al., 1998), optimisation of culture methods was 
performed to identify the factors required for the maintenance of pluripotency. It has 
been established that in the case of mouse ESCs, LIF/Stat3 is required to maintain 
pluripotency (Smith et al., 1988) and BMP4 can be used to block the MAPK/ERK 
differentiation signalling pathway and therefore maintain cell renewal (Qi et al., 2004). 
Interestingly, the factors required to maintain pluripotency differ between mouse and 
human cells; human ESC require basic fibroblast growth factor to alter MAPK/ERK 
signalling (Xu et al., 2005). Thus it was possible to isolate cells from the inner cell mass 
of explanted blastocysts that could either be differentiated into cells of the three germ 
layers or be cultured with the appropriate growth factors to maintain renewal and 
pluripotency. Following experiments performed initially in tadpoles (Gurdon, 1962) and 
later in mammals such as Dolly the sheep (Wilmut et al., 1997), the observation that 
oocytes contain the necessary factors required to reprogram the genetic information 
found in the nuclei of differentiated somatic cells was incorporated with knowledge 
garnered from the discovery of the existence of master transcription factors (Davis, 
Weintraub and Lassar, 1987) to design experiments to identify the factors capable of 
inducing pluripotency in somatic cells. 
Takahashi and Yamanaka generated a panel of 24 candidate genes that are found at 
high levels in pluripotent cells and, through the use of integrating retroviruses to 
express them in differentiated adult cells, were able to systematically narrow down the 
cocktail of genes required for expression of Fbx15, a gene essential for the 
maintenance of pluripotency not found in adult somatic cells. Thus, the essential 
combination of Klf4, Sox2, Oct4 and c-Myc, now known as the Yamanaka factors, was 
identified. The efficacy of this combination in reprogramming cells was confirmed by 
comparing the iPSCs to ESCs in a variety of assays: the gene expression profiles were 
assessed using DNA microarrays, the ability to form differentiated cells derived from all 
three germ layers was assessed by teratoma formation assays and the contribution to 
chimeric mice following injection into blastocysts was assessed by 
immunohistochemistry. These experiments together showed that only four factors were 
required to induce pluripotency in adult cells.  
Only a year later, the Yamanaka group reported modifications of the mouse protocol for 
the generation of human iPSCs. Retroviral transduction and cell culture methods were 
optimised but the four key factors required for reprogramming were found to be the 
same (Takahashi et al. 2007a). Following this initial publication, various other 
combinations of transcription factors that are also able to induce pluripotency with 
similar efficacies have been discovered (Yu et al., 2007; Buganim et al., 2012; 
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Apostolou and Hochedlinger, 2013). This wide range of factors capable of 
reprogramming cells indicates that a lot more is to be learnt about the networks that 
allow cells to regain pluripotency through different signalling pathways. 
Initially lentivirus or retroviruses were used to transfect cells with reprogramming 
factors but these viruses carry risks of insertional mutagenesis and integration of 
vectors into the genome. Modifications have therefore been made to transfection 
protocols in order to minimise the likelihood of integration whilst simultaneously 
increasing the efficacy of transfection. The adenovirus and the sendai virus have been 
used as alternatives because they are both non-integrating viruses, although 
reprogramming efficacies of adenovirus methods are only 0.0002% in human cells 
(Zhou and Freed, 2009) compared with the 0.02% found using retroviruses in the 
original protocols (Takahashi et al. 2007a). The sendai virus is one of the most 
commonly used methods (Hockemeyer and Jaenisch, 2016) as it is an RNA virus that 
does not enter the nucleus so can be diluted from cells through passaging, it generates 
large amounts of protein and has been shown to have an efficacy of approximately 1% 
in reprogramming fibroblasts (Fusaki et al., 2009). The delivery of exogenous proteins 
to reprogram fibroblasts has also been trialled (Kim et al. 2009a) as well as 
synthesised mRNAs (Warren et al., 2010) and episomal vectors (Yu et al., 2009). 
iPSCs offer a wide range of benefits over the use of primary cells and immortalised cell 
lines. By definition, these pluripotent cells are capable of being differentiated into 
virtually all cell types as well as being easily accessible and expandable, unlike most 
terminally differentiated primary cells. The use of somatic cells as a starting point 
means that ESCs are no longer required, avoiding any ethical issues and difficulties 
arising from a limited supply of embryos. Similar ethical advantages are found through 
the use of human iPSCs rather than animal model-derived primary cells, in addition to 
being more applicable for the study of human disease. This is particularly relevant in 
the case of neurodegenerative diseases such as AD where the accurate recapitulation 
of pathology in animal models has been challenging. Furthermore, if the differentiated 
cells are to be used for cell replacement therapies, the use of ESCs could result in 
immune rejection, which can be avoided through the use of self-derived cells for each 
individual patient. iPSCs generated from patients carrying disease-causing mutations 
are extremely useful for modelling and studying the mechanisms underlying disease, 
as well as screening potential drug therapies in the most relevant patient population. 
iPSC-derived neurons for cell replacement therapy have been  trialled successfully 
recently in non-human primate models of Parkinson’s disease (Kikuchi et al., 2017) and 
could pave the way for the use of this technology in humans. 
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Through the modification of cell culture conditions, iPSCs can be differentiated in a 
multitude of different cell types, including microglia. The increasingly recognised role of 
microglia in neurodegenerative diseases has led to the publication in quick succession 
of multiple methods for iPSC-derived microglia-like cells in order to produce cells of 
human origin that avoid the karyoptic abnormalities of cell lines and the low yields of 
primary cells.  
Initial efforts to generate iPSC-derived microglia involved driving embryoid bodies 
through neuronal differentiation (Almeida et al., 2012), which does not represent the 
yolk sac ontogeny of microglia. The recapitulation of microglial yolk sac ontogeny is a 
key element in more recent microglia differentiation protocols; it is important that cells 
are Myb-independent and are not derived from monocytes in order to truly model 
microglial development. Human iPSC-macrophage differentiation protocols have been 
generated (Van Wilgenburg et al., 2013), which, despite initially being described as a 
method to produce monocyte-derived macrophages, have been shown to produce cells 
that are Myb-independent (Hoeffel et al., 2015; Buchrieser et al., 2017) and thus model 
the primitive tissue macrophages that populate the brain during development. Other 
publications have since utilised this theory of generating Myb-independent macrophage 
precursors (Muffat et al., 2016; Abud et al., 2017; Haenseler et al., 2017) and then 
utilising factors in the culture conditions to skew differentiation towards microglia of the 
CNS, rather than the Kuppfer cells of the liver or the Langerhans cells of the skin. 
A differentiation protocol generated by Abud et al. incorporates factors that are 
secreted by other CNS cell types, including neurons, astrocytes and endothelial cells, 
to mimic the cues present during microglial development with the hypothesis that the 
inclusion of CX3CL1, CD200 and TGFβ will recapitulate the cellular interactions that 
influence microglial gene expression and function (Abud et al., 2017). A more complex 
differentiation medium has been developed by Muffat et al. in which the concentrations 
of the various components are matched to those found in human CSF, which can be 
used for the differentiation of both neuronal and glial cultures (Muffat et al., 2016). This 
multifaceted medium has also been shown to maintain primary microglial cultures for 
up to a month without passaging (Muffat et al., 2016) demonstrating its successful 
recreation of the endogenous CNS environment.  Co-culture with neurons has been 
shown to alter microglial gene expression, including the downregulation of early 
microglial genes which are typically expressed in iPSC-derived microglia generated in 
monoculture (Abud et al., 2017).  Muffat et al demonstrated that culturing iPSC-derived 
microglia with conditioned medium from differentiating neural cultures resulted in a shift 
in gene expression patterns away from foetal primary microglia and towards adult 
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primary microglia. The development of co-culture systems may therefore result in the 
generation of more mature genotypes and phenotypes in iPSC-derived microglia.  
Published protocols differ in their medium definition with some containing serum, which 
can have batch variation, whilst others use defined factors to model the signals found 
in the extracellular milieu of the brain. Despite the use of different growth factors and 
variations in time frames, all protocols have the same aim; to define and recreate the 
endogenous environment of microglia in order to stimulate the differentiating cells with 
developmentally relevant cues in the hopes of producing the most microglia-like cells. 
The precise definition of microglia is not yet known so it is difficult to determine when 
successful recapitulation of this cell type has been performed. A unique gene 
expression signature capable of distinguishing microglia from peripheral monocytes 
and monocyte-derived macrophages (Butovsky et al., 2014) is the current gold 
standard for determining the efficacy of iPSC differentiation protocols for the generation 
of microglia. The highly plastic nature of these cells means that challenges remain in 
defining the expression signature of physiological microglia though as the process of 
isolating the cells can have dramatic effects on their gene expression (Gosselin et al., 
2017). 
1.2.4 CRISPR-Cas9 Genome Editing of Microglia 
 
A benefit of iPSC-derived microglia-like cells over primary microglia is the ability to 
perform genome modification at the iPSC level, when the cells are more amenable to 
transfection. Genome editing can also be performed on differentiated iPSC-derived 
microglia, primary cells and microglial cell lines although large numbers of cells are 
needed because the transfection efficiencies are low, likely due to the recognition and 
clearance of foreign DNA and RNA via microglial pathogen-associated molecular 
pattern responses.  Genome editing can provide cell models in which a specific gene of 
interest is knocked down or knocked out through disruption or removal of regions of the 
DNA sequence. These knockout models are useful for understanding the function of 
the gene products and also can be used to model disease in which loss of function 
mutations are found. Various methods of genome editing for the knockdown of gene 
expression exist including RNA interference, transcription activator-like effector 
nucleases (TALENs), zinc finger nucleases (ZFNs) and finally CRISPR (clustered 
regularly interspaced short palindromic repeats)/Cas9 technology, which has greater 
cleavage efficiency and is easier to design and generate.  
CRISPR is a component of the bacterial adaptive immune system (Barrangou et al., 
2007) which acts to protect against viruses and plasmids through the acquisition of 
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DNA fragments from invading pathogens into CRISPR arrays in the host genome 
(Bhaya, Davison and Barrangou, 2011; Wiedenheft, Sternberg and Doudna, 2012). 
These protospacers are then transcribed to generate CRISPR RNAs (crRNAS) that 
allow direct cleavage by Cas (CRISPR-associated) proteins of the invading RNA or 
DNA through complementary base pairing to the invading targets. The Cas9 protein is 
an RNA-guided DNA endonuclease that can be reprogrammed to make site-specific 
DNA breaks by interacting with single guide RNA (sgRNA) designed to be 
complementary by Watson-Crick base pairing to a region of the gene of interest (Jinek 
et al., 2012). This sgRNA replaces the invading RNAs that are endogenously 
incorporated in to the CRISPR machinery in order to recognise and attack pathogen 
DNA. Thus Cas9 introduces a blunt double stranded break in DNA that complements 
the 20nt sequence in the sgRNA, triggering enzymes to repair the break at the 
cleavage site by non-homologous end joining, disrupting the sequence of the target 
DNA and therefore expression of the gene of interest. The discovery of the ability to 
easily modify this prokaryotic immune response mechanism in order to perform 
precise, sequence-specific targeting of DNA regions of choice has opened up a wealth 
of opportunities for basic biology and translational research. 
Modifications have been made to the Cas9 protein to function as a nickase (nCas9) by 
incorporating an inactivating mutation allowing the generation of staggered rather than 
blunt breaks in both strands of the target DNA. The use of paired guide RNAs and 
engineered nCas9 results in enhanced specificity and fewer off target effects (Cho et 
al., 2014; Shen et al., 2014). The staggered DNA breaks facilitate the insertion of repair 
DNA in the correct orientation during homology-directed repair, allowing the insertion of 
specific point mutations which is frequently used in order to study or repair disease-
associated mutations. This genetic editing can be performed on individual cells to 
generate lines carrying the genetic modifications or can be used to generate new 
animal models carrying specific mutations.  
Increasing numbers of groups are now utilising CRISPR/Cas9 to generate new models 
of microglia. Kleinberger et al used CRISPR/Cas9 to insert a frontotemporal dementia 
and Nasu-Hakola disease-associated mutation into the Trem2 gene to generate 
transgenic mice, from which primary microglia were isolated for experiments 
investigating the functional effects of the T66M mutation (Kleinberger et al., 2017). 
RANK knockout BV2 microglia cell lines have also been generated to determine the 
role of RANK signalling in modifying microglia responses to TLR3/4 signalling (Kichev 
et al., 2017). CRISPR/Cas9 has also been used in iPSC-derived tissue macrophages 
to demonstrate that they mimic the ontogeny of microglia (Buchrieser et al., 2017). The 
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list of publications demonstrating the usefulness of this technology for generating new 
models of iPSC-derived, primary and immortalised microglia will no doubt continue to 
grow as CRISPR/Cas9 technology becomes increasingly accessible and widespread. 
1.3 Alzheimer’s Disease 
 
First described by German psychiatrist Alois Alzheimer in a 50 year old female patient 
in 1901, Alzheimer’s disease is the most common form of dementia, with over 46.5 
million people diagnosed with the disease worldwide and 13% of people aged 60 or 
over requiring long-term care. The prevalence of AD is expected to triple by 2050 to 
130 million, according to the World Alzheimer’s Report in 2016. AD is a progressive 
neurodegenerative disorder characterised by cognitive impairment and 
histopathological hallmarks of extracellular Aβ plaques and hyperphosphorylated tau-
associated neurofibrillary tangles, in addition to brain shrinkage and loss of synapses 
and neurons, particularly in the hippocampus and cerebral cortex (Huang and Mucke, 
2012). Patients present with symptoms of memory loss and other cognitive declines, 
however it is thought that the causal neuronal loss and brain atrophy commences up to 
20 years prior to the deterioration of memory function. Despite extensive research into 
the field, at the moment there is no cure to halt disease progression with currently 
approved therapies only providing transient symptomatic relief.  
AD cases can be categorised in to two main groups depending on the age of symptom 
onset: late onset Alzheimer’s disease (LOAD) and early onset Alzheimer’s disease 
(EOAD). Only 1-2% of all AD cases are classed as EOAD, characterised by an age of 
onset of less than 65 (Rogaeva, 2002). LOAD is far more common, with 50% of people 
over the age of 85 suffering from the disease.  
Genetic linkage analysis of families affected by EOAD allowed the identification of 
pathogenic variations in three key genes: Amyloid precursor protein (APP) (Goate et 
al., 1991), Presenilin 1 (PSEN1) (Sherrington et al., 1995) and Presenilin 2 (PSEN2) 
(Sherrington et al., 1996). These rare autosomal dominant mutations alter the 
production of Aβ, providing evidence for the importance of Aβ in AD pathogenesis.  
APP is proteolytically cleaved by α-, β- and γ-secretases to form both non-pathogenic 
fragments (sAPPα and C-terminal fragments) and Aβ peptides of varying length with 
varying propensity to aggregate. Aβ1-42 constitutes 10% of the Aβ species, is the most 
aggregation prone form and is found in the AD-associated Aβ plaques. Both presenilin 
proteins are found in the γ-secretase complex, responsible for catalysing the 
generation of Aβ through APP cleavage. Mutations in PSEN1 or PSEN2 affect APP 
cleavage and result in increased Aβ1-42 generation. 
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Mechanisms of AD pathogenesis are not fully known but an imbalance of Aβ 
processing and clearance is thought to result in the formation of the hallmark senile 
plaques. Aβ oligomers, which are the building blocks of the fibrillar plaques, impair the 
proper functioning of synapses, altering neuronal signalling as well as triggering the 
activation of microglia, resulting in the release of neurotoxic inflammatory mediators 
(Reviewed by Selkoe 2002). The dysfunction and loss of synapses and dendritic spines 
are thought to be some of the earliest stages of AD pathology and ultimately lead to 
cognitive impairment. The pathogenesis of AD does not only silence neurons and their 
networks, but also causes atypical network activity thought to disrupt complex 
processes essential for learning and memory, which may result in excitotoxic cell death 
(Huang and Mucke, 2012). 
LOAD is a genetically complex, heterogeneous disease and multifaceted interactions 
between multiple risk factors, including genetic, epigenetic and environmental aspects, 
are likely to exist. Twin studies have indicated that 60-80% of LOAD risk is inherited 
(Gatz et al., 2006), leaving a considerable proportion of AD susceptibility resulting from 
non-genetic risk factors. Age is the greatest non-genetic risk factor for the development 
of AD with other environmental risk factors including head injury, low education levels, 
vascular risk factors, lifestyle choices and depression (Jiang et al., 2013).  
The Apolipoprotein E4 (APOE ε4) allele has been identified as a strong genetic risk 
factor for the development of both familial and sporadic EOAD and LOAD (Saunders et 
al., 1993). Indeed, it is the greatest genetic risk factor for the development of LOAD 
and has a gene-dose effect on increasing risk and lowering the age of disease onset 
(Corder et al., 1993). Heterozygous carriers of the APOE ε4 allele have a 3-fold 
increased risk for AD, which increases to 15-fold for those who are homozygous, whilst 
the ε2 allele has protective effects (Corder et al., 1993; Saunders et al., 1993). ApoE is 
a glycoprotein that plays a role in cholesterol transport and metabolism, and supports 
neuronal growth, tissue repair responses, immunoregulation and contributes to the 
clearance of soluble and aggregated Aβ. The ApoE4 isoform is less effective at this Aβ 
clearance (Deane et al., 2008), whilst simultaneously promoting Aβ deposition through 
modifying γ-secretase activity via lipid environment dysregulation (Osenkowski et al., 
2008). Furthermore, under stress, neurons upregulate expression of ApoE to facilitate 
neuronal repair, however, ApoE4 is more susceptible to proteolytic cleavage than other 
isoforms resulting in the generation of neurotoxic fragments that cause tau pathology 
and mitochondrial damage (Huang, 2006). The APOE ε4 allele is not an invariant 
cause of AD and is thought to act concurrently alongside other environmental or 
genetic risk factors to cause disease. 
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These four aforementioned AD genes account for less than 30% of the genetic 
variance found in EOAD and LOAD (Guerreiro, Gustafson and Hardy, 2012). Thanks to 
genome wide association studies (GWAS) and whole genome/exome sequencing, at 
least 20 additional genetic risk factor variants for LOAD have now been identified (Van 
Cauwenberghe, Van Broeckhoven and Sleegers, 2016). Many of these risk variants 
have been found to cluster in several common physiological pathways, highlighting and 
confirming three pathobiological processes that have previously been thought to 
contribute to the development of AD (Guerreiro and Hardy, 2014): the immune system 
and the inflammatory response; cholesterol and lipid metabolism; and endosomal 
vesicle recycling.  
Recently, common variances in the receptors CR1 (Lambert et al., 2009) and TREM2 
(Jonsson et al. 2013; Guerreiro et al. 2013a) have been identified as risk factors for 
LOAD. A copy-number variation in the intronic region of the gene encoding CR1 was 
identified by GWAS and is thought to alter protein isoform expression (Brouwers et al., 
2012). A low frequency, rare TREM2 AD risk variant was identified through exome 
sequencing following the discovery of homozygous TREM2 mutations in dementia 
families presenting with other disease phenotypes (Guerreiro et al. 2013a). The 
heterozygous R47H TREM2 mutation was the first gene with a moderate risk effect on 
AD (OR>3) to be identified since APOE ε4. 
Both CR1 and TREM2 are thought to be expressed on microglia and play important 
roles in directing microglial and immune activation cascades. Inflammation is essential 
in the healthy brain for the removal of debris, apoptotic cells and, in the case of AD, Aβ. 
The failure of a clinical trial of anti-inflammatory medication in AD patients 
demonstrated that low-levels of immunological and inflammatory activity are essential 
for tackling the disease (Imbimbo, 2009). However, prolonged inflammation, often 
attributed to chronic microglial activation, is neurotoxic and implicated in the 
pathogenesis of multiple neurodegenerative diseases, including AD (Eikelenboom et 
al., 2006). 
1.3.1 The Role of Microglia in Alzheimer’s disease 
 
The amyloid cascade hypothesis, which has been the major AD pathogenesis theory 
since first being described by Hardy and Higgins in 1992, posits that Aβ deposition and 
accumulation precedes the formation of neurofibrillary tangles, the loss of synapses 
and neurons, and cognitive decline found in AD (Hardy and Higgins, 1992). However, 
increasing genetic, clinical trial and experimental evidence suggest that 
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neuroinflammation, rather than simply being an epiphenomenon, plays a crucial role in 
driving and maintaining AD pathogenesis.  It has even been suggested that immune 
processes are capable of inducing AD pathology independently of Aβ by inducing 
neurodegeneration and neuronal cell loss (Heppner, Ransohoff and Becher, 2015). 
Inflammation in the brain is typically attributed to microglial activity and recent GWAS 
have highlighted several mutations linked to increased LOAD risk in genes which 
encode microglial expressed proteins including CR1, CD33, MSA4, CLU, ABCA7, HLA-
DRB5-HLA-DRB1 and APOE (Reviewed by Villegas-Llerena et al. 2016).  
AD pathology-associated microglia were first described nearly 100 years ago during 
the initial observations of microglia by del Rio Hortega and Penfield. The presence of 
microglia surrounding Aβ plaques and neurofibrillary tangle-bearing neurons in the AD 
patient brains is near universal (Mrak, 2012). The lesion-associated microglia are 
typically found in an activated state, which is associated with the release of pro-
inflammatory cytokines. Multiple cytokines are known to be upregulated in both the 
human AD brain and cerebrospinal fluid (CSF), and in AD mouse models, including IL-
1, IL-6, IL-8, IL-12, TNFα, MIP1α, IL-23 and MCSF (Griffin et al., 1989; Walker, Kim 
and McGeer, 1995; Meda et al., 1999; Lue et al., 2001; Patel et al., 2005). Microglial 
activation has been shown to correlate with AD pathology load and clinical scoring of 
dementia (Xiang et al., 2006). Furthermore, conditions that increase the risk of the 
development of AD, including head injury, diabetes, vascular disease and normal aging 
are also associated with microglial activation (Griffin et al., 1994; Sheng, Mrak and 
Griffin, 1998; Valente et al., 2010). 
There are two primary routes through which Aβ is removed: proteolytic degradation by 
enzymes such as neprilysin and insulin degrading enzyme, or uptake by astrocytes and 
microglia for intracellular degradation. As microglia are capable of producing these 
extracellular proteases and express receptors that recognise Aβ for phagocytosis and 
macropinocytosis, they are capable of exerting protective effects through both of these 
Aβ clearance pathways (Lee and Landreth, 2010). There are numerous receptors 
expressed on the surface of microglia that bind to both soluble and fibrillar Aβ including 
CD14, CD36, CD47, α6β1 integrin, class A scavenger protein, RAGE and TLRs 
(Heppner, Ransohoff and Becher, 2015) resulting in a range of microglial responses 
including the production of inflammatory cytokines.  
Aβ deposition induces reactive microgliosis; the expansion and activation of brain-
resident microglia. Knockout of chemokine receptors, such as CCR2, has been shown 
to increase Aβ deposition and accelerate mortality in mouse AD models (El Khoury et 
al., 2007), suggesting that recruitment of microglia is protective through Aβ clearance. 
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Paradoxically, during the late stages of disease, the build-up of Aβ continues despite 
increasing numbers of microglia, likely due to prolonged microglial exposure to Aβ and 
plaque-associated cytokines causing microglial functional impairment (Heneka et al., 
2015). Aβ-induced phenotypic changes result in microglia becoming overwhelmed and 
contributing to disease progression by inducing the adoption of a pro-inflammatory 
phenotype and the release of further cytokines. In turn, these cytokines downregulate 
both the microglial receptors responsible for Aβ phagocytosis and also Aβ-degrading 
enzymes (Hickman, Allison and El Khoury, 2008).  
Moreover, the pro-inflammatory molecules secreted by Aβ-activated microglia further 
increase the activity and expression of the γ- and β-secretases that generate Aβ (Hong 
et al., 2003; Liao et al., 2004), exacerbating the accumulation of toxic Aβ. 
Consequently, the toxic effects of microglial inflammatory responses are twofold: firstly 
by promoting neurotoxic, pro-inflammatory cytokine and reactive oxygen species 
generation and secondly by inducing the further generation of Aβ, generating a 
feedback loop that accelerates pathology. Furthermore, the microglial dysfunction may 
further damage cells via a loss of physiological functions such as tissue homeostasis 
and provision of supportive trophic factors, resulting in additional loss of neuronal 
integrity throughout the course of disease (Heppner, Ransohoff and Becher, 2015).  
Therefore, microglia play a dichotomous role in the pathogenesis of AD. In the early 
stages of disease, microglia help to clear Aβ however, this ability declines with time. 
Chronic Aβ accumulation drives microglial activation resulting in the generation of a 
proinflammatory environment that is capable of propagating further inflammation, Aβ-
accumulation, microglial dysregulation and ultimately augmented disease progression. 
1.4 TREM2 
 
TREM2 has been known to play a role in neurodegeneration since the discovery that 
homozygous mutations cause a form of early onset dementia known as polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL), or 
Nasu Hakola Disease (Paloneva et al., 2002). However, huge interest in the gene 
expression and function was only sparked upon identification of TREM2 variants as risk 
factors for Alzheimer’s disease (Guerreiro et al. 2013a; Jonsson et al. 2013). Mutations 
in the TREM2 gene have also been identified in other neurodegenerative diseases 
suggesting that immune dysregulation through alterations to TREM2 function could be 
a primary contributor to the pathogenesis of multiple neurodegenerative diseases. 
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As the name suggests, Triggering Receptor Expressed in Myeloid Cells 2 (TREM2) is 
expressed on the surface of many myeloid cells including dendritic cells, granulocytes, 
monocyte-derived macrophages, tissue resident macrophages, osteoclasts and 
microglia. TREM2 is also reported to be expressed on circulating monocytes (Hu et al., 
2014; Chan et al., 2015) but evidence is conflicting (Forabosco et al., 2013; Song et al., 
2017). RNA sequencing data indicates that in the CNS, under steady-state conditions, 
TREM2 RNA is specifically expressed only in microglia (Butovsky et al., 2014). Indeed, 
when microglia are depleted from the brain, TREM2 expression in the brain is 
eliminated (Hsieh et al., 2009; Thrash, Torbett and Carson, 2009; Elmore et al., 2014). 
TREM2 is one of the highest expressed receptors in microglia (ranked at 31) and is 
expressed 300 times higher in microglia compared with astrocytes (Hickman and El 
Khoury, 2014).  
The TREM gene family encodes for three receptors each with an immunoglobulin 
superfamily domain in their extracellular domain. The TREM2 gene is found on 
chromosome 6p21.1 and encodes for 5 exons that are translated into a 230 amino acid 
long transmembrane glycoprotein consisting of an extracellular Ig-like domain, a 
transmembrane domain and a cytosolic tail. The intracellular region lacks a cytoplasmic 
signalling element so is reliant on the signalling capacity of its transmembrane adaptor 
protein, DNAX-activating protein of 12kDa (DAP12; also known as tyrosine kinase 
binding protein, TYROBP) (Daws et al., 2001). DAP12 signalling results in Src-family 
mediated phosphorylation of ITAM (immunoreceptor tyrosine-based activation motif) 
domains, subsequent Syk recruitment and the activation of downstream signalling 
mediators (Figure 1.1). DAP12 is the only adaptor protein associated with TREM2, 
however DAP12 couples to other receptors, including CSF1R, members of the lectin 
family and the Ig superfamily, including TREM1 (Hamerman et al., 2009). 
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TREM2 expression is widely distributed with high levels in the white matter, 
hippocampus and neocortex (Guerreiro et al. 2013a). Expression levels increase with 
age in the human brain (Forabosco et al., 2013) and correlate with aging in mouse 
models (Jiang et al. 2014a; Raha et al. 2017). TREM2 expression is highly responsive 
to inflammation, injury and disease-associated stimuli although marked differences are 
found between responses in vitro and in vivo. In vitro stimulation with pro-inflammatory 
factors such as TNFα, IL-1β, LPS and IFNγ cause a decrease in TREM2 expression 
 
Figure 1.1 Summary of proposed TREM2 ligands, signalling and function 
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levels (Bouchon et al., 2001; Turnbull et al., 2006; Zheng et al., 2016), whereas 
conditions of inflammation in vivo including sepsis, macular degeneration, traumatic 
brain injury, stroke and models of demyelination lead to augmented TREM2 levels 
(Kawabori et al. 2015; Chen et al. 2013; Bhattacharjee et al. 2016; Saber et al. 2017; 
Takahashi et al. 2007b). These contrasting effects could be due to recruitment of other 
cell types to sites of inflammation in vivo, which provide additional sources of TREM2 
expression, or due to alterations to cell expression signatures following isolation for in 
vitro analysis (Bohlen et al., 2017; Gosselin et al., 2017). 
Endogenous ligands of TREM2 have not been categorically identified but are thought 
to include anionic and zwitterionic lipids (Wang et al., 2015),  highly anionic bacterial 
products such as dextran sulphate (Daws et al., 2003) and lipoproteins including ApoA-
1, clusterin, low-density lipoprotein and ApoE (Atagi et al., 2015; Bailey, DeVaux and 
Farzan, 2015; Yeh et al., 2016; Jendresen et al., 2017). Putative TREM2 ligands have 
been found on primary neurons and neuronal cell lines, which increase significantly 
following induction of apoptosis (Hsieh et al., 2009). The TREM2/DAP12 complex was 
later shown to be activated by cell membrane components that become exposed 
during neuronal death and degeneration including sulfatide, sphingomyelin, 
phosphatidylserine and myelin lipids (Poliani et al., 2015). The binding of TREM2 to 
lipids that are exposed during neuronal cell death, which also associate with fibrillar Aβ, 
suggests TREM2 may detect local cell damage, promoting microglial responses to Aβ 
accumulation and cellular toxicity (Wang et al., 2015). TREM2 reporter assays suggest 
that Aβ alone does not result in TREM2 activation however, interestingly, ApoE is 
capable of binding to both Aβ (Atagi et al. 2015; Kim et al. 2009b) and apoptotic cells 
(Atagi et al., 2015). Thus, if ApoE is a ligand of TREM2 it may act as an intermediary 
enabling TREM2 recognition and uptake of these factors. 
A key function of TREM2 is phagocytosis signalling. Overexpression of FLAG-tagged 
TREM2 and subsequent FLAG antibody-mediated crosslinking induces actin 
cytoskeletal reorganisation and phagocytosis of microsphere beads in a DAP12 
dependent manner (Takahashi, Rochford and Neumann, 2005). TREM2-mediated 
phagocytosis requires Src kinase phosphorylation of DAP12, Syk recruitment and 
downstream GTPases Rac1 and Cdc42 (N’Diaye et al., 2009), which are activated by 
Vav (Turner and Billadeau, 2002). Subsequently, Arp2 has been identified, along with 
the genes encoding the other components of phagocytic signalling, as being highly 
connected to TREM2 expression (Forabosco et al., 2013). Phagocytic deficits in 
TREM2-lacking cells have been reported in studies utilising a range of substrates 
including apoptotic neurons (Takahashi, Rochford and Neumann, 2005; Atagi et al., 
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2015), bacterial products (Kleinberger et al., 2014; Gawish et al., 2015), Aβ (Jiang et al. 
2014a; Kleinberger et al. 2014) and lipids (Yeh et al. 2016; Park et al. 2015b). The role 
of TREM2 in phagocytosis is further demonstrated by overexpression or activation of 
the receptor resulting in augmented uptake of Aβ, apoptotic neurons and other cellular 
debris (Melchior et al. 2010; Takahashi et al. 2005; Takahashi et al. 2007b). 
Furthermore, transfection of CHO cells with a TREM2/DAP12 chimera expression 
construct was sufficient for enabling phagocytosis of bacteria by these endogenously 
non-phagocytic cells (N’Diaye et al., 2009). 
Typically TREM2 has been viewed as playing a critical role in the regulation of pro-
inflammatory genes. However, there appears to be a complex interplay of stimulation, 
cell type and disease condition which results in TREM2 induction of pro-inflammatory 
effects in certain conditions (Jay et al. 2017b). In vitro, TREM2 signalling has anti-
inflammatory effects as demonstrated by TREM2 knockdown resulting in increased 
expression of iNOS, TNFα, IL-6 and IL-1β following stimulation with apoptotic cells 
(Takahashi, Rochford and Neumann, 2005), TLR2/6, 9 and 4 ligands (Hamerman et al. 
2006; Takahashi et al. 2007b) and Aβ (Jiang, et al. 2014b). Downstream of TREM2, 
anti-inflammatory signalling is reported to be mediated via DAP12 ITAM association 
with Src-phosphorylated Dok3, which becomes trapped at the cell membrane and thus 
is unavailable for interactions with Ras-Mek, reducing the activation of Erk and 
downstream transcription of pro-inflammatory cytokines (Peng et al., 2013). 
Furthermore, in models of aging, siRNA mediated knockdown of TREM2 resulted in 
significant increases in brain TNFα and IL-6 expression (Jiang et al. 2014a; Jiang et al. 
2015). TREM2 overexpression in AD models of Aβ and tau was shown to result in 
reduced expression of mRNA encoding inflammatory factors and had neuroprotective 
effects on synaptophysin expression and pathology-related neuronal loss (Jiang et al. 
2014b; Jiang et al. 2016b).  
However, other data conflicts with this suggestion of anti-inflammatory TREM2 activity, 
including decreased transcription of inflammation associated genes in TREM2 
knockout AD models (Wang et al. 2015; Jay et al. 2015; Jay et al. 2017a) and  
diminished pro-inflammatory cytokine release in TREM2-deficient models of TBI, 
ischemia and demyelination (Sieber et al., 2013; Poliani et al., 2015; Saber et al., 
2017). Conflicting results may result from analysis being conducted on whole tissue 
versus individual cell types in isolation. As mentioned previously, significant alterations 
to gene expression are found in cells that have been isolated (Bohlen et al., 2017; 
Gosselin et al., 2017), which may also explain these discrepancies.  
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TREM2 has also been reported to affect myeloid cell proliferation and survival. 
Modulation of TREM2 expression has shown varying effects on cell number in 
physiological conditions (Paloneva et al., 2003; Humphrey et al., 2006; Zheng et al., 
2016) however, it has a marked impact on myeloid cell expansion in response to 
inflammation and disease. A lack of TREM2 resulted in blockade of proliferation in 
models of traumatic brain injury, ischaemia and aging (Kawabori et al., 2015; Poliani et 
al., 2015; Saber et al., 2017). In models of AD, decreased numbers of microglia were 
found associated with Aβ plaques in TREM2 knockdown and knockout brains (Wang et 
al. 2015; Yuan et al. 2016; Ulrich et al. 2014; Jay et al. 2017a). Whether this is due to 
the decreased overall number of microglia that has been reported in some TREM2-/- 
AD mice (Wang et al., 2015, 2016) or due to a loss of cells in the plaque specific 
regions is not yet known (Yuan et al. 2016; Jay et al. 2017a). 
Evidence for a role of TREM2 in cell survival has also been identified which could 
explain why TREM2 deficient models have decreased accumulation of myeloid cells in 
the toxic, inflammatory environment surrounding Aβ plaques. TREM2 knockout cells 
were found to have augmented levels of apoptosis markers including caspase 3, 
annexin V and TUNEL positivity (Otero et al., 2012; Wu et al., 2015), as well as 
decreased expression of survival pathway factors (Zheng et al., 2017). Equally, TREM2 
activation promoted survival of dendritic cells and osteoclasts (Bouchon et al., 2001). 
The anti-apoptotic signalling of TREM2 was marked in cells undergoing MCSF-
starvation induced cell stress, in which microglia and bone marrow derived 
macrophages were more likely to undergo apoptosis if TREM2 was abrogated, when 
compared with wildtype cells (Wang et al., 2015; Wu et al., 2015). MSCF and its 
receptor CSF1R are thought to be important for TREM2/DAP12 survival signals as 
DAP12 phosphorylation is required for the subsequent Pyk2-dependent β-catenin 
activation (see Figure 1.1) (McVicar and Trinchieri, 2009; Otero et al., 2009, 2012). 
TREM2 has recently been further linked to β-catenin signalling through the stabilisation 
of the protein and therefore the promotion of the survival-associated Wnt signalling 
pathway (Zheng et al., 2017). 
Full length, surface-expressed TREM2 undergoes sequential regulated intramembrane 
proteolysis (RIP) by ADAM10 and γ-secretase (Wunderlich et al., 2013; Kleinberger et 
al., 2014) to generate soluble TREM2 (sTREM2). The catalytically active components 
of the γ-secretase complex are presenilins-1 & -2, both of which have been linked to 
AD via altered Aβ generation pathways. Inhibition of γ-secretase leads to accumulation 
of TREM2 c-terminal fragments (CTFs) tethered at the cell surface, which trap and 
impair DAP12 signalling with full-length TREM2 (Wunderlich et al., 2013). The role of γ-
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secretase in TREM2 processing provides evidence of a functional connection between 
two identified pathways in AD pathogenesis. Disease-associated TREM2 variants 
R47H, T66M and Y38C alter the generation of sTREM2 in in vitro models (Kleinberger 
et al., 2014; Piccio et al., 2016). Decreased levels of sTREM2 are also found in the 
CSF of T66M heterozygous and homozygous carriers compared to age and gender 
matched control individuals (Kleinberger et al., 2014; Piccio et al., 2016). 
The function of sTREM2 is not yet known but the fact that it is generated 
physiologically and upregulated during inflammatory disease (Heslegrave et al., 2016; 
Piccio et al., 2016) suggests that it may play a role in TREM2 signalling. Treatment with 
sTREM2 resulted in increased survival in microglial cell lines (Zhong et al., 2017) and 
bone-marrow derived macrophages (Wu et al., 2015), including those that were 
deficient in TREM2, suggesting that sTREM2 signalling does not require full length 
TREM2 to function. In addition to improving microglial survival, sTREM2 treatment 
caused a proinflammatory response in primary cultured microglia and in the 
hippocampus of mice injected with sTREM2 (Zhong et al., 2017). Interestingly, CSF 
levels of sTREM2 have been found to peak specifically at the early symptomatic stages 
of AD (Suárez‐Calvet et al. 2016a; Suárez-Calvet et al. 2016b), suggesting that 
increased sTREM2 generation may be a responses to early stage AD pathology.  
Variants in TREM2 have been identified as genetic risk factors for a range of 
neurodegenerative diseases including Alzheimer’s disease, Parkinson’s disease, 
amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Nasu Hakola 
disease (Guerreiro et al. 2013a; Guerreiro et al. 2013b; Cady et al. 2014; Thelen et al. 
2014; Rayaprolu et al. 2013; Jonsson et al. 2013). All TREM2 variants associated with 
these neurodegenerative diseases are thought to cause loss of receptor function (Jay 
et al. 2017b). The association of TREM2 with multiple neurodegenerative diseases 
indicates that it may play an important role in the common biological pathways that 
underlie multiple pathologies. 
Links have also been identified between TREM2 and other genes associated with AD 
and neurodegeneration. CD33, variants in which have also been associated with AD, 
has been reported to modulate TREM2 expression, such that variants increasing 
monocyte expression of CD33 exhibit decreased levels of TREM2 (Chan et al., 2015). 
MSA4, SNPs in which have recently been identified as conferring risk for AD (Lambert 
et al., 2013), may play a role in regulating TREM2 expression as carriers of AD-
associated SNPs have altered CSF levels of sTREM2 (Piccio et al., 2016). 
Furthermore MSA4 expression is augmented on monocytes isolated from carriers of 
TREM2 variants (Piccio et al., 2016). Furthermore ApoE, the greatest risk factor for 
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LOAD, is also a putative TREM2 ligand (Atagi et al., 2015; Bailey, DeVaux and Farzan, 
2015). 
A link between TREM2 and neurodegenerative diseases was first identified in Nasu-
Hakola patients carrying homozygous TREM2 and DAP12 mutations (Paloneva et al., 
2002). Nasu-Hakola patients present typically with bone-cysts and fractures, and early 
onset dementia around the age of 30 and a life expectance of 40-50 years. Despite the 
characteristic bone features, Nasu-Hakola can also occur in the absence of osteopathic 
symptoms (Bock et al., 2013; Yamazaki et al., 2015). To date multiple variants have 
been identified as causing Nasu-Hakola disease including E14X, W44X, T66M, W50C, 
W78X, D134G and K186N (Guerreiro et al. 2013b; Paloneva et al. 2002; Dardiotis et 
al. 2017).These predicted autosomal recessive loss of function mutations are thought 
to cause the disease manifestations by affecting osteoclasts and microglia, both 
myeloid lineage cell types. Pronounced inflammatory responses are found including 
microgliosis and astrocytosis (Satoh et al., 2011) and neuropathological hallmarks 
comprise of axonal degeneration, white matter loss in the corpus callosum and basal 
ganglia, and cortical atrophy (Paloneva et al., 2001; Bianchin et al., 2004; Sasaki et al., 
2015). The manifestation of Nasu-Hakola disease in the CNS has provided insight into 
TREM2 function and has indicated that TREM2 activity is important for normal brain 
function and cognition. 
Analysis of dementia families has also identified TREM2 variants previously linked to 
NHD as risk factors for FTD/FTLD, both in homozygosity or heterozygosity. These 
variants include T66M, W198X, Q33X and Y38C (Guerreiro et al. 2013b; Giraldo et al. 
2013). However, it is not yet clear whether TREM2 mutations increase the risk of FTD 
in the general population. 
1.4.1 TREM2 in Alzheimer’s Disease 
 
A rare missense mutation (rs75932628-T) in the TREM2 gene, conferring an arginine-
47-histidine (R47H) substitution, was identified as causing a substantial increase in risk 
of developing AD (Guerreiro et al. 2013a; Jonsson et al. 2013). In simultaneously 
published reports, the R47H TREM2 variant was identified by GWAS (Jonsson et al., 
2013) and by exome and Sanger sequencing (Guerreiro et al. 2013a). From pooling 
further studies, it is thought that variants are rare (population frequency of 0.3%) but 
the effect size is high (odds ratio >3) which is similar to that of a single copy of the 
ApoE ε4 allele. So far, five further variants have been associated with risk for AD when 
found in heterozygosity (Lu et al. 2015; Jin et al. 2015; Guerreiro et al. 2013b; Jonsson 
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et al. 2013; Jiang et al. 2016a), although none have surpassed the odds ratio found in 
the case of R47H. 
In AD patients, R47H mutations in TREM2 are associated with an earlier age of 
symptom onset (Jin et al., 2014; Slattery et al., 2014) and a more rapid rate of disease 
progression (Rajagopalan, Hibar and Thompson, 2013; Korvatska et al., 2015). 
Compared with healthy controls, increased TREM2 expression is found in AD patient 
brains (Lue et al., 2015; Strobel et al., 2015; Perez et al., 2017) and, in mouse models, 
increased TREM2 expression coincides with the onset of Aβ pathology (Jiang, et al. 
2014b; Chan et al. 2015). In tau models, upregulation occurs with a delay, and is only 
identified following formation of neurofibrillary tangles (Matarin et al., 2015).  
Despite TREM2 upregulation being found to be concomitant with Aβ deposition, it is not 
yet known how, or if, Aβ alters TREM2 expression. Myeloid cells associated with 
plaques have increased TREM2 expression (Frank et al., 2008; Jay et al., 2015; 
Savage et al., 2015; Yin et al., 2017) and injection of Aβ1-42 into the cortex and 
hippocampus of mice induced upregulation of TREM2 mRNA within 24 hours (Jiang et 
al. 2014b). There is currently controversy over the origin of the TREM2 expressing cells 
that are found surrounding Aβ plaques in AD brains. Jay et al found that these myeloid 
cells lacked expression of the key microglial-specific marker P2YR12, suggesting that 
these TREM2+ cells were monocyte-derived macrophages that had infiltrated the 
brain. On the other hand, Wang et al used parabiosis experiments to demonstrate that 
peripheral macrophages from WT mice did not contribute to the pool of cells in the AD 
mice. In vitro, Aβ1-42 stimulation failed to elicit a TREM2 expression response in 
microglia cultured in isolation, however microglia in mixed glial cultures upregulated 
TREM2 expression in response to Aβ1-42 (Melchior et al., 2010). This suggests that 
Aβ may not act directly upon the TREM2 expressing microglia and upregulation may be 
induced through signals from another cell type. 
AD-associated TREM2 variants have been shown to attenuate ligand binding affinities 
(Bailey, DeVaux and Farzan, 2015; Kober et al., 2016) and therefore are likely to affect 
the downstream signalling for key functions such as phagocytosis. These mutations 
may alter the ability of microglia to clear Aβ since TREM2-/- AD models have increased 
accumulation of Aβ and neuronal loss (Wang et al., 2015), whilst expression of R47H 
mutations also decreased microglial phagocytosis of Aβ1-42 (Kleinberger et al., 2014). 
Indeed, in AD patients carrying R47H mutations, increased Aβ plaque loads have been 
identified compared with non-carriers (Roussos et al., 2015). The exact mechanisms 
through which AD-associated variants contribute to AD pathogenesis are not yet 
certain but the fact that they are found in the coding regions of the TREM2 gene makes 
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them relatively more amenable for the necessary ongoing in vitro studies and modelling 
required to further understand these disease-altering mutations. 
1.5 The Complement System 
 
The complement system, consisting of over 30 plasma and membrane bound proteins, 
was discovered in the 1890s as a heat-labile component of serum that was found to 
‘complement’ the antibacterial activity of antibodies (Walport, 2001). It is a 
phylogenetically ancient part of the innate immune system which acts swiftly to protect 
the host from a wide range of stimuli through surveillance and rapid activation, 
incorporating essential, strict regulation to prevent complement-mediated damage to 
host cells. Despite primarily functioning to opsonise pathogens, recruit innate and 
adaptive immune cells and amplify signals to stimulate the immune response, 
complement has an increasingly appreciated role in orchestrating a range of 
immunological and homeostatic responses. Complement has been found to be more 
than just an innate first line of defence; it is involved in angiogenesis, lipid metabolism, 
synapse maturation and tissue regeneration as well as playing a key role in the 
adaptive immune system (Walport, 2001; Dunkelberger and Song, 2010). 
Complement activation can occur through either the classical, alternative or lectin 
pathways depending on the source of stimulation. Activation can occur on the surface 
of recognised pathogens or on host tissues and results in a series of specific proteolytic 
cleavages, finally resulting in the formation of the membrane attack complex (MAC).  
All three pathways converge on the assembly of C3 convertases which cleave C3, 
resulting in the formation of activation products and the MAC (Sarma and Ward, 2011) 
(See Figure 1.2).  The MAC assembles in the membrane of the target cell, causing 
membrane disruption and cell lysis.  The complement system is capable of identifying 
pathogens or perturbations to tissue homeostasis via defence collagens such as C1q 
and then marks these risks by opsonisation for clearance via phagocytosis. 
Complement recruits immune cells using fluid-phase inflammatory mediators known as 
anaphylatoxins which act as chemoattractants for phagocytic cells, vasodilators and 
smooth muscle contractors (Miwa and Song, 2001).  
The classical pathway is activated in response to C1q binding antigen-antibody 
complexes as well as direct binding to pathogen surfaces and some host surfaces such 
as Aβ and phosphorylated tau (Afagh et al., 1996). The lectin pathway is activated by 
the binding of the mannan-binding lectin protein to residues and sugars on the outer 
surface of pathogens. In the alternative pathway of complement activation, there is a 
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low level of constant C3 hydrolysis, known as ‘tick over’, to form C3b which is capable 
of binding carbohydrates, lipids and proteins found on microbial and eukaryotic 
surfaces with low sialic acid content (Veerhuis, Nielsen and Tenner, 2011). This 
spontaneous hydrolysis allows priming of the complement system and continually 
probes for challenged host cells or foreign cells. C3b inactivation by factor H and factor 
I is much more efficient on sialic acid rich surfaces, such as host cells, which prevents 
damage to the host. These different routes for the activation of complement are no 
longer viewed as three separate, linear pathways but as a network of tightly regulated 
proteins that continually survey the environment and cooperate to clear infection. 
 
A critical component of the complement system is the network of regulators of 
complement (CREGs) that is in place, including CR1, Factor H, DAF, CD59 and C4b-
binding protein which act not only to prevent inappropriate activation but to also 
determine what level of response is appropriate. For example, in the case of apoptotic 
cells, debris that would otherwise cause inflammation is tactfully removed avoiding 
further complement activation and the particularly inflammatory components 
downstream of C3 (Ricklin et al., 2010), which are not necessary for the clearance of 
Figure 1.2: Diagram showing the convergence of the three pathways of complement 
activation 
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this low risk debris. This fine balance between activation and regulation within the 
system is carefully maintained, but if allowed to go awry, can contribute to the 
underlying pathology of several inflammatory, neurodegenerative, ischaemic and age-
related diseases (Ricklin et al., 2010). 
1.5.1 Complement in the Brain 
 
Due to the integrity of a healthy BBB, neither the immune cells circulating in the 
periphery nor the primarily liver-derived complement proteins are able to penetrate the 
brain parenchyma (Veerhuis, Nielsen and Tenner, 2011). Therefore, any complement 
found in the brain must be synthesised locally in order to ensure essential local 
surveillance and defence in this immuno-privileged site. Although levels of production 
are typically low under non-pathological conditions, it has been confirmed that 
complement activators and regulators are synthesised in the human brain by neurons 
(Walker and McGeer, 1993; Thomas et al., 2000), microglia (Walker, Kim and McGeer, 
1995; Veerhuis et al., 1998), astrocytes (Barnum, Jones and Benveniste, 1992) and 
oligodendrocytes (Gasque and Morgan, 1996; Hosokawa et al., 2003). The expression 
of these complement factors and receptors have been found to increase following 
infection (Stahel and Barnum, 1997), inflammatory stimulation (Stahel et al., 1997) and 
in neurodegenerative disease (Yasojima et al., 1999).   
Complement proteins and receptors have been found to have functions beyond innate 
immune responses including mediating neurogenesis, synaptogenesis, cell migration, 
neuroprotection, proliferation and regeneration. In the brain, complement receptors and 
proteins are expressed in a temporally- and spatially-regulated manner, suggesting that 
the complement system has more than just an immunological role. During CNS 
development, various complement components are upregulated resulting in contrasting 
promotion of cell survival and induction of synapse removal. 
Complement anaphylatoxins are primarily known for their role in recruitment of 
phagocytes and activation of immune cells to clear infections. However, C3aR and 
C5aR, the receptors for the anaphylatoxins C3a and C5a, have been shown to be 
transiently expressed on cerebellar granule cells during rat CNS development (Bénard 
et al., 2004). Furthermore, activation of C5aR with C5a resulted in inhibition of 
Caspase-9 mediated apoptotic cell death in serum starved ex vivo granule cell neurons 
(Bénard et al., 2004). C3a is reported to play a role in the differentiation and maturation 
of neural progenitor cells in vitro (Shinjyo et al., 2009). In vivo, C3a knockdown or 
C3aR blockade results in decreased basal neurogenesis and decreased migration of 
neuroblasts in models of ischaemia (Rahpeymai et al., 2006).  
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Supernumerary synapses are generated in the developing brain, which are refined 
during post-natal development (Hooks and Chen, 2006). Microglia play an important 
role in refining and shaping the synaptic connectivity during development in an activity 
and complement dependent manner (Schafer et al., 2012). Engulfment of synapses by 
microglia is dependent upon C1q, C3 and CR3, the expression of which is regulated in 
a spatiotemporal manner in the lateral geniculate nucleus and cortex during 
development and downregulated in the adult brain to prevent excessive synapse 
stripping (Stevens et al., 2007). This removal of excessive synapses is essential for 
appropriate signalling within the neuronal circuitry, as demonstrated by the observation 
of epileptogenesis in mouse models deficient in C1q, due to inefficient refinement of 
networks in the sensorimotor cortical regions (Chu et al., 2010). This removal of 
weaker, inappropriate synapses allows the remaining connections to be strengthened. 
Therefore, in addition to the anti-apoptotic signalling of the anaphylatoxins, a carefully 
balanced and regulated interplay between complement, neurons and microglia results 
in the refinement and careful sculpting of spontaneous, immature circuits into 
organised, experience-based synaptic connections (Katz and Shatz, 1996). 
In the adult brain, complement interacts with microglia to ensure that homeostatic 
conditions are maintained. Through initiating responses to infection and injury, the 
complement system acts to induce a local inflammatory response in order to promote 
healing and protection. Despite the risks of causing inflammation and cell damage if 
activation becomes dysregulated, this local inflammation is key for the removal of cell 
debris and neurotoxic protein aggregates.  
C1q is important for the clearance of misfolded proteins, apoptotic cells and neuronal 
blebs (Fraser, Pisalyaput and Tenner, 2010) due to its ability to recognise 
phosphatidylserines exposed on the surface of apoptotic cells, thus flagging them for 
removal by microglia. This recognition results in downstream complement activation 
and opsonisation by C3b/iC3b for clearance via phagocytosis (Mevorach et al., 1998) 
thereby preventing the release of neurotoxic intracellular factors, such as glutamate. 
Interactions between complement pattern recognition molecules, complement 
regulators and opsonins result in the safe removal of apoptotic cells and immune 
complexes whilst also minimising off target, collateral damage. The ability to 
differentiate between severe threats and endogenous factors that currently pose no 
danger, such as apoptotic cells, but could affect cell survival if left unchecked, ensures 
that responses are appropriate. Residual expression of complement regulators on the 
surface of apoptotic cells prevents excessive late complement pathway amplification, 
stopping terminal MAC and induction of inflammatory cytokines (Ricklin et al., 2010). 
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Therefore, potentially harmful debris is removed without triggering danger signals and 
exaggerated immune responses. Furthermore, C3b/iC3b and CR3-mediated 
phagocytosis downregulates IL-12 and oxidative burst responses (Mevorach et al., 
1998; Kim, Elkon and Ma, 2004) to safeguard clearance without augmented 
inflammation. C1q has also been shown to downregulate pro-inflammatory cytokine 
secretion by monocytes (Fraser et al., 2006). Neurotrophins, such as nerve growth 
factor (NGF), are important for neuronal survival and function during development and 
in the adult brain. C5a and C3a induce secretion of NGF by astrocytes and microglia 
(Heese, Hock and Otten, 1998; Jauneau et al., 2006) therefore these anaphylatoxins 
may act to preserve neuronal function and abundance in both physiological and 
pathological conditions.  
Thus complement also plays an important role in the adult brain, ensuring that any 
debris and dying cells that could potentially cause harm are efficiently cleared without 
initiating any further inflammation whilst also promoting the survival of CNS cells in 
both physiological conditions and following injury.  
Despite evidence suggesting that complement is neuroprotective, there is a significant 
body of work demonstrating that complement activation paradoxically contributes to the 
pathogenesis of various neurodegenerative diseases. The role of complement 
activation in exacerbating neuroinflammatory disease and injury is highlighted by 
models in which inhibition of complement results in improved responses and decreased 
pathology; these models include ischaemia and stroke, multiple sclerosis and 
Alzheimer’s disease (Fonseca et al., 2004; Mocco et al., 2006; Elvington et al., 2012; 
Ramaglia et al., 2012). 
Inhibition of the alternative pathway results in improved neurologic function and 
demyelination in murine ischemic stroke models (Elvington et al., 2012). Additionally, 
concurrent deficiencies in classical and lectin pathway activators provided protection 
from cerebral ischemia-reperfusion injuries (Elvington et al., 2012). Disease 
progression in the EAE model of MS is more rapid and severe in Crry-/- mice (Ramaglia 
et al., 2012), suggesting that C3 products, the formation of which are negatively 
regulated Crry activity, the CR1 rodent orthologue, contribute to EAE pathogenesis. 
Furthermore, C3-/- mice have improved outcomes following focal cerebral ischaemia, 
including decreased infarct and neurological deficit scores (Mocco et al., 2006). C1q 
deficient AD mice had decreased loss of the synaptic markers synaptophysin and 
MAP2 in the CA3 hippocampus compared with controls (Fonseca et al., 2004), 
suggesting that classical complement activation is detrimental to synapse integrity. C1q 
is also found to be upregulated in glaucoma (Stasi et al., 2006) and may explain why 
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extensive synapse loss has been identified in the early stages of disease (Rosen and 
Stevens, 2010). Dysregulated synapse removal and altered synaptic activity is also 
found in the early stages of AD (Selkoe, 2002). 
In contrast to the pathological effects of complement activation in various disease 
models, C5a has been shown to be protective against apoptotic cell death in the EAE 
model of MS (Niculescu et al., 2004) and the kainic acid model of excitotoxicity via 
Erk1/2 inhibition of Caspase-3 (Osaka et al., 1999). Neurons in C5aR knockout mice 
are reportedly more vulnerable to glutamate excitotoxicity compared to WT mice due to 
a lack of C5a regulation of GluR2 subunit expression, resulting in augmented 
glutamate-mediated apoptosis (Mukherjee, Thomas and Pasinetti, 2008). Complement 
has also been shown to play a paradoxical and currently unclear role in Alzheimer’s 
disease-associated neuroprotection and pathogenesis, which will be discussed further 
in the next section. Therefore, different complement components may counteract each 
other and can be protective and detrimental at different stages of disease and 
development.  
1.5.2 Complement in Alzheimer’s Disease 
 
The presence of complement in Alzheimer’s pathology is well established; all native 
complement proteins as well as the terminal MAC are upregulated in the brains of 
confirmed AD patients (Shen et al., 1997; Yasojima et al., 1999) and C1q and C3c/d, 
C4c/d, C5-9 have all been found to interact with Aβ plaques (Afagh et al., 1996; 
Rozemuller et al., 2000).  Additionally, neurofibrillary tangles of phosphorylated tau, 
another classical hallmark of AD, are capable of activating complement via C1q binding 
(Shen et al., 2001). In vitro, it has been demonstrated that Aβ activates both the 
classical and alternative pathways via C1q and C3 binding (Rogers et al., 1992; Jiang 
et al., 1994). CR3 has also been shown to bind to Aβ and, in addition to being found to 
colocalise with Aβ plaques in AD brains (Strohmeyer et al., 2002), is involved in uptake 
and clearance of Aβ in vivo and in vitro (Maier et al., 2008; Choucair-Jaafar et al., 
2011; Fu et al., 2012). However, conflicting results using models of AD and 
complement deficiencies mean that it is unclear whether complement has a causative 
role or is a protective mechanism that is upregulated during the course of the disease.  
In the brains of C1q-/- Tg2576 AD mice, a similar Aβ load was found to that in the C1q 
sufficient mice however there was less microglial recruitment to plaques and decreased 
levels of synaptic marker loss (Fonseca et al., 2004), suggesting that complement 
activation in this model is detrimental. In APP23 mice treated with enoxaparin, which 
inhibits Aβ-induced complement activation, decreased Aβ load was found 
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(Bergamaschini et al., 2004), which indicates that complement plays a role in mediating 
neuropathology. The use of the C1 complex inhibitor C1-Inh, which is found at reduced 
levels in the plasma of AD patients,  protected cultured rat hippocampal cells from Aβ-
induced classical pathway activated lysis (Sarvari et al., 2003). The inhibitor CD59 is 
also reduced in the hippocampus and frontal cortex of AD patients (Yang et al., 2000), 
which would make cells more vulnerable to MAC-induced lysis, suggesting that 
dysregulation of complement in AD may contribute to neuronal loss. Inhibition of C1q, 
C3 or CR3 has recently been shown to be protective in models of AD against 
excessive synaptic removal by microglia in response to Aβ (Hong et al., 2016). Indeed, 
C1q and CR3 are both necessary for the toxic effects of Aβ on synapse function and 
long term potentiation in addition to engulfment of synapses, as demonstrated through 
the use of C1q-/- and CR3-/- AD models (Hong et al., 2016).  
Anaphylatoxins are thought to contribute to the neuroinflammatory aspect of 
Alzheimer’s disease due to their recruitment of microglia and astrocytes that, upon 
activation, release cytokines, proteases and reactive oxygen species that may 
accelerate neuronal damage and dysfunction. Tight regulation of complement is in 
place in healthy brains but this may go awry during the course of disease resulting in a 
neurotoxic microenvironment. Through the same mechanisms that improper synaptic 
connections are pruned in the developing brain, dysregulated complement could result 
in the removal of neurons, augmenting the neuronal loss found in Alzheimer’s disease. 
Despite the body of work suggesting that complement can be detrimental in the 
progression of AD, there is also evidence that complement plays a neuroprotective 
role. Complement opsonins play an important role in marking plaques, tangles and 
apoptotic cells for clearance. This removal of debris and immunogenic fragments from 
the brain minimises the risk of inappropriate immune responses being raised, which 
can cause damage to host cells. C3 cleavage products are thought to play an important 
role in amyloid plaque clearance since C3-/-  AD mice have an increased cortical and 
hippocampal plaque burden as well as increased neuronal loss (Maier et al., 2008). 
Furthermore, overexpression of Crry, a complement regulating receptor, in mouse AD 
model lead to increased Aβ pathology (Wyss-Coray et al., 2002).C1q has been found 
to be upregulated following injury or infection and is neuroprotective against Aβ-
induced toxicity and neuronal loss in vitro (Pisalyaput and Tenner, 2008) despite the 
fact that it is the activator of the classical pathway.  
Anaphylatoxins are also important for plaque and debris clearance as they recruit 
phagocytic cells to the area of injury or insult. Both neurons and glia express C5aR, the 
primary receptor for the potent anaphylatoxin C5a (Woodruff et al., 2010) and, in vitro, 
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C5a has been found to be directly neuroprotective to differentiated SH-SY5Y 
neuroblastoma cells against Aβ (O’Barr et al., 2001). C5a and C5aR may also 
contribute to signalling that augments phagocytosis (Lee, Whitfeld and Mackay, 2008; 
Tsuboi et al., 2011), as well as increasing microglial uptake of glutamate (Persson et 
al., 2009), a neuroprotective activity.  
Conflicting results on the effect of complement activation in AD could be due to the use 
of different animal modes, cells being at varying stages of differentiation or locations 
leading to different environmental cues and subtle changes in the net result of toxic and 
protective consequences of complement (Veerhuis, Nielsen and Tenner, 2011). 
Expression of all complement components have been found to be upregulated by CNS 
injury and disease, including AD (Walker and McGeer, 1993), likely in an attempt to 
increase the activity of neuroprotective factors. However, as pathology worsens and 
induces dysfunction of complement and complement-producing cells, dysregulation of 
complement factors to a harmful level could lead to amplification of inflammation and 
propagation of a neurotoxic environment. 
In addition to in vitro and in vivo studies of complement interactions with AD pathology 
and the effect of complement knockout in animal models of AD, GWAS have identified 
common genetic variations in CR1,  as a risk factor for the development of late-onset 
AD along with CLU (Harold et al., 2009; Lambert et al., 2009), which encodes for 
clusterin, a regulator of MAC. CR1 is a regulator of complement activation and the 
identification of a genetic link between complement regulators and an increased risk of 
developing AD further highlights the importance of maintaining the fine balance 
between the neuroprotective and neurotoxic effects of complement activation. 
1.5.3 CR1 
 
Complement receptor type 1 (CR1), also known as CD35 or C3b/C4b receptor, is a 
single chain, type-1 transmembrane glycoprotein that is expressed widely in 
erythrocytes, B cells, polymorphonuclear cells and macrophages. CR1 is a 
multifunctional receptor which acts to clear immune complexes from the blood, induce 
phagocytosis of immune complexes and inhibit complement activation. The 
extracellular domain of CR1 is made entirely of 30 short consensus repeats (SCRs), 
each containing 60-70 amino acids. There is also a transmembrane domain and a 
short 41 amino acid intracellular domain, which is thought to be too small to be an 
enzyme but may interact with the cytoskeleton to mediate phagocytosis (Ahearn and 
Fearon, 1989). Every eighth SCR is a highly homologous repeat so that seven SCRs 
form a long homologous repeat (LHR). The functions of CR1 are mediated by two 
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distinct but extremely similar sites, each made up of 3 SCRs (Figure 1.3). The multiple 
ligand binding sites on the receptor mean that CR1 is well suited for interacting with 
complexes containing multiple C3b and C4b molecules, such as the polymers of C3b 
and C4b that cluster on the surface of immune complexes. 
In humans, the CR1 gene can be found on chromosome 1q32 on a locus termed the 
Regulatory of Complement Activation (RCA), alongside the genes for CR2, DAF, C4-
binding protein, Factor H and MCP (Ahearn and Fearon, 1989). Host cells express 
these membrane-bound complement regulatory proteins to prevent complement-
mediated autologous tissue damage (Miwa and Song, 2001). These proteins all have 
C3b/C4b binding properties and the same basic structural element of the SCRs as 
CR1. 
 
 
 
 
 
 
CR1 prevents the activation of the alternative pathway at multiple stages (Ross et al., 
1982) acting to reduce the formation of the C3b opsonin, which can act as an initiator 
of further complement activation. Firstly CR1 impairs the uptake of factor B by C3b, 
minimising the formation of the C3 convertase. It also displaces Bb from the C3 
convertase to prevent the cleavage of C3 into more C3b. Finally it promotes factor I 
cleavage of C3b to the inactive form iC3b, which is unable to sustain or amplify the 
complement cascade. Therefore, CR1 not only displaces components of the 
convertases, but irreversibly inactivates them. 
In addition to its role in regulation of complement activation, CR1 expression on the 
surface of erythrocytes is important for the transportation of C3b/C4b opsonised 
antigens and immune complexes through the blood to the liver and spleen for 
Figure 1.3: Schematic of CR1 A and B allele structures 
The CR1 gene is made up of long homologous repeats (LHRs) each composed of seven short consensus 
repeats (SCRs). CR1-A/F and CR1-B/S are the two most frequently occurring alleles and are defined by 
the number of LHRs.  
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clearance, preventing the nonspecific trapping of immune complexes in tissues. CR1 
plays a role in neutrophil- and monocyte-mediated phagocytosis by enhancing Fc 
receptor-dependent phagocytosis of IgG and C3b-opsonised particles and immune 
complexes, particularly following activation by cytokines (Wright and Silverstein, 1982; 
Fällman, Andersson and Andersson, 1993). The two receptor types work synergistically 
as ligation of CR1 by target-bound C3b may direct Fc receptors to sites where an 
interaction with target-bound IgG is more likely to occur.  
There are four different allotypes of CR1, the differences between which are found in 
the extracellular domain. Each one contains varying numbers of LHRs, hence the 
difference in size being roughly equivalent to a single LHR (~30kDa or 1.3-1.5kb) 
(Khera and Das, 2009). The number of LHRs is determined by the number of 18-kb 
long low-copy repeats (LCRs); the most common allele has LCR1 & LCR2 but CR1-
B/S also possesses LCR1’ which results in the additional C3b/C4b binding site (see 
Figure 1.3) (Brouwers et al., 2012). The other isoforms result from a triplication or 
deletion of one LCR1 copy producing allotypes with varying numbers of C3b/C4b 
binding sites. 
CR1 Allotype Molecular Weight Frequency 
CR1-C (or F’) 190kDa 0.01 
CR1-A (or F) 220kDa 0.83 
CR1-B (or S) 250kDa 0.15 
CR1-D 280kDa <0.01 
Table 1.1 Frequencies and molecular weights of CR1 allotypes 
The frequencies of expression within the general population vary between the different CR1 allotypes, with 
CR1-A/F being the most common (Holers et al., 1987). The molecular weights vary depending on the 
number of LHR repeats within the gene. 
 
1.5.4 CR1 in Alzheimer’s Disease 
 
A GWAS published in 2009 by Lambert et al. first identified a linkage disequilibrium 
block within CR1 as being associated with increased risk of developing late onset 
Alzheimer’s disease (Lambert et al., 2009). Since then, nine small nuclear 
polymorphisms (SNPs) in CR1 have been found to be associated with Alzheimer’s 
disease (Harold et al., 2009; Lambert et al., 2009; Carrasquillo et al., 2010; 
Hollingworth et al., 2011; Naj et al., 2011). Six of these are in the intronic region of CR1 
so do not encode for the protein but may function in regulating gene expression levels. 
The SNP rs6656401 showed the strongest association with AD (odds ratio of 1.21) 
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(Lambert et al., 2009) and has also been found to be associated with greater cognitive 
decline and vascular and neuritic plaque Aβ pathology (Chibnik et al., 2011; Biffi et al., 
2012; Farfel et al., 2016). Associations of the rs6656401 SNP with AD have been 
extended beyond European Caucasians and has been found to have an increased OR 
of 1.31 in East Asian populations (Shen et al., 2015). Lambert et al. showed an 
interaction between rs6656401 CR1 SNP and APOE genotype, with the strongest 
association found in APOE ε4 carriers. Another CR1 SNP that has been found to have 
significant association with AD risk is rs3818361, which had an odds ratio of 1.14, 
however no association was found between this SNP and  APOE ε4 carriers (Jun et al., 
2010). In a study investigating associations between AD risk SNPs and disease 
progression in patients, carriers of the G allele of the rs3818361 SNP had higher rates 
of medium-term disease progression as measure by annual MMSE loss (Schmidt et al., 
2014). 
It was thought that CR1 might be involved in clearance of Aβ from the brain since Aβ is 
known to activate complement by binding to C1q and also binding to C3b opsonins. In 
plasma, C3b mediates binding of Aβ peptides to erythrocyte-expressed CR1, a process 
aberrantly regulated in the early stages of AD (Rogers et al., 2006). The peripheral sink 
hypothesis states that Aβ can be cleared from the brain by Aβ-binding molecules in the 
periphery, hence CR1 variants may contribute to AD by altering the clearance of Aβ in 
the periphery or complement activation in the brain. 
Further work has shown that the common AD risk association could be explained by 
expression of the CR1-S allotype, which contains an additional C3b/C4b binding site, 
as carriers of this longer form of CR1 had around 30% increased risk for AD compared 
with those expressing CR1-F (Brouwers et al., 2012). CR1-S expression occurs at a 
frequency of 15% in the population and has an extra C3b/C4b binding site compared to 
the more common CR1-F. The authors also showed that the LCR (low copy repeat) 
copy number variation that causes the expression of the longer form of CR1 was in 
high linkage disequilibrium with the most highly associated risk factor SNP rs6656401, 
suggesting that that the CR1 association with AD can be explained by the intragenic 
copy number variation resulting in increased C3b/C4b binding sites in CR1-S 
compared to CR1-F.  
CR1-S, due to its increased cofactor activity sites, may be a more potent inhibitor of 
complement cascade amplification leading to a reduction in C3b available to opsonise 
Aβ and also a reduced complement reaction.  Studies in mouse AD models have 
shown that inhibition of complement activation correlated with increased Aβ plaque 
formation and damage to neurons  (Maier et al., 2008). Despite the fact that excessive 
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complement activation causes neurotoxic inflammation (Afagh et al., 1996; Fonseca et 
al., 2004), the association between increased AD risk and the longer isoform of CR1 
could suggest that the over-inhibition of complement is more damaging. 
However, four other SNPs have been linked to elevated cerebrospinal fluid levels of 
Aβ1-42 in AD patients (Brouwers et al., 2012) suggesting that CR1 variants may be 
pathogenic via an Aβ-associated effect. It has since been discovered that the CR1-S 
isoform is expressed at lower protein levels in the brain than CR1-F in both AD patients 
and controls, with CR1-S AD cases having higher Braak stages than CR1-F 
homozygous carriers (Hazrati et al., 2012). Analysis of the expression levels of CR1 on 
erythrocytes of AD patients and controls showed that there was lower surface 
expression of CR1 in AD cases compared to controls in groups expressing the CR1-S 
isoform (Mahmoudi et al., 2015). The level of CR1 protein expression on erythrocytes 
was not the only considerable difference between allotype carriers; individuals with F/S 
genotype had a 1.8 times increased risk for AD compared to F/F genotype carriers and 
each genotype had distinct protein expression patterns in neurons. The neuronal CR1 
staining in F/F genotype samples was threadlike, filiform profiles in the soma and 
proximal segments of the dendrites whereas the F/S genotype has vesicular, dot-like 
punctate profiles. This difference in distribution suggests that the CR1-F may shuttle 
through protein sorting organelles whilst CR1-S accumulates in the membrane of 
cytoplasmic vesicles (Hazrati et al., 2012). A decrease in expression levels of CR1 
would mean that there are fewer C3b/4b binding sites available on the surface of the 
cell to bind opsonised Aβ, despite the fact that the few CR1 molecules present each 
have a greater than average number of binding sites. This could result in impaired 
clearance of Aβ from both the periphery and the brain, allowing accumulation of 
neurotoxic fibrils and plaques. Additionally, the reduction in total C3b/C4b binding sites 
leads to inefficient regulation of complement activation resulting in toxic 
neuroinflammation that can cause neurodegeneration. 
1.5.5 C1q  
 
C1q is a pattern recognition molecule which, through its ability to recognise and bind a 
wide range of self and non-self ligands, is the initiator of the classical pathway of 
complement activation.  C1q is the first subunit of the C1 complex which is recruited 
following C1q ligand binding and comprises the C1r and C1s serine proteases. These 
serine proteases initiate sequential cleavage of various complement proteins 
generating the components required for the formation of the C3-convertase complex, in 
addition to the anaphylatoxin C4a. The C3 convertase cleaves C3 into C3a and C3b 
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which is also a pattern recognition molecule that mediates CR3 phagocytosis as well 
as contributing to the formation of the C5 convertase, which later forms the terminal 
MAC complex.  
C1q is expressed by a wide variety of cells including macrophages, microglia, mast 
cells, dendritic cells and oligodendrocytes (Schwaeble et al., 1995; Hosokawa et al., 
2003; Färber et al., 2009; Castellano et al., 2010; van Schaarenburg et al., 2016). 
Furthermore, expression is induced in other cell types, such as astrocytes and neurons 
during specific stages of development or following infection or injury (Fan and Tenner, 
2004; Rambach et al., 2008; Bialas and Stevens, 2013). There are two primary 
receptors for C1q; calreticulin (cC1qR) which binds the collagen-like, ‘stem’ domain 
and gC1qR which binds the globular, ‘tulip-head’ domains.  
In addition to initiating complement cascades through the generation of C3b opsonins, 
C1q has been shown to play roles in enhancing phagocytic clearance of apoptotic cells 
(Païdassi et al., 2008) and immune complexes as well as maturation of dendritic cells 
(Csomor et al., 2007), activation of microglia (Färber et al., 2009) and induction of 
expression of neuroprotective factors (Benoit and Tenner, 2011). C1q is upregulated in 
the developing brain (Stevens et al., 2007; Bialas and Stevens, 2013) and plays an 
essential role in the refinement of synaptic networks during development, as 
demonstrated by C1q defective mice developing behavioural seizures and epileptoform 
activity (Chu et al., 2010). 
C1q has a hexameric, tulip-like structure comprised of 6 heterotrimeric collagen-like 
fibres each topped with a C-terminal globular domain. These globular domains mediate 
C1q’s ability to recognise a wide range of ligands including immunoglobulins, altered 
and misfolded endogenous proteins, such as prion protein, Aβ and apoptotic cells, as 
well as molecular motifs on bacteria and viruses (Albertí et al., 1993; Stevens et al., 
2007; Erlich et al., 2010; Fraser, Pisalyaput and Tenner, 2010; Gaboriaud et al., 2011). 
The binding of C1q to Fc regions of IgG is strengthened by up to 1000-fold by the 
presence of multiple, clustered Fc regions, such as those found in immune complexes 
(Kishore and Reid, 2000). 
1.5.6 Complement Receptor 3 
 
The complement receptor 3 (CR3), also known as Mac-1, CD11b/CD18, or integrin 
αMβ2, is an extremely versatile pattern recognition receptor best known for its role as a 
phagocytic receptor of C3b/iC3b opsonised particles, however it also regulates 
cytokine responses, leukocyte trafficking and synapse formation (Whitlock et al., 2000; 
 
 58 
 
Kinashi, 2005; Phillipson et al., 2006; Stevens et al., 2007). It is a member of the β2 
integrin family, a family of heterodimeric transmembrane receptors which are all 
composed of a CD18 β chain associated with a variable α chain, the composition of 
which defines the receptor. The other members are LFA-1 (CD11a/CD18), CR4 
(CD11c/CD18) and adβ2 (CD11d/CD18). 
CR3 is a pattern recognition receptor with the ability to recognise a vast array of host 
and non-host ligands including, but not limited to, ICAM-1 (Diamond et al., 1990), 
fibrinogen (Wright et al., 1988) and LPS (Wright and Jong, 1986). The CD11b I domain 
binds ICAM-1, iC3b and fibrinogen whilst a lectin-like domain recognises mannose and 
β-glucans (reviewed by (Ehlers, 2000)). It is expressed on monocytes, macrophages, 
microglia, dendritic cells and neutrophils. 
Information on the multiple roles of CR3 has been ascertained from natural and 
artificially generated knockouts. LAD syndrome (leukocyte adhesion deficiency) is 
caused by decreased or total absence of β2 integrin surface expression arising from 
mutations in CD18 component. Patients present with defective pus formation and 
wound healing due to defective leukocyte adhesion, migration and phagocytosis 
(Larson and Springer, 1990; Hogg et al., 1999), highlighting the importance of β2 
integrins and CR3 in the response to infection and injury. In order to investigate the 
effects of mutations on CR3 in isolation from the other β2 integrins, mutations and 
knockouts of the unique CD11b component of the receptor have been studied. Lupus-
associated mutations in CD11b reduced CR3-mediated phagocytosis of iC3b-
opsonised particles in monocytes, macrophages and neutrophils (Rhodes et al., 2012; 
Fossati-Jimack et al., 2013). CD11b-/- models of CR3 knockout have shown that 
adhesion between neutrophils and epithelial cells during migration is mediated by CR3 
(Balsam, Liang and Parkos, 1998) and CR3 is required for maintenance of mast cells 
for bacterial clearance in a model of acute sepsis (Rosenkranz et al., 1998). Defective 
phagocytosis has been reported in neutrophils from CR3-/- mice as well as impaired 
adherence and degranulation (Lu et al., 1997). CR3 also exerts anti-inflammatory 
effects. CD11b deficiency leads to increased inflammatory cytokine and interferon 
release following TLR4 stimulation in macrophages (Han et al., 2010) whilst 
phagocytes downregulate IL-12 and oxidative bursts performing CR3-mediated uptake 
of C3b/iC3b-opsonised particles (Marth and Kelsall, 1997; Kim, Elkon and Ma, 2004) 
CR3 has been reported to phagocytose opsonised and non-opsonised zymosan in type 
I and type II phagocytosis (Le Cabec et al., 2002). Type 1 phagocytosis is usually 
mediated by FcγR receptors binding to IgG-coated particles and results in RAC and 
Cdc42-mediated membrane ruffling to engulf material. Type II involves C3b/iC3b 
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particles that sink into the membrane and only requires RhoA (Caron and Hall, 1998). It 
has also been shown to be involved in antibody mediated phagocytosis as CD18-
deficient macrophages had reduced phagocytosis of IgM and IgA opsonised C. 
neoformans (Taborda and Casadevall, 2002).  
Various studies have indicated that CR3 cooperation with other surface expressed 
receptors is important for its optimal functioning. In the case of LPS, CR3 can bind 
particles in both a CD14 independent and dependent manner (Zarewych et al., 1996), 
resulting in NF-κB signalling and iNOS production by macrophages (Matsuno et al., 
1998).CR3 has also been shown to interact with CR1 to induce conversion of particle 
bound C3b to C3bi for more effective uptake by phagocytosis (Sutterwala, Rosenthal 
and Mosser, 1996). CR3 also cooperates with FCγRIII to stimulate respiratory burst 
and antibody-dependent phagocytosis (Krauss et al., 1994; Zhou and Brown, 1994).  
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1.6 Aims 
 
1) Determine suitability of iPSC-derived microglia-like cells (iPSC-MGLC) as a model of 
human microglia 
- Characterise expression of genes identified as unique to the microglial 
transcriptome signature (Butovsky et al. 2014). 
2) Characterise TREM2 expression in knockdown and mutation-harbouring microglia 
cell lines 
- Characterise CRISPR/Cas9 edited BV2 microglial cell lines in which one or 
two copies of TREM2 gene have been knocked out 
- Assess effects of patient-derived TREM2 mutations on the expression of 
TREM2 in iPSC-MGLC  
3) Identify resultant defective responses following TREM2 loss of function in gene 
edited cell lines and mutation carrying iPSC-MGLC 
- Assess effects on key microglial and TREM2-associated functions including 
phagocytosis and cytokine secretion 
4) Investigate expression of CR1 in human CNS  
- Establish expression at both whole tissue and individual cell type level 
- Investigate crosstalk between TREM2 and CR1 to further understand 
potential AD pathogenesis mechanisms 
5) Assess suitability of iPSC-MGLC for the study of other microglial genes associated 
with Alzheimer’s disease 
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2. Materials and Methods 
2.1 Materials 
 
A: Adenosine triphosphate disodium salt (ATP, >99% purity, Tocris, Bristol, United 
Kingdom) 
B: Bone morphogenetic protein 4 (BMP-4, human, >98% purity, Peprotech, Rocky Hill, 
New Jersey, United States), Bovine serum albumin (BSA, Sigma-Aldrich, St. Louis, 
Missouri, United States), Bradford reagent (Sigma-Aldrich) 
C: C1q Human ELISA Kit (Thermo Fisher Scientific, Waltham, Massachusetts, United 
States), CD14 MicroBeads (human, Miltenyi Biotec, Bergisch Gladbach, Germany), 
Cell filter (40µm nylon, BD Bioscience Franklin Lakes, New Jersey, United States), 
Complement component 5a (C5a, mouse, >97% purity, R&D Systems, Minneapolis, 
Minnesota, United States), CytochalasinD (Santa Cruz Biotechnology, Dallas, Texas, 
United States) 
D: DAB kit (3,3'-diaminobenzidine, Vector Laboratories, Peterborough, United 
Kingdom), Dextran 500 (Sigma-Aldrich), Duoset ELISA kits (R&D Systems), 
E: E8 medium (Thermo Fisher Scientific), Ethylenediaminetetraacetic acid (EDTA, 
Sigma-Aldrich) 
F: Foetal bovine serum (FBS, heat-inactivated, endotoxin free, Thermo Fisher 
Scientific) 
G: Glutamax (Thermo Fisher Scientific), 
H: Halt™ Protease and Phosphatase Inhibitor Single-Use Cocktail (100x, Thermo 
Fisher Scientific), Hanks’ balanced saline solution (HBSS, Thermo Fisher Scientific), 
HiFi HotStart Ready Mix (Roche, Basel, Switzerland), High-capacity RNA-cDNA kit 
(Thermo Fisher Scientific), Histopaque (Sigma-Aldrich), 
I: Interleukin-3 (IL-3, human, >95% purity, Cell Guidance Systems, Cambridge, United 
Kingdom) 
L: Lipopolysaccharide (Sigma-Aldrich) 
M: Macrophage colony-stimulating factor (MCSF, human, >98% purity, Peprotech), 
Macrophage colony-stimulating factor (MCSF, mouse, >98% purity, Peprotech), MACS 
separator (Miltenyi Biotec), MaxiSORP 96 well plates (Nunc, Roskilde, Denmark), β-
mercaptoethanol (Thermo Fisher Scientific), Mini-PROTEAN TGX Precast Gels 
(Biorad, Hercules, California, United States), miRNeasy mini kit (QIAGEN, Hilden, 
Germany) 
N: Nitrocellulose membrane (Biorad), NucleofectorTM SF-kit (Lonza, Basel, 
Switzerland), NuPAGE sample reducing agent (10x, Thermo Fisher Scientific) 
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P: Paraformaldehyde (16% tissue culture grade, Alfa Aesar, Ward Hill, Massachusetts, 
United States), peptide:N-gycosidase (PNGase, New England Biolabs, Ipswich, 
Massachusetts, United States), Penicillin/streptomycin (Thermo Fisher Scientific), 
Phalloidin CF568 (Biotium, Fremont, California, United States), Phosphate-buffered 
saline (PBS, without calcium chloride and magnesium chloride, Thermo Fisher 
Scientific), pHrodo green E. coli BioParticles conjugated for phagocytosis (Thermo 
Fisher Scientific), Precision Plus Protein™ All Blue Prestained Protein Standards 
(Biorad) 
Q: QIAzol (QIAGEN) 
R: RNase-free DNase set (QIAGEN), RNeasy mini kit (QIAGEN), ROCK inhibitor Y-
27632 (Cell Guidance Systems), Roswell Park Memorial Institute medium 1640 (RPMI, 
Thermo Fisher Scientific) 
S: Sample loading buffer (4x, Li-cor, Lincoln, Nebraska, United States), Stem cell factor 
(SCF, human, >97% purity, Miltenyi Biotec), Streptavidin-HRP (horseradish 
peroxidase, Thermo Fisher Scientific) 
T: TaqMan probes (Thermo Fisher Scientific), TaqMan universal mastermix II (Thermo 
Fisher Scientific), TMB (3,3',5,5'-tetramethylbenzidine, Thermo Fisher Scientific), TrpLE 
Express Enzyme (Thermo Fisher Scientific), Tween (Sigma-Aldrich) 
V: Vascular endothelial growth factor (VEGF, human, >98% purity, Peprotech), 
Versene (Lonza), Vectashield antifade mounting medium with DAPI (4',6-diamidino-2-
phenylindole, Vector Laboratories), Vectastine Elite ABC HRP kit (horseradish 
peroxidase, Vector Laboratories) 
X: XL cytokine proteome array (mouse, R&D Systems), X-vivo 15 medium (Lonza) 
 
2.2 BV2 Cell Culture & Maintenance 
 
The BV2 cell line is an immortalised murine microglial line generated by transfecting 
primary microglial cell cultures with a v-raf/v-myc oncogene carrying retrovirus (J2) 
(Blasi et al., 1990). BV2 cells were obtained from the Banca Biologica and Cell Factory 
(Genoa, Italy) and cultured according to Blasi et al, 1990. BV2 cells were cultured in 
T175 culture flasks in Roswell Park Memorial Institute (RPMI) 1640 medium 
supplemented with 10% heat-inactivated foetal bovine serum (FBS), 100 U/ml 
penicillin/streptomycin in a humidified incubator at 37°C with 5% CO2. For passaging 
and plating cells for experimental procedures, BV2 cells were harvested by washing 
and incubation with Dulbecco’s phosphate buffered saline (PBS, without calcium 
chloride and magnesium chloride) for 5 minutes at 37°C followed by tapping of the 
flasks to lift the cells. The cells were then pelleted by centrifugation at 300 g for 3 
minutes at room temperature (Eppendorf Centrifuge 95 5804R) and resuspended in 10 
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ml of warmed fresh medium. For quantification of cell number, 10 µl of the cell 
suspension was administered to a haemocytometer, and cells in four quadrants were 
counted, which equated to the number of cells present in 0.1 µl of the suspension 
volume. For experimental procedures, BV2 cells were plated in medium supplemented 
with FBS in order to encourage cell attachment, which was changed to serum-free 
medium prior to sample collection where required. 
2.3 Primary Cell Culture 
2.3.1 Human Neutrophil Isolation 
 
Phlebotomy was performed with 60 ml of blood taken from each subject into heparin 
coated tubes. This study was approved by University College London (UCL)/UCL 
Hospitals Joint Research Ethics Committee and all subjects gave informed written 
consent. Neutrophils were isolated using a standard protocol (Nauseef, 2007). The 
heparinised blood was mixed at a 2:1 ratio with 3% Dextran 500/HBSS solution in a 50 
ml falcon tube and incubated in an upright position for 60 minutes at room temperature 
upon which two layers will form. The upper, leukocyte-rich plasma layer was collected 
and cells were pelleted by centrifugation at 4°C for 6 minutes at 460 g. The supernatant 
was discarded and the cell pellet was resuspended in 25 ml ice-cold PBS (without 
calcium chloride and magnesium chloride) by gently tapping and swirling the tube. 
Resuspended cells were gently layered over 15 ml Histopaque and centrifuged at 720 
g for 20 minutes at room temperature with low acceleration and low brake. Using a 
pipette, the peripheral blood mononuclear cell (PBMC) layer was collected and saved 
for monocyte isolation (see 2.3.2 Human Blood-derived Monocyte Isolation). The 
Histopaque and PBS were removed leaving a cell pellet containing erythrocytes and 
granulocytes, including neutrophils. In order to lyse the erythrocytes, the pellet was 
resuspended in 1 ml of ice cold double distilled water (ddH2O) for 20 seconds, upon 
which the isotonicity was quickly rebalanced through the addition of 50 ml PBS. The 
cells were centrifuged at 4°C for 6 minutes at 460 g. If the cell pellet was still red, the 
lysis and centrifugation steps were repeated until the resulting pellet was white. Cells 
were then resuspended in pre-warmed RPMI medium and counted prior to lysis in 
QIAzol for RNA analysis. 
2.3.2 Human Blood-derived Monocyte Isolation 
 
The same samples used for the isolation of neutrophils (see 2.3.1 Human Neutrophil 
Isolation) were used for the isolation of monocytes using standard protocols. Magnetic 
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CD14 MicroBeads (Miltenyi Biotech) were used to positively select monocytes 
(Ohradanova-Repic et al., 2016), which highly express CD14 (Haugen et al., 1998), 
from the PBMC layer generated using Histopaque separation, according to the 
manufacturer’s instructions (Miltenyi Biotech). The samples were centrifuged at 300 g 
for 10 minutes, the cell pellet was resuspended in 80 µl MACS buffer (PBS, 0.5% 
bovine serum albumin (BSA) 2mM EDTA) and 20 μl Microbeads per 107 cells, and left 
to incubate at 4°C for 15 minutes. Cells were washed with MACS buffer, centrifuged, 
resuspended in 500 μl of MACS buffer, and applied to a rinsed MACS LS cell 
separation column. The column was placed in the magnetic field of a MACS separator 
in order to positively select the CD14 positive cells. Unlabelled cells passed through the 
column during the 3 wash steps. The magnetically labelled cells were flushed from the 
column following the washes using the plunger. CD14 positive monocytes were 
counted using a haemocytometer and were lysed for RNA analysis or plated to 
differentiate into monocyte-derived macrophages (see 2.3.3 Human Monocyte-Derived 
Macrophages). 
2.3.3 Human Monocyte-Derived Macrophages 
 
Human blood-derived monocytes (see 2.3.2 Human Blood-derived Monocyte Isolation) 
were differentiated to generate macrophages using standard protocols (Rey-Giraud et 
al., 2012; Erbel et al., 2013). Monocytes were plated at a density of 5 x 105 in a 6 well 
plate in X-Vivo medium supplemented with 100 U/ml penicillin/streptomycin, 1% 
Glutamax and 100 ng/ml human MCSF for 6 days to differentiate into monocyte 
derived macrophages. 
2.4 Generation of human induced Pluripotent Stem Cell-derived 
Microglia-like Cells (iPSC-MGLC) 
 
For the experiments performed in this thesis, iPSC lines were generated and 
characterised at the NIHR Cambridge Biomedical Research Centre Human Induced 
Pluripotent Stem Cells core facility (Cambridge, United Kingdom). iPSCs were 
differentiated into microglia-like cells (iPSC-MGLC) by Dr Pablo Garcia Reitbӧck and 
Dr Thomas Piers, Cell Signalling Lab, UCL Institute of Neurology. Unless otherwise 
stated, the characterisation and functional experiments using the differentiated cells 
were performed by me, Alexandra Phillips.  
TREM2 mutant primary fibroblast lines were generated from 4mm skin punch biopsies, 
which were obtained under informed consent. Ethical permission for this study was 
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obtained from the National Hospital for Neurology and Neurosurgery and the Institute 
of Neurology joint research ethics committee (study reference 09/H0716/64 for 
collection of W50C mutant fibroblasts) or approved by the Ethics Committee of Istanbul 
Faculty of Medicine, Istanbul University (for collection of T66M mutant fibroblasts). 
iPSC were generated from fibroblast cultures using 4 factor Sendai virus 
reprogramming and characterised by RT-PCR for plasmid integration, 
immunofluorescence for expression of pluripotent markers, and 3-germ layer 
differentiation (Brownjohn et al., in preparation) at the NIHR Cambridge Biomedical 
Research Centre Human Induced Pluripotent Stem Cells core facility (Cambridge, 
United Kingdom). Chromosomal abnormalities were also checked for by karyotyping 
and CNV analysis using OmniExpress-24 chips run on the Illumina Infinum platform by 
the NIHR Cambridge Biomedical Research Centre Human Induced Pluripotent Stem 
Cells core facility. The following control iPSC lines were used: CTRL1 (kindly provided 
by Dr Selina Wray, UCL Institute of Neurology), ND (referred to as CTRL2 in this 
thesis, from Coriell Institute of Medical Research Biorepository, kindly provided by Dr 
Rickie Patani, UCL Institute of Neurology), and SFC840 (referred to as CTRL3 in this 
thesis, kindly provided by Dr Sally Cowley, University of Oxford). iPSC colonies were 
maintained in E8 medium, and split every 4-5 days using Versene. iPSC colonies were 
differentiated within 5 passages. 
Human iPSC-derived microglia-like cells (iPSC-MGLC) were generated using recently 
published protocols (Van Wilgenburg et al., 2013), with minor modifications. To 
generate embryoid bodies at day 0 in vitro (D0), iPSC colonies at 60-80% confluence 
were dissociated for 4 min with TrypLE, collected in 10 x the volume of PBS (without 
calcium chloride and magnesium chloride), pelleted for 3 min at 300 g and 
resuspended in 1 ml EBDiff medium (E8 medium with 10 µmol Y27932 ROCK inhibitor, 
50 ng/ml BMP-4, 50 ng/ml VEGF, 20 ng/ml SCF). Cells were counted and diluted in 
EBDiff medium to give a density of 105 cells/ml, and 100 μl was added to each well of 
an ultra-low adherence 96 well plate to give 104 cells/well. Plates were centrifuged at 
115 g for 3 min, and gently transferred to a tissue culture incubator at 37°C with 5% 
CO2. On D2, 50 µl of EBDiff medium was gently added to each well. On D4, embryoid 
bodies were collected with a P1000 Gilson pipette, transferred into a 15 ml Eppendorf 
tube, and left to settle at the bottom. The old medium was aspirated and myeloid 
differentiation medium (X-vivo 15 medium supplemented with 1% Glutamax, 10U 
Penicillin/Streptomycin and 0.05 mM mercaptoethanol, with 100 ng/ml MCSF and 25 
ng/ml IL-3 added. Approximately 150 embryoid bodies were transferred into a 175 cm2 
flask. Myeloid differentiation medium was changed every 5-7 days, making sure that 
the medium did not become acidotic. After 3-4 weeks, iPSC-MGLC were harvested 
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once a week by replacing 2/3 of the medium and filtering the cells through a 40µm tube 
filter. Harvested iPSC-MGLC were further differentiated in X-Vivo 15 medium with 1% 
Glutamax, 100U Penicillin/Streptomycin and 100 ng/ml MCSF. iPSC-MGLC were used 
for experiments 7 days post harvesting. 
 
Table 2.1 Table of iPSC lines used  
iPSC line Age Sex Clinical Details 
TREM2 
mutation 
CTRL1 78 M Control No mutation 
CTRL2 64 M Control No mutation 
CTRL3 31 F Control  No mutation 
T66Mhet1 75 F 
Unaffected relative of 
T66Mhom 
Heterozygous 
T66M 
T66Mhet2 47 M 
Unaffected relative of 
T66Mhom 
Heterozygous 
T66M 
T66Mhom 51 F Nasu Hakola disease 
Homozygous 
T66M 
W50Chom 36 F Nasu Hakola disease 
Homozygous 
W50C 
R47Hhet1 75 F Alzheimer’s disease 
Heterozygous 
R47H 
R47Hhet2 54 F 
Possible Alzheimer’s 
disease (MCI, anxiety 
disorder) 
Heterozygous 
R47H 
BionCtrl 19 M Control No mutation 
BionR47H 19 M 
Control modified to 
insert mutations 
Homozygous 
R47H 
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2.5 CRISPR/Cas9 Mediated Generation of TREM2 Knockdown and 
TREM2 Knockout BV2 Cell Lines 
 
CRISPR/Cas9 gene editing technology was used to generate TREM2 knockout lines 
from mouse BV2 microglial cells by Claudio Villegas-Llerena, Cell Signalling Lab, UCL 
Institute of Neurology. Characterisation and functional experiments utilising these 
gene-edited lines were, unless otherwise stated, performed by me, Alexandra Phillips. 
BV2 cells were transfected with CRISPR/Cas9n nickase plasmids targeting the second 
exon of the Trem2 gene (SC-429903-NIC; Santa Cruz Biotechnology Inc.) using the 
NucleofectorTM SF-Kit for 4DNucleofectorTM according to manufacturer’s 
recommendations. Selection of GFP positive clones and single cell sorting was carried 
out using a fluorescence activated cell sorter 48 hours post-transfection. Single cell 
clones were then cultured and expanded with serum containing RPMI (10% FBS) for 2 
weeks followed by screening for genetic modifications in Trem2 by PCR amplification 
and Sanger sequencing (Source Bioscience). PCR amplification for sequencing 
analysis was performed in a 25 μl reaction volume. PCR mix was composed of the 
following; 5μl x 1 μM of each Forward and Reverse primers (Fw-sT2; 
ACCCAAGGACCAGAACTTATC, Rv-sT2; TCCCATTCCGCTTCTTCAG) 12.5 μl 2x 
KAPA HiFi HotStart Ready Mix and 2.5 μl of gDNA (~12.5ng). PCR was conducted in a 
Mastercycler benchtop thermocycler (Eppendorf, Germany). Cycling conditions were 
as follows: 3 min at 95°C, followed by 35 cycles of amplification (30 sec at 95°C, 30 sec 
at 62°C and 30 sec at 72°C) and 5 min at 72°C. 
No full knockout (Trem2-/-) clones were obtained in the first round of CRISPR/Cas9n 
modification. We obtained 6 cell clones with partial Trem2 knockout, referred to as 
TREM2 knockdown clones (Trem2+/-: 1 allele KO and 1 WT allele); of those we 
selected two for further experimentation; clones BV2-A7 (4bp deletion) and BV2-C8 
(34bp deletion). Confirmation of heterozygous mutations was performed with Single 
colony Sanger sequencing of PCR products. 
A second round of CRISPR/Cas9n modification was carried out using the previously 
modified clone BV2-C8. The second round of CRISPR/Cas9n modification was 
performed as described previously. Selection of clones was performed by PCR 
amplification, enzyme restriction and Sanger sequencing. After selection, we obtained 
3 clones with homozygous 23 bp deletions in Trem2, rendering these clones complete 
Trem2 knockout. Two were selected for further experimentation: clones BV2-B5 and 
BV2-G4. 
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2.6 Cell Treatments 
 
Cells were routinely plated 24 hours prior to treatment. ATP and MCSF treatments 
were performed in serum free medium. Cells were treated as follows: 
Table 2.2 Cell culture treatments 
2.7 Microscopy 
 
2.7.1 Immunocytochemistry 
 
For immunocytochemical analysis of protein expression, cells were plated on 13mm 
glass coverslips at a density of 5,000 cells per coverslip. Following the required 
treatment, cells were washed in PBS, fixed in 4% paraformaldehyde (PFA) for 20 
minutes at room temperature and washed again in PBS. Coverslips were stored in PBS 
at 4°C until use. 
For staining, coverslips were quenched with 50 mM ammonium chloride (NH4CL in 
PBS) for 10 minutes at room temperature. NH4CL was aspirated and cells were 
permeabilised by incubation with 0.2% Triton-X100 for 5 minutes at room temperature, 
washed 3 times with PBS and blocked for 30 minutes at room temperature with 
blocking solution (Table 2.3). Primary antibodies were prepared in blocking solution 
and incubated with the cells for 2 hours at room temperature in a humidified 
atmosphere with gentle rocking. Primary antibody was aspirated and coverslips were 
washed 3 times with PBS for 10 minutes per wash. Secondary antibodies were 
Compound Final Concentration Catalogue Number 
Lipopolysaccharide (LPS) 
1μg/ml for BV2 cells, 
100ng/ml for iPSC-MGLC 
(in ddH2O) 
Sigma #L2880 
Mouse macrophage colony 
stimulating factor (MCSF) 100ng/ml (in ddH2O) Peprotech #315-02 
Adenosine triphosphate 
(ATP) 50µM (in ddH2O) Tocris #3245 
Mouse complement 
component 5a (C5a) 25ng/ml (in ddH2O) R&D Systems #2150-C5 
CytochalasinD (CytoD) 10µM (in ddH2O) 
Santa Cruz Biotechnology 
#SC201442 
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prepared in PBS and incubated with coverslips for 1 hour at room temperature with 
gentle shaking, followed by 3 further 10 minute washes. Following the final wash, the 
coverslips were mounted on slides using Vectashield mounting medium with DAPI for 
fluorescent staining of nuclei. Coverslips were left to dry overnight and were sealed 
with nail varnish prior to image acquisition on a Zeiss LSM710 confocal microscope. 
 
Table 2.3 Antibodies used for immunocytochemistry 
Target 
Blocking 
Solution 
Primary Antibody Secondary Antibody 
TREM2 
5% Normal 
donkey serum 
Mouse: 10µg/ml sheep 
anti-TREM2 (AF1729, 
R&D Systems) 
Human: 10µg/ml goat 
anti-TREM2 (AF1828, 
R&D Systems) 
Mouse: 1:1000 donkey 
anti-sheep Alexa Fluor 
568 (A-21099, Life 
Technologies) 
Human: 1:500 donkey 
anti-goat Alexa Fluor 568 
(A-11057, Life 
Technologies) 
Golgi 
Complex 
 
3% Bovine 
Serum Albumin 
Mouse: 1:100 rabbit anti-
Golgin97 (13192, Cell 
Signalling Technology) 
Human: 1:500 mouse 
anti-Golgin97 (A21270, 
Life Technologies) 
Mouse: 1:1000 goat anti-
rabbit Alexa Fluor 488 
(R37116, Life 
Technologies) 
Human: 1:500 goat anti-
mouse Alexa Fluor 568 
(A11004, Life 
Technologies) 
Calnexin 
3% Bovine 
Serum Albumin 
1:50 mouse anti-Calnexin 
(sc-23954, Santa Cruz 
Biotechnology) 
1:500 goat anti-mouse 
Alexa Fluor 568 (A11004, 
Life Technologies) 
Iba1 
3% Bovine 
Serum Albumin 
1:500 rabbit anti-Iba1 
(019-19741,Wako) 
1:1000 goat anti-rabbit 
Alexa Fluor 488 (R37116, 
Life Technologies) 
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For golgin97 staining, fixation and permeabilisation using methanol was found to result 
in improved staining. Instead of using 4% PFA and Triton-X100, cells were fixed and 
permeabilised in ice-cold methanol for 20 minutes at -20°C. The coverslips were 
washed, blocked in BSA and the protocol continued as for PFA fixation. 
 
2.7.2 Phalloidin labelling of F-actin 
 
Phalloidin staining was performed using Phalloidin CF568 and a standard protocol 
(Chazotte, 2010), with adjustments made to concentrations and incubation times 
according to the manufacturer’s instructions (Biotium). Phalloidin, a high affinity actin 
probe conjugated to a fluorescent dye, was used to study the morphological 
phenotypes of microglial cells. Cells were plated on 13mm glass coverslips at a density 
of 5,000 cells per coverslip for BV2 cells. Following treatment with murine macrophage 
colony-stimulating factor (MCSF, 100ng/ml) or adenosine triphosphate (ATP, 50μM) in 
serum free RPMI for 5 minutes, cells were washed with PBS and fixed by incubation 
with 4% PFA for 20 minutes. Cells were washed again and stored in PBS at 4°C until 
use. Cells were permeabilised with 0.5% Triton-X100 (made up in PBS) at room 
temperature for 10 minutes. Coverslips were washed 3 times with PBS and incubated 
with a 1:40 dilution of fluorescent phalloidin at room temperature for 20 minutes, 
protected from light. Coverslips were washed 3 times with PBS and mounted on slides 
using Vectashield mounting medium with DAPI for fluorescent staining of nuclei. 
Coverslips were left to dry overnight and were sealed with nail varnish prior to image 
acquisition on a Zeiss LSM710 confocal microscope using Zeiss Zen Microscope 
software. 
Cytoskeletal analysis was carried out using ImageJ software (version 1.50). For 
analysis of filopodia formation, the samples (3 independent experiments, 40-50 cells 
per sample) underwent blinded measurement of filopodia length and quantification of 
filopodia number per cell. The samples (5 independent experiments, 40-50 cells per 
sample) underwent blinded morphological scoring for membrane ruffle formation as: 
absence, 0, ruffling response 1. Membrane ruffles were defined as wave-like regions of 
intense F-actin staining at extended cell edges. Immunohistochemistry was performed 
to confirm that regions counted as ruffles possessed F-actin and Iba1 colocalisation as 
reported in the literature (Ohsawa et al., 2000). 
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2.7.3 Immunohistochemistry 
 
Frozen tissue sections were acquired pre-sliced and mounted from the Queen Square 
Brain Bank (human temporal lobe samples) and from Amsbio (human kidney samples, 
Abingdon, United Kingdom) and were stored at -80°C until use. Ethical permission for 
this study was obtained from the National Hospital for Neurology and Neurosurgery 
and the Institute of Neurology joint research ethics committee (study reference 
IONMTA19/16 with corresponding RNA samples acquired under study reference 
IONMTA8/15). Immunohistochemistry performed using standard protocol with fixation 
modifications due to the use of fresh frozen tissue (Davies et al., 2013). Slides were 
fixed and permeabilised immediately upon removal from the freezer with ice cold, 
100% methanol for 20 minutes at 4°C, followed by 3 x 5 minute PBS washes. Samples 
were blocked in 5% horse serum for 1 hour at room temperature, followed by primary 
antibody incubation (1:250 mouse anti-CR1 SC-7308, Santa Cruz) overnight at 4°C. 
The slides were washed 3 times with PBS prior to treatment with 0.3% hydrogen 
peroxide (diluted in PBS) for 15 minutes to block endogenous peroxidases found in the 
tissue. After further 3 x 5 minute PBS washes, biotinylated secondary antibody was 
added to the slides (1:200 horse anti-mouse, BA-2001, Vector) for an hour at room 
temperature. DAB visualisation of antibody staining was performed using Vectastine 
Elite ABC HRP kit followed by DAB kit according to the manufacturer’s instructions. 
The slides were dehydrated in serial alcohol dilutions followed by xylene and were 
mounted in DPX. Images were acquired on a Zeiss Axiophot light microscope. 
2.8 Western Blotting 
 
Western blotting was performed using standard techniques. For samples to be used for 
western blotting, cells were plated at a density of 8 x 104 in 6 well plates. In order to 
solubilise cellular proteins, medium was aspirated from cells and ice cold lysis buffer 
(1% NP-40, 150 mM NaCl, 50 mM Tris HCl (pH 7.2) and HaltProtease and 
Phosphatase Inhibitor (100x)) was added to wells and incubated at 4°C with shaking 
for 30mins. Lysates were collected and centrifuged at 12,000 g to pellet the nuclear 
fractions as well as any cellular debris. The supernatant was collected and stored at -
20°C until required. 
A Bradford protein assay was used to determine the total protein concentration of each 
cytoplasmic fraction sample using BSA as a standard. The principle of the assay is 
based upon a colour change shift by an acidic solution of Coomassie dye, from 465 nm 
to 595 nm, upon binding to proteins (Bradford, 1976). This visible colour change allows 
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BSA to be used to generate a standard curve to plot known BSA concentrations 
against absorbance at 595nm, allowing the total protein concentration of a lysate 
sample to be determined.  Samples were run in triplicate in a 96 well plate. Briefly, 200 
μl of Bradford reagent was added to 2 µl of sample lysate, as well as to a BSA 
standard curve, and was mixed on an orbital shaker for 5 minutes. The resultant colour 
change was measured using a Tecan Genios plate reader on the basis of the greater 
the concentration of protein, the greater the intensity of the colour shift from brown to 
blue. 
For sodium dodecyl polyacrylamide gel electrophoresis (SDS-PAGE), the volume of 
lysate sample equivalent to 35 μg of protein was added to 4X protein sample loading 
buffer + 10% NuPAGE sample reducing agent and denatured by heating at 100°C for 5 
minutes. Samples were loaded into gel wells alongside All Blue Prestained Protein 
Standards molecular weight markers to show the molecular weight of visualised bands. 
Proteins were separated by SDS-PAGE using 4-20% BIO-RAD mini-PROTEAN TGX 
Precast Gels in a Bio-Rad mini gel tank filled with running buffer (125mM Tris-Base, 
1M glycine, 0.01% SDS) at 120 V until the gel front from the sample buffer reached the 
bottom of the gel. 
Following SDS-PAGE, the gel was removed, trimmed and equilibrated in ice cold 
transfer buffer for 5 minutes (25mM Tris-Base, 192mM glycine, 20% methanol, 0.01% 
SDS).  3MM chromatography paper, fibre pads and nitrocellulose membrane cut to the 
size of the gel were also immersed in ice cold transfer buffer. A sandwich of transfer 
buffer-soaked fibre pads, 3MM chromatography paper, the gel and the nitrocellulose 
membrane was constructed on a transfer cassette, ensuring that any air bubbles were 
removed. The cassette was inserted into a Bio-rad mini gel transfer apparatus and 
proteins were transferred onto the nitrocellulose membrane for 1.25 hours at 100V. 
After transfer, membranes were washed in 1x PBS/0.1% Tween-20 (PBS-T) for 10 
minutes and then blocked in 5% non-fat milk solution in PBS-T for 1h at room 
temperature to reduce non-specific antibody interactions. The membranes were 
incubated with primary antibody diluted in 5% milk solution overnight at 4°C followed by 
3 x 10 minute washes in PBS-T. The membranes were incubated with the appropriate 
fluorescent secondary antibody (see table) at room temperature for 1 hour and then 
underwent further 3 x 10min washes. Membranes were visualised using the Odyssey 
infrared imaging system (Odyssey V3.0 Software) and the resulting bands were 
subjected to densitometry analysis using ImageJ software. Treatments and conditions 
were replicated 3 times and quantified for statistical analysis. 
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In order to accurately quantify the highly glycosylated TREM2 protein, the equivalent 
volume of 35µg protein was treated with peptide:N-gycosidase (PNGase, according to 
the manufacturer’s instructions) to induce sample deglycosylation. Samples were then 
prepared for gel electrophoresis as above. 
Primary and secondary antibodies were used as follows: 
 
Protein of 
Interest 
Primary Antibody Secondary Antibody 
β-actin 
1:10,000 mouse monoclonal anti-
β-actin (Sigma #A5441) 
1:15,000 Goat anti-Mouse Alexa 
Fluor 680 conjugate  (Life 
Technologies #A21058) 
TREM2 
(mouse) 
1:500 sheep polyclonal anti-
TREM2 (R&D Systems #AF1729) 
1:60,000 Donkey Anti-Sheep 
Alexa Fluor 790 conjugate 
(Jackson ImmunoResearch 713-
655-147) 
TREM2 
(human)  
1:500 goat anti-TREM2 (R&D 
Systems # AF1828) 
 
1:1000 rabbit anti-TREM2 D8I4C 
(Cell Signalling Technology 
#91068) 
1:10,000 donkey anti-goat IRDYE 
800CW (Li-cor #925-32214) 
 
1:10,000 goat anti-rabbit IRDYE 
800CW (Li-cor #925-32211) 
 
Iba1 
1:1000 rabbit anti-Iba1 (019-
19741,Wako) 
1:15,000 Goat-anti rabbit Alexa 
Fluor 790 conjugate (Life 
Technologies #A11369) 
Table 2.4 Antibodies used for western blotting 
 
2.9 Enzyme-linked Immunosorbent Assay (ELISA) 
 
For ELISAs, BV2 cells were plated at a density of 8 x 104 cells per well in a 24 well 
plate and iPSC-MGLC were plated at a density of 4 x 104 cells per well in a 96 well 
plate, with the exception of supernatants for C1q ELISA which were cultured at a 
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density of 1 x 10105 cells per well in a 6 well plate. BV2 cells were cultured for 24 hours 
prior to treatment. iPSC-MGLC were differentiated for 7 days prior to treatment. 
Following treatment, cell culture medium samples were collected and centrifuged at 
15,000 g for 2 minutes to pellet any cellular debris. All of the supernatants were 
collected and transferred to new tubes (500 µl)/96 well plates (100 µl), snap frozen on 
dry ice and stored at -20°C until use. Samples were defrosted and used only once to 
preserve the integrity of the soluble factors. 
2.9.1 ELISA analysis of soluble TREM2 in mouse BV2 cell cultures 
 
Quantification of soluble TREM2 (sTREM2) from mouse cell culture supernatants was 
performed using an in-house generated ELISA, developed by Dr Matt Butler. 
MaxiSORP 96 well plates were coated overnight at 4°C with 1 µg/ml rat anti-
human/mouse TREM2 monoclonal antibody (R&D Systems; MAB17291) made up in 
PBS. Plates were washed 3 times with 0.1% PBS-T, blocked with 1% BSA in PBS for 
45 minutes at room temperature followed by 3 more washes with 0.1% PBS-T. 
Recombinant murine TREM2-Fc (R&D Systems; #1729-T2-050) was used to prepare a 
standard curve to allow the concentration of sTREM2 in the samples to be determined. 
100 µl of cell culture supernatants and TREM2 standards were added to the wells and 
incubated for 2 hours at room temperature with gentle shaking, followed by 3 washes. 
In order to detect bound sTREM2, 0.2 µg/ml anti-mouse TREM2 biotinylated polyclonal 
antibody (R&D Systems; #BAF1729) was used as the detecting antibody and was 
incubated on the plates for 2 hours with gentle shaking at room temperature. Plates 
underwent 3 further washes with 0.1% PBS-T prior to the addition of 0.1 µg/ml 
streptavidin-HRP for 45 minutes, with gentle shaking at room temperature. Following 3 
washes with 0.1% PBS-T, a chromogenic substance (TMB) was added to the plates. 
The reaction was stopped with the addition of 0.5M H2SO4 in H2O and absorbance was 
read at 450 nm (Tecan Genios). 
2.9.2 ELISA analysis of soluble TREM2 in human iPSC-MGLC cultures 
 
In order to quantify sTREM2 levels in human samples, the above mouse sTREM2 
ELISA protocol (2.9.1 ELISA analysis of soluble TREM2 in mouse BV2 cell cultures) 
was followed with some modifications. 1 μg/ml of rat anti-mouse/human monoclonal 
antibody (R&D Systems; clone 237920) and 0.1 μg/ml biotinylated polyclonal goat anti-
human TREM2 antibody (R&D Systems BAF1828) were used as the capture and 
detecting antibody, respectively. Recombinant human TREM2-His (Life Technologies 
11084H08H25) was used to generate a standard curve. 
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2.9.3 Mouse TNFα Cytokine Quantification 
 
Analysis of TNFα secretion by mouse BV2 cells was carried out using a Mouse TNF-
alpha Quantikine ELISA Kit (R&D systems, MTA00B) according to the manufacturer’s 
instructions. Briefly, plated cells were either unstimulated or stimulated with 1μg/ml 
lipopolysaccharide (LPS) for 24 hours. 100 µl cell samples were incubated on the pre-
coated plate alongside kit standards in order to determine TNFα concentrations. After 2 
hours of incubation, the TNFα conjugate was added to the wells for a further 2 hours. 
The substrate solution was incubated for 30 minutes and the reaction was stopped 
through the addition of a stop solution. The resultant colour change was read using a 
Tecan Genios plate reader. 
2.9.4 Human TNFα & IL-6 Cytokine Quantification 
 
Quantification of TNFα and IL-6 secretion by human iPSC-MGLC was conducted using 
human ELISA kits from DuoSet (R&D systems, DY210 for TNFα and DY206 for IL-6) 
according to the manufacturer’s instructions. Briefly, 100µl of supernatants from cells 
treated with LPS were added to 96-well plates that had been coated overnight with 
TNFα capture antibody and blocked with 1% BSA for an hour. Sample supernatants 
were incubated on the plate alongside serial dilutions of recombinant protein standards 
for the generation of a standard curve for 2 hours at room temperature. Following 3 
PBS-T washes, detection antibody was added for 2 hours at room temperature, 
followed by 3 further washes and incubation with streptavidin-HRP for 45 minutes. 
Following 3 final washes with PBS-T, a chromogenic substance (TMB) was added to 
the plates. The reaction was stopped with the addition of 0.5M H2SO4 in H2O and 
absorbance was read at 450 nm (Tecan Genios). 
2.9.5 Human C1q ELISA 
 
Quantification of human C1q secretion by the iPSC-MGLC was performed using a 
human C1q ELISA kit (Thermofisher, BMS2099), according to the manufacturer’s 
instructions. Supernatants were collected from unstimulated cells and added to the pre-
coated plated alongside diluted C1q standards to provide a standard curve from which 
the C1q concentration of samples was determined. After 2 hours of incubation, the 
biotin-conjugate was added for a further hour. Streptavidin-HRP (1:1000) was 
incubated in the wells for an hour, followed by TMB substrate solution (undiluted). The 
reaction was stopped with the provided stop solution and absorbance was read at 450 
nm (Tecan Genios). 
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2.9.6 Mouse Cytokine Array  
 
The proteome profiler mouse XL cytokine array (R&D Systems, ARY028) was used to 
determine the secretion of 111 mouse cytokines in a membrane-based antibody array, 
according to the manufacturer’s instructions. Following treatment with LPS (1µg/ml), 
BV2 supernatants were collected, centrifuged to remove debris and incubated with the 
membranes overnight at 4°C. The detection antibody cocktail was added for an hour, 
followed by streptavidin-HRP. Chemiluminescence was performed to develop the 
membrane array and the membranes were exposed to autoradiography film. Data were 
analysed using the Protein Array Analyser Palette plugin (ImageJ), normalising to both 
reference and negative control points. 
2.10 Quantitative Polymerase Chain Reaction (qPCR) for evaluation 
of mRNA expression levels 
 
For qPCR analysis of mRNA expression levels, BV2 cells were cultured for 24 hours 
prior to treatment or sample collection and iPSC-MGLC were differentiated for 7 days 
prior to treatment or sample collection. BV2 cells were lysed and homogenised using 
QIAzol buffer and total RNA was extracted using miRNeasy mini kit with an additional 
on-column DNase digestion step using RNase-free DNase set. For human iPSC-
MGLCs, cells were lysed and homogenised using RLT buffer (QIAGEN) and total RNA 
was extracted from cells using an RNeasy minikit according to the manufacturer’s 
instructions, with an on-column DNase digestion step using RNase-free DNase set. 
The concentration of total RNA extracted was determined using a NanoDrop 
spectrophotometer. Sample volumes equivalent to 500ng RNA were used to generate 
complementary DNAs using the High-Capacity RNA-cDNA kit, according to the 
manufacturer’s instructions. Quantitative PCR was conducted using TaqMan Universal 
Mastermix II in the Stratagene Mx3000p qPCR system and MxPro qPCR software. 
Expression was normalised to GAPDH and for primers used for mouse and human 
samples see table below: 
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Species Gene name Primer ID 
Human  
Aif1 Hs00610419_g1 
Apoe Hs00171168_m1 
Axl Hs01064444_m1 
C1qa Hs00381122_m1 
Cd33 Hs01076281_m1 
Cr1 Hs00559348_m1 
Csf1r Hs00911250_m1 
Gapdh Hs0278991_g1 
Gpr34 Hs00758331_m1 
Itgam Hs00355885_m1 
Itgb2 Hs00164957_m1 
Mertk Hs01031979_m1 
P2y12 Hs00224470_m1 
Pros1 Hs00165590_m1 
Spi1 Hs02786711_m1 
Tgfβ1 Hs00998133_m1 
Tmem119 Hs01938722_u1 
Trem2 Hs00219132_m1 
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Tyrobp Hs00182426_m1 
Mouse 
Actb Mm00607939_s1 
Aif1 Mm00479862_g1 
Gapdh Mm99999915_g1 
Spi1 Mm00488140_m1 
Tnf Mm00443258_m1 
Trem2 Mm04209244_g1 
Table 2.5 Primer IDs for TaqMan qPCR probes (Thermo Fisher Scientific) 
 
2.11 Analysis of phagocytic activity by flow cytometry 
 
Cells were plated at a density of 1x105 per well in a 24 well plate for 24 hours prior to 
the assay. As a negative control, cells were pre-incubated with 10µM cytochalasinD for 
30 minutes, a potent inhibitor of actin polymerisation, which is vital for the changes in 
cell structure required for the phagocytosis of particles. Cells were incubated with 50 µg 
pHrodo green E. coli particles for 30 minutes at 37°C, rinsed in PBS and incubated with 
PBS (without CaCl2 and MgCl2) for 10 minutes to dissociate cells, all conducted whilst 
taking care to avoid excessive exposure to light. Cells were collected and washed twice 
in ice cold FACS buffer (0.5% BSA, 0.05% sodium azide and 2mM EDTA in PBS 
without CaCl2 and MgCl2). Cells were diluted in FACS buffer and were analysed with a 
BD FACS Calibur flow cytometer and results were analysed with Flowing software (Cell 
Imaging Core of the Turku Centre for Biotechnology, flowingsoftware.btk.fi). Mean 
fluorescence intensities were calculated for each sample. 
2.12 Statistical Analysis 
 
Results were analysed using Prism software (Version 7, Graphpad). Unless otherwise 
stated, one-way ANOVA analysis with post-tests, such as Dunnett’s multiple 
comparison test, used as indicated in figure legend. 
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3. Characterisation of CRISPR/Cas9 TREM2 gene editing in 
mouse BV2 microglial cell line 
 
In this chapter, the generation of the CRISPR/Cas9 gene edited BV2 cell lines was 
performed by Claudio Villegas Llerena (UCL Institute of Neurology). 
3.1 The generation of TREM2 knockdown and knockout cell lines 
 
Following the identification of TREM2 as a risk factor for Alzheimer’s disease (AD), 
studies have been ongoing to elucidate TREM2 function, as well as dysfunction, in AD 
pathogenesis. In the healthy central nervous system, TREM2 expression has been 
found to be limited to microglia (Butovsky et al., 2014); in fact it is one of the highest 
expressed microglial receptors, ranked at number 31 out of 75 in an analysis of the top 
10% of receptors expressed by microglia (Hickman and El Khoury, 2014). The TREM2 
mutations associated with Alzheimer's disease are predicted to be loss of function 
mutations (Kober et al., 2016) and as such are amenable for modelling with knockdown 
and knockout cell lines. Therefore, in order to further investigate TREM2, 
CRISPR/Cas9 gene editing technology was used to generate TREM2 knockout lines 
from the mouse BV2 microglial cell line (performed by C. Villegas Llerena). BV2 cells 
were transfected with CRIPSR/Cas9 nickase plasmids designed to target exon 2 of the 
Trem2 gene (Santa Cruz Biotechnology Inc). Targeting 5’ regions of a gene helps to 
ensure intervention in the translation of the protein of interest at an early stage, thus 
minimising the likelihood of generating truncated proteins and translating other 
isoforms. As exon 1 of Trem2 is only 194bp long, this makes it more difficult to 
generate guides to compared with exon 2, which is 5472bp long.  Transfection with 
CRIPSR/Cas9 nickase plasmids resulted in the generation of clones with heterozygous 
Trem2 knockout (1 allele KO and 1 WT allele): the A7 clone (5bp deletion) and the C8 
clone (34bp deletion) (Figure 3.1), henceforth known as TREM2 knockdown lines. A 
second round of CRISPR Cas9 modification was performed on the C8 clone in order to 
generate homozygous Trem2 knockout clones with 34bp deletion in each allele, known 
as the G4 and B5 cell lines. Single colony Sanger sequencing confirmed the presence 
of genetic modifications in the Trem2 gene.  
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qPCR analysis showed that Trem2 mRNA levels were significantly reduced following 
TREM2 gene editing in both knockdown (A7 & C8) and knockout (G4 & B5) cell lines 
(**, p<0.01, Figure 3.2a). The resultant effect of decreased levels of Trem2 mRNA on 
protein production was assessed by western blotting, ELISA and 
immunocytochemistry.  Prior to western blotting, protein lysates were deglycosylated 
using PNGaseF as TREM2 exists in forms with varying degrees of glycosylation 
(Wunderlich et al. 2013; Park et al. 2015a; Kleinberger et al. 2014) resulting in multiple 
bands of different protein sizes on western blots that are difficult to accurately quantify. 
Therefore, samples were treated with PNGase to generate one single protein band for 
quantification of TREM2 expression levels. As shown in the representative western blot 
and subsequent densitometry quantification (Figure 3.2b and c), TREM2-targeting 
CRISPR/Cas9 modification resulted in a reduction of TREM2 protein expression to 
38% and 15% of WT levels in the A7 and C8 clones respectively (**, p<0.01) and to 
12% and 14% of WT levels in the knockout G4 and B5 clones (**, p<0.01). 
1 2 3 4 5 
ATG STOP 
A7 Allele 
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 C8 Allele 
 C8 Allele
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G4 Allele 
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Reference 
gRNA 
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Figure 3.1 CRISPR/Cas9 nickase modification of the Trem2 gene in BV2 cells 
Schematic of the mouse Trem2 locus and sequence alignment of the WT Trem2 sequence and Trem2
CRISPR/Cas9 modified mutants. gRNAs are aligned to their target sequences on exon 2 of the Trem2 
gene. Protospacer-adjacent motifs (PAM) for each gRNA are marked with a line. Clones A7 and C8 were 
obtained during a first round of CRISPR modification, while clones B5 and G4 were obtained during a 
second round of CRISPR modifications using the clone C8 as the starting cell line. Figure kindly provided 
by Claudio Villegas Llerena, UCL Institute of Neurology. 
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Figure 3.2 Characterisation of TREM2 knockdown and knockout clones generated using 
CRISPR/Cas9 modification 
qPCR used to determine TREM2 mRNA expression levels in wildtype (WT), TREM2 knockdown (A7 and 
C8) and TREM2 knockout (G4 and B5) CRISPR/Cas9-edited BV2 cell lines (a). Graph represents Trem2
mRNA expression normalised to Gapdh mRNA expression. Values relative to WT levels expressed as 
mean ±SEM for 3 individual experiments (** p<0.01; one way ANOVA with Dunnett’s multiple comparison 
test). Representative western blot (b) and subsequent densitometric analysis (c) of TREM2 expression in 
WT, TREM2 knockdown (A7 and C8) and knockout (G4 and B5) cells. Lysates were treated with PNGase 
to deglycosylate proteins to accurately quantify total TREM2 protein levels. Recombinant extracellular 
mouse TREM2 was used as the positive control.  Graph represents protein level relative to WT.  Values 
were normalised to β-actin levels.  Values are expressed as mean ±SEM for 3 individual experiments, **
<0.01; one way ANOVA with Dunnett’s multiple comparison test. 
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Immunocytochemical analysis of WT BV2 cells indicated that TREM2 protein 
expression exists as perinuclear puncta that preferentially co-localised with the golgi 
complex marker golgin97 (Figure 3.3). TREM2 is principally expressed in the golgi 
complex (Sessa et al., 2004) but is shuttled to the cell surface, where it is readily 
cleaved by ADAM10-mediated ectodomain shedding (Kleinberger et al., 2014). In the 
TREM2 knockdown and knockout cell lines, TREM2 staining was not punctate, was 
less intense and did not colocalise with golgin97 staining (Figure 3.3a & b). Golgin97 
staining was not found to be affected by TREM2 knockdown. 
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Interestingly, despite TREM2 being a cell surface receptor, low levels of TREM2 
expression at the cell surface were found by immunocytochemistry in all of the BV2 cell 
lines (Figure 3.3). Following this observation, the levels of soluble TREM2 (sTREM2) 
secreted into the cell supernatant following cleavage of the receptor at the cell surface 
were determined by ELISA. sTREM2 production was significantly reduced in the 
TREM2 modified clones compared with the WT cells (**, p<0.01, Figure 3.4) with 
knockdown and knockout cell lines having similar sTREM2 levels. Despite differences 
Figure 3.3 Characterisation of TREM2 cellular localisation by immunocytochemistry in 
WT, knockdown and knockout BV2 clones 
Representative images of immunofluorescent labelling of TREM2 (red), golgi complex (green) and DAPI 
(blue) illustrating the differences in TREM2 staining intensity and cellular localisation in the  (a) TREM2 
knockdown (A7 and C8) and (b) TREM2 knockout (G4 and B5) cell lines. Top panel shows merged 
images. Scale bar represents 25µm. 
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existing between the western blotting results for the knockdown and the knockout lines 
regarding protein expression levels, similar levels of sTREM2 may be due to defects in 
the trafficking of truncated TREM2 protein from the golgi to the surface of the TREM2 
knockdown cells, resulting in low surface expression but detectable protein in the 
cytoplasm. 
 
 
 
 
 
 
 
Figure 3.4 Quantification of soluble TREM2 release from WT, TREM2 knockdown and 
TREM2 knockout BV2 cells by ELISA 
Soluble TREM2 (sTREM2) secretion levels determined by ELISA. Graph represents sTREM2 level relative 
to WT. Values expressed as mean ±SEM for 3 individual experiments (** p<0.01; one way ANOVA with 
Dunnett‘s multiple comparison test). 
 
3.2 TREM2 knockdown alters LPS-induced TNFα gene transcription 
 
TREM2 is thought to play a role in regulating pro-inflammatory responses in 
microglia/macrophages, however data demonstrating the directionality of its influence 
on TNFα production are conflicting (Turnbull et al., 2006; Sieber et al., 2013). 
Therefore, the effect of TREM2 gene editing on the generation and secretion of the 
pro-inflammatory cytokine TNFα in response to LPS treatment was assessed in the 
BV2 cell lines. LPS is a well characterised ligand of the TLR4 receptor, stimulation of 
which results in robust increases in TNFα secretion in microglia and macrophages. 
Treatment of WT BV2 cells with 1µg/ml LPS for 2 hours resulted in a 45 fold increase in 
Tnf mRNA expression compared with untreated cells (**, p<0.01), with expression 
remaining augmented 6 hours post-LPS treatment albeit lower than at 2 hours (22 fold 
increase compared with 45 fold) (Figure 3.5a and b). Tnf mRNA expression levels were 
significantly lower post-LPS treatment in the TREM2 knockdown and knockout cell 
lines than in the LPS-treated WT cells at both the 2 hour and 6 hour time points 
(*p<0.05, **p<0.01, Figure 3.5a and b), with the exception of the heterozygous C8 cell 
line after 6 hours (ns, p>0.05).  
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The effect of TREM2 knockdown on the LPS-induced secretion of TNFα protein was 
further investigated by ELISA. Treatment of cells with 1µg/ml LPS for 24 hours induced 
a robust release of TNFα from undetectable level to concentrations of approximately 
1.8µg/ml (Figure 3.6). With the exception of the G4 knockout cell line, there was no 
significant difference in the secretion of TNFα following 24 hours of LPS stimulation 
between WT cells and TREM2 knockdown and knockout cell lines (Figure 3.6). These 
data conflict with the mRNA results, as one would expect decreased generation of Tnf 
mRNA to result in decreased production of TNFα protein to be released into the cell 
supernatants.  
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Figure 3.5 Expression of Tnf mRNA by WT, TREM2 knockdown and TREM2 knockout 
cells following 2hr and 6hr of LPS treatment 
qPCR used to determine Tnf  mRNA expression levels following (a) 2 hours  or (b) 6 hours of LPS 
treatment (1µg/ml) in WT, TREM2 knockdown (A7 and C8) and TREM2 knockout (G4 and B5) BV2 cell 
lines. Graph represents Tnf mRNA expression normalised to Gapdh mRNA expression and data are
shown relative to untreated WT levels. Values expressed as mean ±SEM for 4 individual experiments (* 
p<0.05, ** p<0.01; one way ANOVA with Dunnett’s multiple comparison test). 
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qPCR analysis of baseline Tnf mRNA levels showed that there is no difference 
between the WT and the TREM2 knockdown lines, and a reduction of 30% in the B5 
knockout line (**, p<0.01, Figure 3.7), which concurs with data showing that microglia 
isolated from TREM2-/- mice have downregulated expression of Tnf mRNA (Mazaheri 
et al., 2017). Therefore, differences in Tnf mRNA levels are only found between the WT 
and knockdown cells following LPS treatment, suggesting that, in heterozygosity, 
TREM2 has an effect on the LPS-induced expression of Tnf rather than baseline 
expression. 
 
Figure 3.7 Expression of Tnf mRNA in untreated WT, TREM2 knockdown and TREM2 
knockout cells 
Baseline Tnf mRNA expression levels assessed using qPCR. Graph represents Tnf mRNA expression 
normalised to Gapdh mRNA expression. Data are shown relative to WT levels and values expressed as 
mean ±SEM for 4 individual experiments (** p<0.01; one way ANOVA with Dunnett’s multiple comparison 
test). 
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Figure 3.6 ELISA quantification of TNFα secretion by WT, TREM2 knockdown and TREM2 
knockout BV2 cells 
TNFα secretion following 24 hours of LPS treatment (1µg/ml) in WT, TREM2 knockdown (A7 and C8) and 
TREM2 knockout (G4 and B5) BV2 cell lines determined by ELISA. Values expressed as mean ±SEM for 
4 individual experiments (* p<0.05; one way ANOVA with Dunnett’s multiple comparison test). 
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Subsequently, the secretion of TNFα following priming with LPS was also assessed, as 
defects exist in the transcriptional response to LPS stimulation rather than in untreated 
cells. A 2 hour pulse of LPS treatment was used to release any existing pools of TNFα 
from the cells prior to culturing cells with fresh LPS-containing medium for a further 24 
hours. The aim of this experiment was to allow the effects of any deficits in LPS-
induced Tnf mRNA transcription to be seen in the TNFα protein released from the cells. 
Supernatants were collected after the initial priming 2 hour LPS treatment and TNFα 
levels were quantified by ELISA (Figure 3.8a). Similar to the ELISA results following 24 
hours of treatment without priming (Figure 3.6), the only cell type with a marked 
difference from WT was the TREM2 knockout G4 line (Figure 3.8a). Primed cells were 
treated with 1µg/ml LPS for a further 24hours and, following ELISA analysis of the 
supernatants, the TREM2 knockdown A7 and C8 lines and the G4 knockout lines had 
significantly reduced levels of TNFα compared with WT (Figure 3.8b), reflecting the 
lower levels of Tnf mRNA found previously by qPCR (Figure 3.5). Interestingly, the 
levels of TNFα secreted by the knockout B5 cells has remained high at all time points 
of supernatant analysis both with and without the priming designed to clear existing 
stores of the cytokine (Figure 3.6, and Figure 3.8a & b). This is in contrast to the 
significantly decreased levels of Tnf mRNA both in baseline conditions and following 
LPS treatment (Figure 3.5a & b, and Figure 3.7). 
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3.3 TREM2 knockdown and knockout microglia have altered actin 
cytoskeletal structures 
 
Cells with TREM2 gene modifications were observed to have markedly different 
phenotypes to WT cells, displaying rounded morphology and lacking the extended 
processes found in WT cells (Figure 3.9). As actin signalling is thought to be 
downstream of TREM2 receptor activation (Peng et al., 2010), the filamentous actin (F-
actin) structures of the cells were investigated using fluorescently-conjugated 
phalloidin. Phalloidin is high-affinity actin probe derived from a toxin found in Amanita 
phalloides (the death cap mushroom) which binds and stabilises F-actin, preventing 
depolymerisation (reviewed in Cooper 1987), which when coupled to a fluorescent 
probe, allows the visualisation of actin cytoskeletal structures of cells 
  
Figure 3.8 ELISA analysis of LPS-induced TNFα secretion after depletion of existing 
stores 
TNFα secretion quantified by ELISA after 2 hours of priming with 1µg/ml LPS (a) and following a further 24 
hours of treatment with 1µg/ml LPS (b) in WT, TREM2 knockdown (A7 and C8) and TREM2 knockout (G4 
and B5)  BV2 cell lines. Values expressed as mean ±SEM for 3 individual experiments (*p<0.05, 
***p<0.001; one way ANOVA with Dunnett’s multiple comparison test). 
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Phalloidin staining of BV2 cells revealed the presence of filopodia on the surface of the 
cells (see arrow heads in Figure 3.10a) which, upon quantification, were found to be 
significantly shorter on TREM2 knockdown and knockout cell lines than on WT cells 
(*** p<0.001, ****p<0.0001, Figure 3.10b). Filopodia are thin, finger-like, plasma-
membrane protrusions that are rich in filamentous actin and are thought to play roles in 
environment sensing, migration and phagocytosis (Pollard and Borisy, 2003; 
Niedergang and Chavrier, 2004; Chhabra and Higgs, 2007). In addition to the average 
length of filopodia on TREM2 knockdown and knockout cells being shorter than that on 
WT cells, the percentage of filopodia that fall in to the medium (6-10µm) or long (10-
15µm) length categories was significantly lower following TREM2 modification (** 
p<0.01, Figure 3.10c). There was, however, no statistically significant difference in the 
average number of filopodia per cell (Figure 3.10d). In order to exclude differential 
expression of β-actin as a cause for the variation found in actin-rich filopodia formation, 
the expression levels of Actb mRNA in the WT and clone lines was assessed by qPCR. 
No statistically significant differences in β-actin expression were found although levels 
appeared to be slightly higher in the B5 knockout cell line (Figure 3.11). 
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Figure 3.9 The effect of TREM2 knockdown and knockout on the morphology of BV2 
cells 
Representative phase contrast images of wildtype (WT), TREM2 knockdown (A7 and C8) and TREM2 
knockout (G4 and B5) CRISPR/Cas9-edited BV2 cell lines. Scale bar represents 100µm. 
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3.4 TREM2 knockdown affects the ability of microglia to alter morphology 
in response to stimuli 
 
One of the hallmarks of microglia is an ability to make rapid and marked morphological 
changes in order to respond to injury or potentially noxious stimuli, alongside making 
alterations to their function and behaviour. Therefore, the morphological responses of 
the cell lines to various stimuli were assessed to establish whether deletions in the 
TREM2 gene affected the cytoskeletal reorganisation, which was visualised by 
phalloidin staining.  The WT cells, following stimulation with LPS (1µg/ml, 24 hours), 
adopted a bipolar morphology, defined as having two symmetrical processes emerging 
from a smaller cell soma (Figure 3.12a). There was a significantly smaller percentage 
of cells forming this bipolar morphology post LPS-stimulation in the TREM2 knockdown 
and knockout cell lines (* p<0.05, ** p<0.01, Figure 3.12b).  
Figure 3.10 The effect of TREM2 knockdown and knockout on filopodia formation by BV2 cells 
(a) Representative confocal microscopy images of BV2 cell lines labelled with phalloidin-568 (red) to 
visualise f-actin and DAPI (blue) to visualise the nucleus. Scale bar represents 20µm. Arrow heads 
showing filopodia. (b) Quantification of the length of filopodia on the surface of the cells visualised using 
phalloidin stain for f-actin. (c) Graph showing the percentage of filopodia that fit into the length categories 
of 0-5µm, 5-10 µm or 10-15µm for each cell line. For the purpose of performing statistical analysis, the 
percentage of filopodia in each category was tested against the WT values for that length category. (d) 
Quantification of the number of filopodia on the surface of the each cell.  For all figures, values expressed 
as mean ±SEM for 3 individual experiments with a minimum of 5 fields of view analysed per experiment 
(** p<0.01, *** p<0.001, ****p<0.0001; one way ANOVA with Dunnett‘s multiple comparison test). 
Figure 3.11 Expression of Actb mRNA in WT, TREM2 knockdown and TREM2 knockout 
BV2 cells 
qPCR used to determine Actb mRNA expression levels in untreated WT, TREM2 knockdown (A7 and C8) 
and TREM2 knockout (G4 and B5) BV2 cell lines. Graph represents Actb mRNA expression normalised to 
Gapdh mRNA expression and data are shown relative to WT levels. Values expressed as mean ±SEM for 
3 individual experiments (one way ANOVA with Dunnett’s multiple comparison test). 
 
 92 
 
   
Untreated LPS 
WT 
C8 
A7 
B5 
G4 
a 
 
 93 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Treatment of BV2 cells with ATP and MCSF also lead to marked morphological 
changes, namely the formation of membrane ruffles, which are wave-like structures 
formed by detachment and movement of the extended cell edges (Imai and Kohsaka, 
2002). As reported in the literature  (Ohsawa et al., 2000), F-actin in the membrane 
ruffles of WT BV2 cells, which were induced by MCSF treatment, co-localised with 
Iba1, therefore confirming that the structures seen are indeed membrane ruffles (Figure 
3.13). 
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Figure 3.12 The effect of TREM2 knockdown and knockout on cytoskeletal 
reorganisation in response to LPS treatment in BV2 cells 
(a) Representative images of immunofluorescent labelling of F-actin using phalloidin (red) and DAPI (blue) 
in BV2 cells treated with 1µg/ml LPS for 24hours. Scale bar represents 20µm. Arrowheads indicate cells 
with bipolar morphology. (b) Quantification of the percentage of cells with bipolar morphology following 
24hours of stimulation with 1µg/ml LPS. Values expressed as mean percentage ±SEM for 3 individual 
experiments with a minimum of 5 fields of view analysed per experiment (* p<0.05, **p<0.01; one way 
ANOVA with Dunnett‘s multiple comparison test).  
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Analysis of cell morphology showed that treatment with ATP (50µM, 5 minutes) or 
MCSF (100ng/ml, 5 minutes) leads to a significant increase in the number of WT cells 
with ruffling morphology (** p<0.01, Figure 3.14). We therefore wanted to investigate 
whether similar morphology response defects were found in knockdown and knockout 
cells in response to ATP and MCSF as those found following LPS treatment. The 
percentage of TREM2 knockdown and knockout cells displaying ruffling morphology 
following treatment with ATP was significantly lower than ATP-treated WT cells (* 
p<0.05, **p<0.01, Figure 3.14b). Similarly, the cell lines with TREM2 gene 
modifications also failed to respond to MCSF in the same as the WT cells, with a 
significantly lower percentage of cells showing ruffling of the cell membrane following 
stimulation (*p<0.05, **p<0.01, Figure 3.14c). 
  
Figure 3.13 Definition of membrane ruffles in BV2 microglial cells  
Representative images of immunofluorescent labelling of f-actin(red), Iba1 (green) and DAPI (blue) 
illustrating the colocalisation of Iba1 in the F-actin rich membrane ruffles in WT BV2 cells stimulated with 
MCSF (100ng/ml for 5 minutes). Scale bar represents 10µm. 
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3.5 TREM2 knockdown and knockout affects the expression of Iba1 
 
Iba1 has been shown to be important for the formation of membrane ruffles (Ohsawa et 
al., 2000; Sasaki et al., 2001); indeed, overexpression of Iba1 is sufficient for the 
generation of ruffles in response to growth factors in non-ruffling cells (Kanazawa et al., 
2002). Therefore the expression of Iba1 in the TREM2 knockdown and knockout cells 
was investigated. The TREM2 modified cells have significantly lower levels of Aif1 
mRNA, the gene that encodes for Iba1, than controls (**p<0.01, ***p<0.001, 
****p<0.0001, Figure 3.15a). Western blot analysis of Iba1 protein expression 
concurred with mRNA data, demonstrating that expression was significantly lower in 
TREM2 knockdown and knockout cells than in controls (**p<0.01, ****p<0.0001, Figure 
3.15b & c).  
0
10
20
30
Untreated
WT C8A7 G4 B5
** ****
100ng/ml MCSF
Ce
lls
 w
ith
 R
uf
fli
ng
M
or
ph
ol
og
y 
(%
) ***
0
5
10
15
20
25
50M ATP
Untreated
WT C8A7 G4 B5
** ****** *
C
el
ls
 w
ith
 R
uf
fli
ng
M
or
ph
ol
og
y 
(%
)
b 
c 
Figure 3.14 The effect of TREM2 knockdown and knockout on membrane ruffling by BV2 
cells in response to ATP or MCSF treatment 
Representative images of immunofluorescent labelling of F-actin using phalloidin (red) in BV2 cells treated 
with 50µM ATP or 100ng/ml MCSF for 5 minutes (a). Scale bar represents 20µm. Arrowheads indicate 
membrane ruffles. Quantification of the percentage of cells with membrane ruffling morphology following 5
minutes of stimulation with 50µM ATP (b) or 100ng/ml MCSF (c). Values expressed as mean percentage 
±SEM for 5 individual experiments  with a minimum of  5 fields of view analysed per experiment (* P<0.05, 
**P<0.01; one way ANOVA with Dunnett‘s multiple comparison test).  
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Figure 3.15 The effect of TREM2 knockdown and knockout on the expression of 
Iba1 in BV2 cells 
(a) qPCR to determine Aif1 mRNA expression levels in WT, TREM2 knockdown (A7 and C8) and TREM2 
knockout (G4 and B5) BV2 cells. Graph represents Aif1 mRNA normalised to Gapdh mRNA expression, 
relative to WT levels. Representative western blot (b) and subsequent desitometry analysis (c) of Iba1 
expression in WT, TREM2 knockdown (A7 and C8) and knockout (G4 and B5) cells. Graph represents 
protein level relative to WT.  Values were normalised to β-actin levels.  Values are expressed as mean 
±SEM for 3 individual experiments, ** <0.01, ***p<0.001, ****p<0.0001; one way ANOVA with Dunnett’s 
multiple comparison test. 
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3.6 Pre-treatment with sTREM2 does not rescue the morphological defects 
in the MCSF response found in TREM2 knockout cells  
 
In order to investigate whether any of the phenotypic deficits in the TREM2 knockout 
cell lines could be rescued through the exposure of cells to sTREM2, the B5 cells, 
which had the most extreme deficits in membrane ruffling (Figure 3.14), were cultured 
in microglia conditioned medium (MGCM) from WT cells for 24 hours prior to 
stimulation with MCSF. MCSF stimulation was chosen as this resulted in higher levels 
of ruffling in WT cells than ATP treatment (Figure 3.14).  sTREM2 is constitutively 
cleaved from the surface of BV2 cells resulting in concentrations of approximately 
150ng/ml in WT MGCM compared with 3ng/ml in B5 MGCM (Figure 3.16a). Neither 
pre-treatment with WT MGCM nor B5 MGCM could restore the ability to form 
membrane ruffles in response to MCSF treatment in the B5 cells, with the percentage 
of cells with ruffling morphology significantly lower than WT cells for all treatment 
conditions (* p<0.05, ***p<0.001, Figure 3.16b). Pre-treatment with MGCM from either 
cell type had no effect on the formation of membrane ruffles by the WT cells.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.16 Pretreatment with soluble TREM2 does not restore deficits in morphological 
responses to MCSF 
Microglia-conditioned media (MGCM) from WT and TREM2 knockout B5 cells were analysed for soluble 
TREM2 (sTREM2) levels by ELISA (a). WT and B5 cells were pre-treated with WT or B5 MGCM for 
18hours prior to stimulation for 5 minutes with 100ng/ml MCSF. The percentage of cells with ruffling 
morphology was then assessed (b). Values expressed as mean percentage ±SEM for 3 individual 
experiments (* P<0.05, ***P<0.001; one way ANOVA with Dunnett‘s multiple comparison test). 
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3.7 TREM2 knockout cells are less able to phagocytose E.coli particles 
 
In microglia, membrane ruffles and filopodia are thought to be important for cell 
migration and phagocytosis, therefore the functional implications of reduced formation 
of these actin structures in the TREM2 knockdown and knockout cell lines were 
investigated. TREM2 is thought to play a role in phagocytosis (Takahashi, Rochford 
and Neumann, 2005; Kleinberger et al., 2014) and, since the TREM2 knockdown and 
knockout cell lines have disrupted actin phenotypes and decreased expression of Iba1, 
which has also been linked to phagocytic abilities (Ohsawa et al., 2000), the effect of 
TREM2 modification on the phagocytic ability of the cells was assessed. Uptake of 
fluorescent pHrodo E.coli particles by FACS analysis was performed. The particles only 
fluoresce in an acidic environment, such as that of a lysosome, which reduces any 
background signal from cell surface binding by the beads. A further control of 
cytochalasinD treatment was used, which inhibits actin polymerisation thus preventing 
the changes in cell structure required for phagocytosis. The TREM2 knockout cell lines 
G4 and B5 had a significantly lower level of phagocytosis compared with WT cells, as 
determined by the mean fluorescence signal from FACS analysis of the cells (* p<0.05, 
** p<0.01, Figure 3.17). 
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Figure 3.17 The effect of TREM2 knockdown and knockout on the phagocytosis of E.coli 
particles by BV2 cells 
FACS analysis of BV2 cell uptake of pHrodo green Ecoli particles as a measure of phagocytosis. CytoD 
(cytochalasinD) treatment used as a negative control. Graph represents mean fluorescence of individual 
cells for each cell type expressed as a percentage of WT values. Values expressed as mean ±SEM for 6 
individual experiments (* P<0.05, ** P<0.01; one way ANOVA with Dunnett’s multiple comparison test). 
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3.8 The effect of TREM2 knockdown and knockout expression of 
chemokines 
 
A proteome array was used in order to identify novel effects of TREM2 gene 
modulation on cytokine release by BV2 cells. Supernatants were collected from 
untreated and LPS-treated WT, TREM2 knockdown A7 and TREM2 knockout G4 and 
B5 cells. Two lines were used for the knockout cells because such large variation was 
seen between the TNFα levels from these cells in previous ELISA analysis (Figure 3.6). 
The array is a membrane-based sandwich immunoassay with bound antibodies for 111 
cytokines and chemokines, which is visualised by chemiluminescence detection 
(Figure 3.18). Densitometry was used to analyse the intensity of the resultant dots on 
the membranes, data from which was used to generate a heat map of expression with 
cytokine values relative to internal controls and densitometry values normalised 
between 0 and 1 for comparison.  
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Figure 3.18 Membrane-based proteome array of cytokines and chemokines secreted by 
untreated and LPS-stimulated BV2 cell lines 
WT, TREM2 knockdown A7 and TREM2 knockout G4 and B5 cells were treated with 1µg/ml LPS for 24 
hours prior to supernatant collection. Supernatants were analysed using the membrane-based mouse XL 
proteome array and results visualised by chemiluminescence. Cytokines and chemokines of interest are 
highlighted in coloured boxes. Two dots are found for each cytokine/chemokine on the membrane. 
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Figure 3.19 Heatmap analysis of cytokines and chemokines secreted by BV2 cells 
Heatmap generated from proteome array results from one experiment. Cells were treated with 1µg/ml LPS 
for 24 hours. Cytokines and chemokines secreted at detectable levels were ranked based on expression
levels in untreated WT cells, with the highest scored 1 and the lowest scored 0. Cytokines and chemokines 
of interested highlighted with coloured boxes.  
In the proteome array analysis, the chemokine CCL12 was the highest expressed at 
baseline levels and, following LPS treatment, the chemokines CCL12, CCL3, and 
CCL5 were in the top 5 highest expressed factors (Figure 3.19). The chemokine CCL6 
was also found to be highly expressed by LPS-treated TREM2 knockout G4 and B5 
cells but not by LPS-treated WT and A7 cells. The levels of TNFα secreted following 
LPS treatment did not appear to differ between the cell types, replicating results found 
by ELISA analysis previously (Figure 3.6) with the exception of G4 knockout cells 
which were found by ELISA to secrete significantly less TNFα than controls. The array 
highlighted the importance of cell recruiting chemokines in the BV2 cells and, since 
actin regulation and membrane ruffling, both of which are defective in TREM2 
knockdown cells, are essential for motility, the motility of these cells should be 
investigated, as this may be a novel functional defect resulting from  TREM2 loss of 
function. 
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3.9 Discussion 
CRISPR-Cas9 gene editing technology has been successfully used to generate mouse 
BV2 microglial cell lines with heterozygous or homozygous deletions in the gene 
encoding for TREM2, a receptor expressed highly in microglia and mutations in which 
have been found to be associated with Alzheimer’s disease.  Characterisation of the 
knockdown and knockout lines demonstrated significant reduction in TREM2 protein 
expression compared with WT cells, determined by western blotting, 
immunocytochemistry and ELISA analysis of the cleavage of TREM2 from the surface 
of the cells. Data from qPCR analysis of TREM2 mRNA levels in the cell lines also 
indicated that knockdown had been successful.  
The generation of these cell lines has provided a valuable tool for studying the role of 
TREM2 in microglia in the absence of transgenic TREM2-/- mice. These cell lines offer 
further advantages by generating a high number of available cells for in vitro 
experiments whilst avoiding the use of animals. The gene edits are predicted to result 
in heterozygous and homozygous loss of function of the receptor, which aims to 
replicate the heterozygous mutations implicated in Alzheimer’s and the more severe 
homozygous loss of function mutations that cause Nasu Hakola disease. 
Despite being described as a cell surface receptor, TREM2 is undetectable at the 
surface of WT BV2 cells in the immunocytochemistry performed in this study. However, 
robust TREM2 staining was found in perinuclear regions of the cell cytoplasm that 
coincided with golgin97 antibody staining for the golgi complex. In other unstimulated 
microglial cell lines, low levels of TREM2 surface expression have also been reported 
(Prada et al., 2006) with strong staining in the golgi complex (Sessa et al., 2004) as 
well as in vesicles that are trafficked to the cell membrane following appropriate 
stimulation, for example, with interferon-γ (Prada et al., 2006). In the TREM2 
knockdown and knockout cells, the TREM2 staining that was found was less intense, 
more diffuse and no longer punctate. There was also a lack of colocalisation with the 
golgi complex suggesting that either as the protein is being generated at reduced 
levels, there is less protein undergoing modification in the golgi or protein that is 
generated with regions of the gene removed is misfolded and is not being trafficked to 
the golgi as found with WT TREM2. 
Despite low detectable surface expression of the protein, high levels of sTREM2, 
generated by sequential, proteolytic cleavage of the receptor at the cell surface, were 
found in the WT cell supernatant. Following TREM2 gene modification, similarly 
reduced levels of sTREM2 were found in the supernatant of both knockdown and 
knockout cells despite the knockdown cells still having one unmodified allele and 
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having higher TREM2 protein and mRNA levels than the knockout cells. This could be 
attributed to failings in the translocation of the protein to the cell surface due to being 
truncated or misfolded or feedback mechanisms may be preventing TREM2 protein 
being translocated to the surface of the cell if low levels exist intracellularly to prevent 
depletion of stores. 
Unexpectedly, some TREM2 mRNA was identified in samples from the knockout G4 
and B5 cell line (approximately 20% of the levels found in the WT cells). The 
CRISPR/Cas9 targeted region of the Trem2 mouse gene is located in exon 2 and, if the 
gene editing did not introduce a stop codon to prevent further transcription, truncated 
TREM2 mRNA could continue to be generated in the knockout cell lines. The primers 
used to detect for the qPCR analysis span exons 4 and 5 of the TREM2 transcript 
(Mm04209424_g1, Thermo Fisher Scientific) and thus may be detecting TREM2 
mRNA transcripts containing the CRISPR/Cas9-induced indel in the 5’ end of the gene. 
Low levels of TREM2 protein are also detected in the knockout cell lines, which may be 
due to the generation of truncated mRNA which, following identification of altered 
protein localisation, almost absent sTREM2 generation and phagocytosis deficits this 
TREM2 protein, is unlikely to be functional.  
When TREM2 mRNA and protein levels are compared between the two different 
TREM2 knockdown cell lines, A7 and C8, there is markedly lower expression in the C8 
line despite both lines expressing one WT TREM2 allele. This could be attributed to 
gene expression regulation existing on the WT TREM2 allele in the C8 cell line altering 
the expression of TREM2 mRNA. For example, epigenetic events such as methylation 
or imprinting could be further contributing to decreases in TREM2 expression resulting 
in lower levels of mRNA in the C8 line compared with the A7. The regulation of the 
expression of TREM2 gene in these lines should be investigated further to confirm this 
hypothesis using techniques such as bisulfite conversion and high resolution melt 
analysis to determine the methylation state of TREM2 gene.  
ELISA data suggest that TREM2 mutations do not have an effect on TNFα secretion 
following initial stimulation with LPS however, once constitutive stores have been 
released, TREM2 modulation affects subsequent LPS-induced Tnf transcription and 
protein secretion following secondary stimulation. No difference in baseline Tnf mRNA 
levels were found in TREM2 knockdown cell lines but decreased mRNA post-LPS 
treatment was found when compared with WT cells. This suggests that TREM2 
influences the expression of Tnf mRNA in response to LPS treatment but not in 
unstimulated conditions. Published data have previously indicated that TREM2 acts to 
decrease TNFα responses following pro-inflammatory microglial activation, with 
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TREM2 knockout and knockdown models resulting in increased TNFα secretion 
(Turnbull et al., 2006; Wang et al., 2015; Zheng et al., 2016). However, in this study, 
the presence of functional TREM2 acted to increase TNFα expression whilst cells with 
TREM2 mutations expressed lower levels, reflecting data published in a model of 
stroke where isolated TREM2-/- microglia had decreased TNFα transcription (Sieber et 
al., 2013). 
Despite carrying identical indels in the TREM2 gene, the G4 and B5 knockout cell lines 
have differential baseline expression of Tnf mRNA, TNFα secretion following initial 
treatment with LPS and TNFα secretion following secondary LPS treatment in priming 
experiments. The G4 cell line followed similar trends to the A7 and C8 TREM2 
knockdown cells but with slightly larger effect sizes, suggesting that the B5 line may be 
behaving anomalously in regard to Tnf transcription and translation. Following the 
generation of the CRISPR/Cas9 modified cell lines, genes found in the predicted top 10 
most likely off target effects of the nickase plasmid were sequenced to confirm that 
none had been unintentionally modified. The Tnf gene was not identified as a top hit by 
the algorithm but off-target effects of the CRISPR/Cas9 process may explain why the 
B5 line responds differently to LPS. Interestingly, the Tnf mRNA levels following LPS 
treatment were similar between the G4 and B5 lines. The reduced baseline Tnf mRNA 
levels found in the B5 knockout lines concurred with published data showing that 
TREM2-/- microglia have downregulated Tnf expression (Mazaheri et al., 2017). In that 
study, TNFα protein was not assessed though so we do not know the implications of 
this reduced level of Tnf mRNA. 
We have shown that TREM2 knockout microglial cell lines display defective 
phagocytosis, resulting in reduced uptake of fluorescent E.coli particles compared with 
WT cells. This result concurs with published data resulting from TREM2 knockdown in 
cell lines (Takahashi, Rochford and Neumann, 2005; Xiang et al., 2016) as well as 
primary microglia from TREM2-/- mice (Kleinberger et al., 2014). Furthermore, TREM2 
overexpression or blocking of TREM2 cleavage from the surface of cells have been 
found to ameliorate particle uptake (Takahashi, Rochford and Neumann, 2005; N’Diaye 
et al., 2009; Kleinberger et al., 2014), demonstrating the importance of TREM2 in 
phagocytosis. The use of cytochalasinD treatment to block actin polymerisation and 
pHrodo particles confirmed that the signal measured by FACS was indeed following 
uptake of the particles rather than passive binding of the particles to the surface of the 
cells. The importance of a loss of microglial phagocytic ability for the progression of AD 
is two-fold: firstly, the clearance of apoptotic cells and debris minimises the risk of 
chronic neuroinflammation, and, secondly, defects in the removal of Aβ may result in 
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increased plaque load as well as higher concentrations of soluble, neurotoxic Aβ 
oligomers. Therefore, loss of function mutations in TREM2 may influence pathology by 
reducing the ability of microglia to clear Aβ as well as allowing the accumulation of 
debris that may activate microglia resulting in a neurotoxic, inflammatory environment.   
The deficiencies in E.coli particle uptake exhibited by TREM2 knockout cell lines may 
be partially attributed to the marked morphological differences identified between WT 
BV2 cells and cells where indels have been generated in one or both of the TREM2 
alleles using CRISPR-Cas9 technology. The TREM2 knockdown and knockout cell 
lines have significantly shorter filopodia, which are actin-rich projections from the cell 
membrane. The process of phagocytosis, namely the engulfment, internalisation and 
degradation of particles, relies entirely upon the ability of the actin cytoskeleton to 
modify the structure of the plasma membrane (Niedergang and Chavrier, 2004). 
Filopodia play a vital role in the early steps of engulfment by acting as ‘cellular 
tentacles’ that bind particles and drag them towards the cell over distances of up to 
10µm (Vonna et al., 2007) and generating forces up to 19pN (Kress et al., 2007). In 
fact, prevention of filopodia formation in amoebae through depletion of myosin VII 
results in an ablation of bead uptake, demonstrating the importance of these structures 
for phagocytosis (Tuxworth et al., 2001). In macrophages and other phagocytes, 
including microglia, particles are pulled towards the cell by filopodia at rapid speeds 
resulting from a combination of retrograde actin flow and rotational dynamics (Leijnse, 
Oddershede and Bendix, 2015). This is followed by slower particle engulfment within 
the phagocytic cup, which is formed by focal exocytosis of intracellular membrane 
stores at the cell surface in order to accommodate the necessary membrane extension 
around the particle (Niedergang and Chavrier, 2004). The phagocytic cup is formed 
following receptor recognition of particles for phagocytosis and resultant signal 
transduction for actin polymerisation and membrane extension. Rac and Cdc42 
signalling activates the actin nucleating Arp2/3 complex, an essential step for the 
formation of the phagocytic cup structures (May et al., 2000). Furthermore, the rapid 
extension and retraction of filopodia from the cell membrane is important for 
maintaining the high level of resting motility and surveillance performed by microglia 
(Nimmerjahn, Kirchhoff and Helmchen, 2005), enabling them to monitor their local 
environment and ensuring the clearance of any debris or infection. Therefore, if TREM2 
knockout cells have shorter filopodia, they may be less able to identify, bind to and pull 
particles towards the cell body for effective phagocytosis.  
Accurate and rapid remodelling of the actin cytoskeleton is essential for generating the 
necessary functional response to stimuli, including phagocytosis and migration, as well 
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as the constant environmental surveillance performed by microglia. Similar to results 
reported in the literature in the case of microglia and macrophages, WT BV2 cells 
underwent actin cytoskeleton remodelling to form membrane ruffles following 
stimulation with MCSF (Boocock et al., 1989; Ohsawa et al., 2000) and ATP (Honda et 
al., 2001). Membrane ruffles are wave-like structures found where the cell membrane 
extends and detaches with high levels of F-actin colocalising with Iba1 expression 
(Ohsawa et al., 2000). TREM2 knockdown and knockout clones exhibited defective 
cytoskeletal responses to both ATP and MCSF treatments; there was a significantly 
lower percentage of cells with ruffling morphology following treatment with both stimuli 
compared with WT cells.  
Despite similar defects in ruffle formation being found in TREM2 mutant cell lines, ATP 
and MCSF induce membrane ruffling through different signalling pathways (Haynes et 
al., 2006). Microglia from P2YR12-/- mice did not form membrane ruffles in response to 
ATP treatment but MCSF-induced ruffling was not affected (Haynes et al., 2006). 
Defects in two different pathways suggests that it is not detection of stimuli that is 
ineffective in TREM2 knockdown and knockout cells but more downstream issues in 
the actin coordination required for ruffle formation. Membrane ruffles have been 
identified as important actin structures for phagocytosis (Cox et al., 1997; Ohsawa et 
al., 2000), macropinocytosis (Racoosin and Swanson, 1989) and chemotaxis (Honda et 
al., 2001). The inability of TREM2 mutant cells to form membrane ruffles and shorter 
filopodia on the surface of the cells may explain the deficits found in phagocytosis 
compared with WT cells.  
In order to investigate whether treatment with sTREM2 could rescue the morphological 
defects found following stimulation with MCSF in the TREM2 knockout cell line, B5 
cells were treated with conditioned medium collected from WT BV2 cells, which has a 
high concentration of sTREM2. Although the role of sTREM2 is not yet known, 
treatment with sTREM2 has been linked to improved microglia viability and survival 
(Wu et al., 2015; Zhong et al., 2017) as well as influencing inflammatory responses 
(Zhong et al., 2017). If sTREM2 has a non-autonomous signalling function, one might 
expect treatment with media containing sTREM2 to improve the functionality of cells in 
which TREM2 has been knocked out. However, this was not this case as there was no 
significant difference in the ruffling morphology following MCSF treatment in cells 
treated with B5-conditioned medium and WT-conditioned medium. This experiment 
could also be performed with recombinant sTREM2 to ensure that other factors 
secreted into the conditioned medium are not having an inhibitory effect on cell 
responses. It has been previously reported that sTREM2 treatment was not effective in 
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rescuing phagocytic defects in TREM2-/- macrophages (Xiang et al., 2016), suggesting 
that sTREM2 released from the surface of the cells does not function to induce non-
autonomous TREM2 signalling to affect phagocytosis by neighbouring cells. 
The altered actin structure formation and subsequent reduced phagocytosis may be 
due to reduced Iba1 expression found following TREM2 knockdown and knockout. Iba1 
(ionized calcium binding adaptor molecule 1) is a microglia/macrophage specific 
protein that interacts with filamentous actin to form actin bundles (Sasaki et al., 2001) 
and Rac  (Ohsawa et al., 2000), a Rho family small GTPase which has been shown to 
be essential for the actin reorganisation required for membrane ruffling (Nobes and 
Hall, 1995). Iba1 and Rac play important roles in membrane ruffling and phagocytosis; 
in separate studies, one with cells expressing mutant Iba1 (Ohsawa et al., 2000) and 
another expressing mutant Rac1 (Cox et al., 1997), membrane ruffles fail to form in 
response to MCSF and decreased phagocytosis is found. Furthermore, expression of 
inhibitory mutant Iba1 resulted in a failure of actin crosslinking and a decrease in 
membrane ruffling (Sasaki et al., 2001). Iba1 protein and mRNA expression levels were 
found to be decreased, in a gene-dose dependent manner, in the TREM2 knockdown 
and knockout cell lines compared with WT cells. If an interaction is found to exist 
between TREM2 and Iba1, decreased Iba1 may explain the defects in actin responses 
and the functional effects of knockdown of TREM2 expression on the phagocytic ability 
of the cells.  
Other downstream effects of defective actin reorganisation should also be investigated 
for example cell migration as ATP-induced membrane ruffling has been found to 
precede chemotaxis (Honda et al., 2001; Haynes et al., 2006). P2YR12 is a purinergic 
receptor expressed on the surface of microglia and, in microglia isolated from P2YR12-
/- mice, a decrease in ruffling coincided with a decrease in microglial chemotaxis 
towards the source of ATP (Haynes et al., 2006). Furthermore, inhibition of Erk1/2, 
which is a signalling mediator of ATP-induced ruffling, leads to a decrease in 
membrane ruffles and inefficient chemotaxis (Lee et al., 2012). ATP is released 
following cell damage so morphological and chemotactic responses to this nucleotide 
are important for microglial responses to CNS injury. If TREM2 knockdown and 
knockout cells have altered abilities to generate membrane ruffles in response to ATP 
stimulation, these cells may be less able to migrate towards the area of CNS damage 
in order to perform their clearance activity, potentially resulting in the build-up of 
noxious debris. Filopodia, the generation of which have also been found to be defective 
in TREM2 modified BV2 cells, have also been shown to play an important role in 
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motility and chemotactic migration (Xue, Janzen and Knecht, 2010; Boer et al., 2015; 
Meyen et al., 2015). 
It is important to note that we are not proposing that it is the detection of the 
chemotactic signals that is defective in these cell lines, but that the cytoskeletal 
responses to the stimuli are lacking. Future investigations into the effect of TREM2 
expression manipulation on chemotactic migration and baseline motility should be 
investigated with transwells, boyden chamber techniques or time lapse, live imaging of 
cells. Studies in animal models have suggested a decrease in the number of microglia 
surrounding Aβ plaques in TREM2-/- AD models compared with WT TREM2 models 
(Ulrich et al., 2014; Jay et al., 2015; Wang et al., 2015), although this could be 
attributed to decreased microglial survival under stress rather than decreased capacity 
to migrate towards stimuli. The effect of TREM2 modulation on migration has been 
investigated in a recent study by Mazarheri et al. which demonstrated reduced 
migration in TREM2 knockout N9 microglial cells in response to CCL2 and C5a, which 
was rescued by TREM2 overexpression. Furthermore, baseline motility of ex-vivo 
microglia was reduced in organotypic brain slices from TREM2-/- mice compared with 
WT, in addition to impaired wound responses (Mazaheri et al., 2017). In this paper, the 
authors attribute this delayed response to the TREM2-/- microglia being locked in a 
resting state from which they are unable to be activated. However this could be due to 
defective actin structure remodelling resulting in delayed responses in cells lacking 
functional TREM2. 
Proteome analysis of the secretion profiles of unstimulated and LPS-stimulated WT 
and TREM2 modified cells highlighted the importance of chemokines in both basal and 
activated cells. Chemokines, including CCL2 which was the highest secreted protein 
found in the array of 111 cytokines and chemokines, signal via surface receptors and 
result in downstream signalling that causes actin remodelling in order to migrate 
towards the source of the chemotactic signal. The release of chemokines is evidently 
important for microglial function so if responses to these signals are impaired due to 
actin cytoskeletal issues, this could have a substantial impact of the ability of microglia 
to function normally. 
Rescue experiments should be performed for all assays to ensure that functional 
effects identified following TREM2 knockdown and knockout are due to loss of function 
of TREM2 rather than artefacts and off target effects from the CRISPR/Cas9 process. 
This should be performed using transient overexpression of WT TREM2 protein in the 
knockdown cells and subsequently ruffling responses, cytokine secretion, phagocytosis 
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and Iba1 expression should be investigated, with cells expected to act as WT cells if 
the effects are due to TREM2 knockdown.  
It is important to consider that these experiments were performed in cells with removal 
of significant sections of the TREM2 gene rather than the specific point mutations that 
are associated with Alzheimer’s disease, so cells may not behave in the same way as 
those expressing endogenous TREM2 levels albeit with point mutations. However, the 
point mutations found in AD are predicted to be loss of function (Dardiotis et al., 2017), 
and, as these CRISPR/Cas9 modifications have caused knockdown of protein 
expression such that the levels of functional protein are significantly reduced, this is a 
good model of loss of function mutations in the absence of BV2 cells harbouring 
disease-associated point mutations. Specific editing of the nucleotide required to 
generate R47H mutations in the BV2 cells was attempted by C. Villegas Llerena as 
part of this project but, due to the extremely low transfection efficiency found in the BV2 
cells, this was not successful. It is likely that highly sensitive microglia become 
activated upon encountering foreign DNA and, as professional phagocytes, 
phagocytoses foreign elements thus clearing away and destroying the nucleic acids 
intended to transfect them. 
Although the use of immortalised cell lines, such as BV2s, has many advantages, 
including convenience, reduced use of animals and high yields, limitations exist in the 
extent to which they successfully recapitulate the microglia that they are originally 
derived from. BV2 cells, which were generated from primary mouse microglia 
transfected with a v-raf/v-myc carrying retrovirus (Blasi et al., 1990), carry oncogenes 
that result in significant differences when compared with primary microglia. They have 
been shown to have increased proliferation and adhesion (Horvath et al., 2008), which 
is important to take into account when studying microglia, a cell type known for its slow 
turnover and low-levels of proliferation in physiological conditions. Furthermore, relative 
to primary mouse microglia, BV2 cells have a dampened immune response to LPS 
(Henn et al., 2009), although as many as 90% of the genes induced by LPS in the BV2 
cells matched those in primary cultures.  
In addition to the limitations of using immortalised cell lines, the suitability of cells of 
murine origin to study human diseases should also be considered. In the case of 
studying AD, the inability of a single mouse model to fully recapitulate all aspects of AD 
pathology, particularly neuronal loss, despite carrying multiple mutations that in 
isolation are capable of causing disease in humans, suggests that a model for studying 
AD as a whole is not available yet (reviewed in (Franco Bocanegra, Nicoll and Boche, 
2017)). However, analysis of murine and human microglia transcriptome demonstrated 
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similarities in gene expression, with 13,253 of 15,768 orthologous gene pairs 
expressed at similar levels (Gosselin et al., 2017). Transcriptional mechanisms that 
regulate microglial gene expression were also found to be largely conserved between 
human and mouse microglia (Gosselin et al., 2017), supporting claims that mouse 
microglia are suitable as a method for studying human microglial expression and 
function. Therefore murine cells may be suitable for investigating microglial genes 
associated with AD and their effect on microglia, even though caveats exist for the 
investigation of these genes in mouse models that aim to recreate AD pathology. 
In conclusion, key findings from the use of these TREM2 modified cells have 
substantiated previous findings from other TREM2 knockdown models including 
decreased surface expression, decreased sTREM2 generation and a reduction in 
phagocytosis, which provides evidence that these CRISPR/Cas9-generated lines are a 
good model of TREM2 loss of function mutations. The observation of a link between 
TREM2 expression and actin cytoskeleton organisation is a novel finding and could 
have significant implications for the understanding of the contribution of TREM2 
mutations to microglial dysfunction, in particular regarding the ability of microglia to 
respond to stimuli and to perform phagocytosis. The BV2 cell line has provided a useful 
tool for studying the effect of TREM2 loss of function but results need to be replicated 
in cells of human origin, ideally in lines that do not carry oncogenes resulting from 
immortalisation. The availability of primary human microglia is extremely limited, 
making conducting these experiments challenging, however the development of human 
iPSC-derived models of microglia (as discussed in the following chapter) is contributing 
to overcoming this limiting factor.   
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4. TREM2 mutations in human iPSC-derived microglia-like cells 
 
The iPSC-derived microglia-like cells used in this chapter were differentiated from iPSC 
cell lines by Dr Pablo Garcia Reitbӧck and Dr Thomas Piers (UCL Institute of 
Neurology). 
Microglia are the tissue-resident macrophages of the CNS (central nervous system) 
and genes expressed by microglia are implicated in a number of neurodegenerative 
diseases, including Alzheimer's disease (reviewed by (Villegas-Llerena et al., 2016)). 
However, there are large gaps in our understanding of human microglial activity during 
homeostasis and their effect on disease due to a lack of reliable, realistic models of 
microglia, in addition to difficulties in acquiring foetal or adult tissue for the isolation of 
primary human microglia.  
Immortalised cell lines are often used as the first resource for microglial modelling as 
they yield a large number of cells, are easily maintained and allow more controlled 
manipulation of specific variables than in vivo studies. However, these cells often carry 
genetic abnormalities derived from the immortalisation process and, as the name 
suggests, immortalised cell lines are highly proliferative and therefore do not accurately 
recreate predominantly non-proliferative microglia (Horvath et al., 2008).  
The use of animals, particularly mice, provides a readily-available source of brain 
tissue and also allows investigation into the role of specific genes in disease 
progression through the generation of genetically modified models. Evolutionarily-
conserved similarities found in key biological features of mice and humans, such as 
metabolic pathways and anatomy, have resulted in the widespread use of mouse 
models (Chinwalla et al., 2002). However, in the case of AD, difficulties and limitations 
exist in the use of mouse models as they fail to fully reproduce all of the components of 
AD pathology, in particular the concurrent deposition of Aβ and tau accumulation, 
which takes decades to amass in human brains (Bales, 2012; LaFerla and Green, 
2012; Franco Bocanegra, Nicoll and Boche, 2017). Additionally, and of particular 
relevance to the study of microglia, an analysis of the genes expressed in mouse and 
human brains found that modules of genes involved in immune responses were found 
to have the highest levels of interspecies divergence (Miller, Horvath and Geschwind, 
2010).  As well as the divergence of immune-related, microglial genes, Miller et al also 
identified significant expression differences in the AD-associated genes encoding for 
tau, presenilin-1 and glycogen synthase kinase 3β. Increasingly identified species-
specific differences between rodents and humans, particularly in the case of the 
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immune system (Franco Bocanegra, Nicoll and Boche, 2017), have highlighted the 
inadequacies of animal models and the importance of using human models where 
possible. 
Due to the lack of available fresh human brain tissue and the inability of primary 
microglia to replicate in culture, peripheral blood-derived monocytes and monocyte-
derived macrophages are frequently used as in vitro human models of microglia. Both 
cells types can be readily isolated from blood samples and are also myeloid cells like 
microglia, although as discussed earlier microglia are derived from erythro-myeloid 
precursors and monocytes are from haematopoietic stem cells (Schulz et al., 2012). 
Monocyte-derived macrophages are generated by isolating and culturing monocytes in 
macrophage colony stimulating factor (MCSF) for 7 days. Despite their frequent use as 
a model of microglia, monocyte-derived macrophages do not accurately recapitulate 
the yolk-sac derived ontogeny of microglia (Ginhoux et al., 2010, 2013). Furthermore, 
limitations also exist in the amount of blood that can be collected from donors so 
animal models are frequently used to provide primary microglia cultures.  
The development of protocols to generate renewable, terminally differentiated, human 
microglia that do not carry the karyotypic abnormalities of immortalised cells lines has 
the potential to revolutionise our understanding of microglia in both physiological and 
pathogenic states. Recently a protocol for the generation of human iPSC (induced 
pluripotent stem cell)-derived macrophages has been published (Van Wilgenburg et al., 
2013). This method recapitulates the embryonic ontology of microglia by generating 
Myb-independent myeloid cells (Buchrieser et al., 2017) and, as will be demonstrated 
in this thesis, following minor modifications, these cells express microglial genes and 
therefore refer to them as iPSC-derived microglia-like cells (iPSC-MGLC). 
4.1 The generation of human iPSC-derived microglia-like cells 
 
A protocol for the culture of iPSC-derived microglia like cells (iPSC-MGLC) was 
generated by Dr Pablo Garcia Reitbӧck (UCL Institute of Neurology) using recently 
developed macrophage differentiation protocols (Van Wilgenburg et al., 2013), with 
minor modifications in the time points of media changes. Fibroblast cultures were 
generated from skin punch biopsies, from which iPSC cultures were derived using 4 
factor Sendai virus reprogramming at the NIHR Cambridge Biomedical Research 
Centre (BRC) Human Induced Pluripotent Stem Cells core facility. Characterisation of 
the iPSC lines was performed by the BRC, including RT-PCR to check for plasmid 
integration, immunofluorescence to demonstrate expression of pluripotency markers 
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(Figure 4.1b) and ensuring the ability of the cells to differentiate into the 3 germ layers 
(Figure 4.1c, Brownjohn et al., manuscript in preparation). iPSCs were harvested and 
centrifuged to generate large, uniform embryoid bodies (Figure 4.1e). Embryoid bodies 
were cultured in media supplemented with growth factors that mimic the environmental 
cues found in the developing embryo in order to encourage haematopoiesis: bone 
morphogenetic factor 4 (BMP4) to induce cells of mesodermal origin, vascular 
endothelial growth factor (VEGF) to induce endothelial precursors and stem cell factor 
(SCF) to induce hematopoietic precursors. After 4 days, embryoid bodies were 
collected and pooled into a flask, in which directed differentiation was induced through 
supplementing myeloid progenitor medium with interleukin-3 (IL-3) and macrophage 
colony stimulating factor (MCSF). Most embryoid bodies floated and generated large 
cystic structures (Figure 4.1f), which non-adherent cells of small diameter started 
budding from after 10-14 days post seeding. After approximately 5 weeks, larger cells 
with fine processes started budding and were able to attach to tissue culture plates. 
Several million of these cells were able to be harvested from a 175cm2 flask of ~150 
embryoid bodies on a weekly basis. The immature progenitor cells were cultured and 
matured in medium supplemented with 100 ng/ml MCSF for 7 days resulting in 
matured, iPSC-microglia like cells (Figure 4.1g & h). In this thesis, one clone from each 
cell line was used. 
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1) Generation of iPSCs 
 
• Fibroblast cultures generated from skin punch biopsies 
• Reprogrammed using 4 factor Sendai virus 
• Pluripotency confirmed by immunofluorescence and scorecard panel 
• Normal karyotype confirmed 
• iPSCs cultured feeder free in E8 medium 
GATA-4 
HAND1 
Otx-2 
a
. 
b
. 
c
. 
d
. 
2) Embryoid Body Formation 
 
• E8 medium supplemented with BMP-4, VEGF, SCF and ROCK inhibitor 
• Cells were centrifuged to aid embryoid body formation 
• Cultured in 96 well plate for 5 days prior to harvesting 
e
. 
3) Myeloid Progenitor Differentiation 
 
• ~150 embryoid bodies per flask in myeloid progenitor differentiation medium (x-vivo 
base with β-mercaptoethanol, MCSF and IL3) 
• After ~ 4 weeks cells start budding from embryoid bodies 
• Budding cells can then be harvested weekly 
f 
4) Microglia-like Cell Maturation 
 
• Harvested cells are matured for 7 days before being used for experiments in x-vivo 
medium supplemented with 100ng/ml MCSF  
DAPI 
P2YR12 
g
. 
h
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4.2 iPSC-MGLC express microglial genes including TREM2 
 
We wanted to investigate whether the expression of various microglial markers by 
iPSC-MGLCs differed from primary blood derived monocytes and monocyte-derived 
macrophages through qPCR analysis of mRNA levels.  Commercially available human 
primary microglia cDNA (Sciencell, San Diego, California, United States) was included 
as a positive control for endogenous microglial expression levels but could not be 
included in statistical tests as only one sample was available for purchase. This sample 
was from a single adult donor although further information on the donor’s age or cause 
of death was not provided. The cell surface receptor TMEM119 is a highly expressed 
microglia-specific receptor, which is reportedly able to distinguish microglia from 
resident macrophages and infiltrating macrophages following CNS injury and 
neuroinflammation (Bennett et al., 2016). Indeed, the iPSC-MGLC cells had 
significantly higher expression levels of TMEM119 mRNA than the monocytes 
(*p<0.05, Figure 4.2a), and 5-fold higher expression than the macrophages (p=0.1). 
Expression of the gene encoding the P2YR12 receptor, preferentially expressed in 
microglia as opposed to monocytes (Butovsky et al., 2014), was significantly higher in 
the iPSC-MGLCs than in macrophages (*p<0.05, Figure 4.2b), however the expression 
in the microglial sample was approximately 4-fold higher than in the iPSC-MGLC 
samples.  
GPR34, PROS1, SPI1, TGFB1  and C1QA  were also identified in the Butovksy paper 
as being highly microglia specific (Butovsky et al., 2014) therefore the expression of 
these genes compared to monocytes and macrophages was also assessed.  The 
iPSC-MGLC expressed significantly higher levels of C1QA, PROS1 and GPR34 than 
both monocytes and macrophages (*p<0.05, **p<0.01, ****p<0.0001, Figure 4.2). The 
expression levels of SPI1 and TGFB1 were found to be consistent across the different 
myeloid cell types. The iPSC-MGLC had comparable expression levels to microglia in 
the case of TMEM119 and TGFB1, and, although expression was lower than the 
Figure 4.1 The generation and characterisation of iPSC-MGLC 
Diagram showing the steps in the generation of iPSC-derived microglia-like cells (iPSC-MGLC). iPSC 
colonies (a) were generated from fibroblast cultures from donor skin punch biopsies. These iPSCs were 
characterised by immunofluorescence (b) and gene expression score cards (c) to ensure expression of 
pluripotency markers. Karyotype was also assessed for abnormalities (d). Brightfield microscopy showing 
an embryoid body in a 96 well low adherence plate (e) and embryoid bodies forming large cystic 
structures in myeloid progenitor differentiation medium (f). Brightfield microscopy of iPSC-MGLC following 
maturation in MCSF and immunofluorescent microscopy showing expression of microglial marker 
P2YR12 (h). Images kindly provided by Dr Pablo Garcia Reitbӧck, UCL Institute of Neurology. 
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microglia sample for C1QA, GPR34 and P2YR12, the expression was significantly 
higher than in monocyte-derived macrophages (*p<0.05, **p<0.01, ****p<0.0001, 
Figure 4.2) therefore the cells can be referred to as ‘microglia-like cells’. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.2 Expression of microglial markers by monocytes, macrophages and iPSC-
MGLC 
qPCR used to determine mRNA expression levels of P2YR12 (a), C1QA (b), TMEM119 (c), SPI1 (d), 
PROS1 (e), GPR34 (f), TGFβ1 (g) in iPSC-MGLC compared to monocytes, monocyte-derived 
macrophages and commercially available cDNA from human microglia (single adult donor obtained from 
Sciencell). Graph represents gene of interest mRNA expression normalised to GAPDH mRNA expression 
and data is shown relative to monocyte expression levels. Values expressed as mean ± SEM (* 
p<0.05,**p<0.01, **** p<0.0001; one way ANOVA with Bonferroni’s multiple comparison test).  n= 5 for 
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monocyte samples, n=3 for macrophage samples, n=6 for iPSC-MGLC samples and n=1 for microglia 
samples. 
 
In addition to the microglial markers, the expression of TREM2 by the different cell 
types was also assessed by qPCR. The iPSC-MGLCs and commercially available 
microglia cDNA sample expressed similar levels of the gene, which was significantly 
higher than the monocytes (**p<0.01, Figure 4.3). The iPSC-MGLCs expressed twice 
as much as the macrophages although there was insufficient power for statistical 
significance to be achieved (p=0.12). Due to the expression of multiple microglial 
markers, above levels found in macrophages, and the robust expression of TREM2, 
the iPSC-MGLCs are a suitable model for studying the role of TREM2 in human 
microglia.  
 
 
 
 
 
 
Figure 4.3 Expression of TREM2 mRNA in iPSC-MGLC 
qPCR used to determine mRNA expression levels of TREM2 in iPSC-MGLC compared to monocytes, 
monocyte-derived macrophages and microglia. Graph represents TREM2 mRNA expression normalised to 
GAPDH mRNA expression and data is shown relative to monocyte expression levels. Values expressed 
as mean ±SEM (** p<0.01; one way ANOVA with Bonferroni’s multiple comparison test).  n= 6 for 
monocyte samples, n=3 for macrophage samples, n=6 for iPSC-MGLC samples and n=1 for microglia 
samples. 
 
4.3 The generation of iPSC-MGLC harbouring TREM2 mutations 
 
One of the main advantages of iPSC technology is the ability to generate patient-
derived cell lines from relatively non-invasive skin punch biopsies, providing new 
opportunities for studying the relationship between disease-associated mutations and 
pathogenesis. Being able to generate microglia-like cells from iPSCs derived from 
patients carrying disease modifying mutations allows us to investigate the effect of 
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these mutations on human microglia function and expression whilst maintaining the 
patients’ genetic background.  
For this study into the role of TREM2 in microglia, iPSC-MGLC were generated from a 
Nasu-Hakola disease (NHD) patient carrying a homozygous TREM2 T66M mutation, 
two unaffected relatives carrying a heterozygous TREM2 T66M mutation, a NHD 
patient carrying a homozygous TREM2 W50C mutation and three control cases (Table 
4.1). The two cases of NHD have been described previously (Guerreiro et al. 2013b; 
Dardiotis et al. 2017) and three control iPSC lines were included for comparison. 
Homozygous TREM2 mutations are thought to cause NHD (Paloneva et al., 2002) 
whilst Alzheimer’s disease is associated with heterozygous TREM2 mutations 
(Guerreiro et al. 2013a; Jonsson et al. 2013). The heterozygous T66M lines may 
provide information that can be applied to the study of Alzheimer’s because, although 
the most common AD-associated TREM2 mutation is heterozygous R47H, T66M 
mutations have been found in heterozygosity in some AD cases so the unaffected 
cases may develop pathology in later life  (Guerreiro et al. 2013a). Therefore, the study 
of these mutations may yield information that can be applied from NHD to AD, two 
diseases linked to different mutations of the same gene. 
iPSC line Age Sex Clinical Details 
TREM2 
mutation 
CTRL1 78 M Control No mutation 
CTRL2 64 M Control No mutation 
CTRL3 31 F Control  No mutation 
T66Mhet1 75 F 
Unaffected relative of 
T66Mhom 
Heterozygous 
T66M 
T66Mhet2 47 M 
Unaffected relative of 
T66Mhom 
Heterozygous 
T66M 
T66Mhom 51 F Nasu Hakola disease 
Homozygous 
T66M 
W50Chom 36 F Nasu Hakola disease 
Homozygous 
W50C 
Table 4.1 Characteristics of TREM2 mutant and control iPSC lines used in this study 
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4.4 iPSC-MGLC harbouring mutations in TREM2 still express microglial 
markers 
 
The expression of microglial markers in iPSC-MGLC with mutations in TREM2 was 
assessed by qPCR to ensure that the mutations had not affected the expression of 
markers and therefore, not affected how ‘microglia-like’ these cells are. The expression 
of SPI1, PROS1 and TGFβ1 were found to be the same in the control cells and those 
with TREM2 mutations (Figure 4.4 d, e, g). The T66Mhet and T66Mhom cells 
expressed lower levels of P2YR12 than controls but expression was still detected 
(Figure 4.4a). The Ct values for P2YR12 in these cells are usually high (30-35), so 
decreases identified in expression are exaggerated. The T66Mhom mutant line had 
significantly higher levels of TMEM119 than controls (*p<0.05, ****p<0.0001, Figure 
4.4b). Levels of C1QA and GPR34 were similar to controls with the exception of the 
T66M homozygous line (*p<0.05, Figure 4.4c & f).  
Following this analysis, we were confident that the mutant lines had maintained their 
microglial expression signature and could be used to study the effect of TREM2 
mutations on microglial function. 
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Figure 4.4 Expression of microglial markers in iPSC-MGLC harbouring TREM2 mutations 
qPCR used to determine mRNA expression levels of P2YR12 (a), TMEM119 (b), C1QA (c), SPI1 (d),
PROS1 (e), GPR34 (f), TGFβ1 (g)  in iPSC-with mutations in TREM2. Graph represents gene of interest 
mRNA expression normalised to GAPDH mRNA expression and data is shown relative to CTRL1 
expression levels. Values expressed as mean ±SEM for three individual experiments (* p<0.05, **** 
p<0.0001; one way ANOVA with Dunnett’s multiple comparison test).   
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4.5 Reduced TREM2 expression in TREM2 mutant iPSC-MGLC 
 
TREM2 expression levels in the control and TREM2 mutant cells were determined by 
qPCR and western blotting. There was no statistically significant difference in TREM2 
mRNA levels between the control and heterozygous iPSC-MGLCs, however mRNA 
levels were significantly lower in both of the lines carrying homozygous TREM2 
mutations (** p<0.01,Figure 4.5a). The expression levels of the TREM2 binding partner 
TYROBP were also assessed by qPCR analysis and no statistically significant 
differences were found between control and mutant iPSC-MGLC lines (Figure 4.5b). 
 
 
 
 
 
 
 
 
 
 
Figure 4.5 The expression of TREM2 and its signalling partner TYROBP in control and 
TREM2 mutant iPSC-MGLC 
qPCR used to determine mRNA expression levels of TREM2  (a) and TYROBP (b) in control and mutant
iPSC-MGLC lines. Graph represents gene of interest mRNA expression normalised to GAPDH mRNA 
expression and data is shown relative to CTRL1 expression levels. Values expressed as mean ± SEM (** 
p<0.01; one way ANOVA with Dunnett’s multiple comparison test). Control values (3 groups) and T66M 
heterozygous values (2 groups) pooled for statistical analysis. N=3 for each cell line. 
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Further evidence of reduced TREM2 expression in the homozygous mutant cells 
compared with the controls resulted from western blot analysis of TREM2 protein 
levels. Reduced protein expression was also found in the heterozygous T66Mhet1 and 
T66Mhet2 cells, which was confirmed with two separate antibodies. The AF1828 and 
D8I4C anti-TREM2 antibodies allowed the visualisation of mature and immature 
TREM2 protein, both of which were found at higher levels in control iPSC-MGLC than 
in the heterozygous and homozygous TREM2 mutation iPSC-MGLC (**p<0.01, 
***p<0.001, ****p<0.0001, Figure 4.6b and c). TREM2 is cleaved at the cell membrane 
by ADAM10 protease activity (Kleinberger et al., 2014) resulting in the secretion of 
soluble TREM2 (sTREM2) in to the cell supernatant leaving a C-terminal fragment 
(CTF) tethered to the cell membrane. This CTF is detectable with the D8I4C anti-
TREM2 antibody and was found to be significantly lower in the heterozygous and 
homozygous iPSC-MGLCs than in the control cells (****p<0.0001, Figure 4.6c). Mature 
TREM2 and TREM2 CTF expression levels were found to be decreased in a gene 
dose dependent manner; heterozygous cells had approximately 50% of the expression 
of control cells whilst homozygous cells had approximately 10% of the control cells.    
Following the observation of reduced TREM2 protein levels in iPSC-MGLC harbouring 
TREM2 mutations, the generation of soluble TREM2 (sTREM2) from the surface of the 
cells was assessed by ELISA analysis. Marked reductions in sTREM2 concentrations 
in cell supernatants were found in heterozygous iPSC-MGLCs compared with control 
cells (**p<0.01, Figure 4.7), whilst sTREM2 levels in the supernatants of homozygous 
T66Mhom and W50Chom cells were almost undetectable (***p<0.001).  
 
 
Figure 4.6 Expression of TREM2 protein in control and TREM2 mutant iPSC-MGLC 
Western blot analysis of TREM2 protein expression in control, T66M heterozygous, T66M homozygous 
and W50C homozygous iPSC-MGLC. Representative blots shown following probing with AF1828 anti-
TREM2, D8I4C anti-TREM2 and anti-βactin antibodies (a). Graphs represent protein levels of mature 
TREM2 (AF1828 antibody)(b), immature TREM2 (AF1828)(c) and TREM2 C-terminal fragment (D8I4C) 
(d) normalised to β-actin levels. Values relative to CTRL1 and expressed as mean ±SEM for 3 individual 
experiments (*p<0.05, **p<0.01, ****p<0.0001; one way ANOVA with Dunnett’s multiple comparison test).
Control values (3 groups) and T66M heterozygous values (2 groups) pooled for statistical analysis. Figure 
kindly provided by Dr Thomas Piers, UCL Institute of Neurology.  
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Immunocytochemical analysis of TREM2 expression in the iPSC-MGLC indicated that, 
as found by western blotting, TREM2 protein expression is lower in the T66Mhet, 
T66Mhom and W50Chom cell lines compared with the controls (Figure 4.8a). 
Preliminary colocalisation analysis was conducted on the control and T66M iPSC-
MGLC using antibodies specific to markers of the golgi complex (golgin97) and the 
endoplasmic reticulum (ER, calnexin) in order to investigate the intracellular localisation 
of the TREM2 protein. In the control iPSC-MGLC, the highest levels of intracellular 
TREM2 staining were found in regions that co-stained for golgin97 (Figure 4.8b), 
indicating that TREM2 protein is primarily found in the golgi, as reported in the literature 
(Sessa et al., 2004). There did not appear to be significant colocalisation between 
TREM2 staining and calnexin staining for the ER (Figure 4.8c). In the T66Mhom iPSC-
MGLC there was less co-localisation with the golgi (Figure 4.8b), which may suggest 
that TREM2 protein is not being trafficked through the cell appropriately. 
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Figure 4.7 Soluble TREM2 release from control and TREM2 mutant iPSC-MGLC 
Soluble TREM2 (sTREM2) secretion levels determined by ELISA. Values expressed as mean ±SEM for 3 
individual experiments (** p<0.01, *** p<0.001; one way ANOVA with Dunnett‘s multiple comparison test). 
Control values (3 groups) and T66M heterozygous values (2 groups) pooled for statistical analysis. 
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Mutations in TREM2 alter the expression of TREM2 mRNA, the processing and 
expression of TREM2 protein and the cleavage of sTREM2 from the surface of the 
cells, with effects found to be more severe in the homozygous lines than in the 
heterozygous iPSC-MGLC. Following these observations, the effect of TREM2 
mutations on key microglial functions was assessed to understand how these 
mutations may contribute to pathogenesis. 
 
  
Figure 4.8 Immunocytochemical analysis of TREM2 expression 
Representative images of TREM2 immunocytochemical analysis. (a) TREM2 expression shown in green 
merged with DAPI showing nuclear staining in blue. (b) Preliminary data showing TREM2 (green), 
Golgin97 (red, indicating golgi complex) and DAPI (blue). (c) Preliminary data showing TREM2 (green), 
calnexin (red, indicating endoplasmic reticulum) and DAPI (blue). Scale bars represents 50μm. 
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4.6 The expression of TREM2 T66M homozygous mutations affects 
phagocytosis by iPSC-MGLC 
 
Modification of TREM2 expression has been shown to affect the phagocytic ability of 
microglia and macrophages, although the directionality of the effect is disputed 
(Kleinberger et al., 2014; Wang et al., 2015; Xiang et al., 2016). Therefore the impact of 
TREM2 mutations on the phagocytic capability of iPSC-MGLC was investigated. 
Phagocytosis of unstimulated cells was measured using pHrodo E.coli particles that 
are designed to fluoresce in an acidic environment, such as that within a phagosome. 
Quantification of particle uptake by the control and TREM2 mutant iPSC-MGLC was 
performed by FACS analysis. CytochalasinD inhibits the cytoskeletal reorganisation 
required for phagocytosis and therefore was used as a negative control, resulting in 
almost complete abolishment of fluorescent signal due to inhibition of particle uptake 
(***p<0.001, Figure 4.9). There was no difference in the mean pHrodo fluorescence of 
T66M heterozygous cells compared with control cells, however, there was a significant 
decrease in the phagocytosis of E.coli particles by T66M homozygous mutant iPSC-
MGLC (*p<0.05, Figure 4.9). 
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Figure 4.9 The effect of TREM2 mutations on the phagocytosis of pHrodo fluorescent 
E.coli particles by iPSC-MGLC 
FACS analysis of iPSC-MGLC uptake of pHrodo green E.coli particles after 2 hours of incubation as a 
measure of phagocytosis. CytochalasinD (cytoD) treatment used as a negative control. Representative 
histograms showing mean fluorescence plotted against cell number for cytoD (a) and T66Mhom (b). Graph 
represents mean fluorescence of individual cells for each cell type normalised to CTRL1 (c). Values 
expressed as mean ±SEM for 3 individual experiments (* p<0.05, *** p<0.001; one way ANOVA with 
Dunnett‘s multiple comparison test). Control values (3 groups) and T66M heterozygous values (2 groups) 
pooled for statistical analysis. 
 
In addition to being a component of the molecular signature that is enriched in 
microglia populations relative to other myeloid cells (Butovsky et al., 2014), MerTK is a 
member the Tyro3, Axl, and MerTK (TAM) family of tyrosine kinase receptors. This 
group of receptors are important phagocytosis receptors that function to clear apoptotic 
cells, membranes and myelin, whilst downregulating pro-inflammatory responses 
(Lemke, 2013). In order to investigate the reason for the decreased phagocytosis found 
in T66M homozygous mutant iPSC-MGLC, and to confirm that defects were due to 
reduced altered TREM2 expression rather than reduced expression of other 
phagocytosis receptors, the expression of MERTK and AXL was assessed by qPCR. 
No significant differences in MERTK or AXL mRNA levels were identified in control or 
TREM2 mutant iPSC-MGLC (Figure 4.10). 
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4.7 Homozygous TREM2 mutant iPSC-MGLC secrete more TNFα in 
response to LPS than controls 
 
The inflammatory aspects of many neurodegenerative diseases, including Alzheimer’s 
disease, are often attributed to the release of proinflammatory cytokines and immune 
cell-recruiting chemokines by activated microglia. Published data regarding TNFα 
release following pro-inflammatory stimulation in TREM2 knockout mice and TREM2 
knockdown cell lines are conflicting (Turnbull et al., 2006; Sieber et al., 2013). 
Therefore, the secretion of TNFα by control and TREM2 mutation-carrying iPSC-MGLC 
was assessed by ELISA. The cells were stimulated for 18 hours with 100ng/ml LPS, a 
well characterised TLR-4 ligand known to activate microglia, prior to collection of 
supernatants. LPS treatment resulted in increased TNFα secretion in all cell lines 
compared to basal levels, however only T66Mhom had significantly higher TNFα 
concentrations in the cell supernatant than the control lines (**p<0.01, Figure 4.11). No 
statistically significant difference was found in the T66M heterozygous and W50C 
homozygous iPSC-MGLC lines.  
 
 
 
Figure 4.10 Expression of MERTK and AXL in iPSC-MGLC 
qPCR used to determine mRNA expression levels of MERTK  (a) and AXL (b) in control and mutant iPSC-
MGLC lines. Graph represents gene of interest mRNA expression normalised to GAPDH mRNA 
expression and data is shown relative to CTRL1 expression levels. Values expressed as mean ±SEM 
(one way ANOVA with Dunnett’s multiple comparison test). Control values (3 groups) and T66M 
heterozygous values (2 groups) pooled for statistical analysis. N=3 for each cell line. 
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Interleukin-6 (IL-6) has previously been reported to be modulated by TREM2 
expression (Turnbull et al., 2006; Jay et al., 2015; Zhong et al., 2015) so it was also 
selected for further ELISA analysis. However, baseline levels and LPS-evoked IL-6 
secretion levels did not differ between control and TREM2 mutant iPSC-MGLCs 
(Figure 4.12). 
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Figure 4.11 ELISA quantification of TNFα secretion by iPSC-MGLC 
TNFα secretion following 18 hours of LPS treatment (100ng/ml). Values expressed as mean ±SEM for 3 
individual experiments (* p<0.05, *** p<0.001; one way ANOVA with Dunnett‘s multiple comparison test). 
Control values (3 groups) and T66M heterozygous values (2 groups) pooled for statistical analysis. 
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Figure 4.12 ELISA quantification of IL-6 secretion by iPSC-MGLC 
IL-6 secretion following 18 hours of LPS treatment (100ng/ml). Values expressed as mean 
±SEM for 3 individual experiments (one way ANOVA with Dunnett‘s multiple comparison test). 
Control values (3 groups) and T66M heterozygous values (2 groups) pooled for statistical 
analysis. 
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4.8 iPSC-MGLC express other dementia-associated microglial genes  
 
Several other microglial genes have been identified as having a genetic association 
with AD and other neurodegenerative diseases, including CSF1R, CD33, APOE and 
SPI1. The ε4 allele of the apolipoprotein APOE is the strongest risk factor for 
developing AD and, in the brain, is mainly expressed by astrocytes and microglia 
(Zhang et al., 2014). Different SNPs in the CD33 gene have been associated with both 
increased and decreased risk of AD (Griciuc et al., 2013; Malik et al., 2013), and in 
human monocytes CD33 has been found to modulate TREM2 expression (Chan et al., 
2015). A common haplotype that lowers the expression of Pu.1, encoded for by SPI1, 
has been found to delay AD onset (Huang et al., 2017) and mutations in the MCSF 
receptor CSF1R have been found to cause leukoencephalopathy with axonal spheroids 
(Rademakers et al., 2011). The expression of these genes in the iPSC-MGLC was 
investigated to determine whether these cells lines would be suitable models for the 
study of microglia and genetic risk factors for other neurodegenerative diseases.   
Expression levels of CSF1R and SPI1 were found to be similar in monocytes, 
macrophages and iPSC-MGLC, with expression slightly lower in the microglia sample 
(Figure 4.13 a & d). iPSC-MGLC also expressed similar levels of CD33 and APOE to 
microglia (Figure 4.13 b & c), indicating that the iPSC-MGLC cell lines are suitable 
models for studying these genes and the subsequent protein products in microglia.  
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4.9 The expression of TREM2 T66M and W50C mutations affects the 
expression of dementia-associated microglial genes 
 
The expression of these neurodegenerative disease risk factors in iPSC-MGLC 
carrying TREM2 mutations was assessed to investigate whether TREM2 mutations 
have any effect on these risk genes. All genes were found to be expressed in the iPSC-
MGLC and no differences were found in the mRNA levels of CSF1R, SPI1 or CD33 
between control and TREM2 mutant iPSC-MGLCs (Figure 4.14a, b & c). Interestingly, 
APOE expression levels were found to be lower in the W50C homozygous iPSC-MGLC 
compared to the controls (*p<0.05, Figure 4.14d). Therefore, as the cells express these 
neurodegeneration-associated genes, they would be suitable models for the further 
study of the role of these genes in human microglia. TREM2 mutations do not affect the 
expression of CSF1R, SPI1 or CD33 but, in this case, may alter the expression levels 
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Figure 4.13 Expression of neurodegenerative disease risk factors in iPSC-MGLC 
qPCR used to determine mRNA expression levels of CSF1R (a), CD33 (b), APOE (c), SPI1 (d) in iPSC-
MGLC compared to monocytes, monocyte-derived macrophages and microglia. Graph represents gene of 
interest mRNA expression normalised to GAPDH mRNA expression and data is shown relative to 
monocyte expression levels. Values expressed as mean ±SEM n= 5 for monocyte samples, n=3 for 
macrophage samples, n=6 for iPSC-MGLC samples and n=1 for microglia samples. 
a b 
c d 
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of the APOE, which is the highest risk factor for the development of late onset 
Alzheimer’s disease.  
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Figure 4.14 Expression of neurodegenerative disease risk factors in TREM2 mutant iPSC-
MGLC 
qPCR used to determine mRNA expression levels of SPI1 (a), CSF1R (b), CD33 (c), APOE (d) in control 
and mutant iPSC-MGLC lines. Graph represents gene of interest mRNA expression normalised to GAPDH 
mRNA expression and data is shown relative to CTRL1 expression levels. Values expressed as mean 
±SEM (*p<0.01; one way ANOVA with Dunnett’s multiple comparison test). Control values (3 groups) and 
T66M heterozygous values (2 groups) pooled for statistical analysis. N=3 for each cell line. 
a b 
c d 
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4.10 Discussion 
 
It has been shown in this thesis that iPSC-derived macrophages cultured by other 
members of the lab (Dr Pablo Garcia Reitbӧck and Dr Thomas Piers) can, after minor 
protocol modifications, express key microglial marker genes, with these cells 
henceforth known as iPSC-derived microglia-like cells (iPSC-MGLC). The iPSC-MGLC 
express higher levels of microglial markers than monocytes and monocyte-derived 
macrophages, and are able to function as phagocytes that respond appropriately to 
pro-inflammatory stimuli, thus making them a valuable model of human microglia. 
Genome-wide association studies continue to link microglia-expressed genes and 
neurodegenerative disease, particularly Alzheimer’s disease (Villegas-Llerena et al., 
2016), resulting in more demand than ever for appropriate human models to study 
these cells. Primary microglia isolated from rodent brain tissue had previously been 
seen as the best model of brain resident microglia, however as limitations in the use of 
rodents as suitable models for the study of immune responses in human CNS health 
and disease continue to be recognised (Miller, Horvath and Geschwind, 2010; Franco 
Bocanegra, Nicoll and Boche, 2017), it is increasingly important to utilise human-
derived cells for these studies. Primary microglia can be isolated from brain tissue but, 
whilst tissue from resective epilepsy surgery can occasionally be obtained at the 
Institute of Neurology, it is difficult to obtain sufficient cell numbers for most 
experimental techniques, and furthermore information on the expression of any AD-
associated mutations is not provided, so these cells do not provide the additional 
benefits of the iPSCs derived from AD patients. Additionally, due to the plastic nature of 
microglia, the process of acquiring and culturing primary cells has been shown to 
significantly alter the expression of key microglial markers and disease risk-factor 
genes in these cells (Gosselin et al., 2017). Gosselin et al showed that culturing ex vivo 
primary human microglia resulted in upregulation of 300 genes by 10 fold, including 
inflammatory and stress response genes, and downregulation of 700 by 10 fold, 
including immune cell function associated genes. Furthermore, with 31% of genes 
associated with AD found to be modified by at least twofold (Gosselin et al., 2017), this 
highlights the limitations of using ex vivo culturing of such responsive cell types, 
particularly for the study of AD.  
In light of this, modifications to a protocol designed for the generation of iPSC-derived 
macrophages (Van Wilgenburg et al., 2013) were made in order to produce iPSC-
derived microglia-like cells. This protocol provides many benefits over culturing primary 
cells, in addition to avoiding isolation steps where expression changes are found. In the 
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iPSC-generation process, fibroblast cultures from donor skin punch biopsies are 
reprogrammed to form iPSCs, providing a starting material that has unlimited capacity 
for self-renewal, normal karyotype, is amenable to genetic modification and can be 
patient derived and thus carry disease-associated mutations. This protocol utilises fully 
defined culture conditions that do not require serum, a potential source of variability 
due to batch effects, ensuring more consistent results across multiple differentiation 
runs. Furthermore, progenitor cells can be harvested for several weeks providing a 
high yield of cells, allowing the application of a range of experimental techniques with 
every batch.  
Recent deciphering of microglial ontogeny allows us to accurately recapitulate 
microglial development in order to appropriately model these cells. Yolk sac-derived 
primitive macrophages populate the developing mouse brain between embryonic days 
E7.5-E8.2, where they develop into microglial progenitors that proliferate slowly, 
develop ramified process and become mature microglia, the resident tissue 
macrophages of the brain and CNS (Ginhoux et al., 2010, 2013). These cells are Myb-
independent and PU.1-dependent, in contrast to the blood monocytes-derived 
macrophages which are constantly renewed in a Myb-dependent manner by 
hematopoietic stem cells. These Myb-dependent cells only populate the fetal liver and 
bone marrow at day E10.5, after the closure of the blood brain barrier (Ginhoux et al., 
2010; Hoeffel et al., 2015). In homeostatic conditions, microglia self-renew and are not 
replenished by peripheral monocytes and macrophages, although infiltration of these 
cells has been reported following infection, injury and neurodegenerative disease (El 
Khoury et al., 2007; Ajami et al., 2011; Menasria et al., 2015; Ritzel et al., 2015). The 
precursors to the iPSC-MGLCs generated by this protocol have been shown to be Myb 
independent and PU.1 dependent (Vanhee et al., 2015; Buchrieser et al., 2017) and 
therefore recapitulate the embryonic ontogeny of microglia.  
This faithful recreation of yolk sac primitive macrophage ontogeny combined with 
modifications to existing macrophage protocols have resulted in the generation of 
iPSC-MGLC that express various key microglial markers. When compared with 
monocytes and monocyte-derived macrophages, the iPSC-MGLC were found to 
express higher levels of the microglial markers C1QA, TMEM119, P2YR12, GPR34 
and PROS1, showing that the modifications to the iPSC-derived macrophage protocol 
produced “microglia-like” cells. These markers have been identified as key components 
of the molecular signature of microglia and are capable of distinguishing microglia from 
the circulating macrophages and monocytes that are recruited into the CNS during 
neuroinflammatory disease (Butovsky et al., 2014). The availability of commercially-
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sourced microglial cDNA as an indicator of the physiological expression of microglia 
markers provided a useful extra tool for evaluating the iPSC-MGLC as a model of 
microglia. The iPSC-MGLC and microglia sample expressed similar levels of 
TMEM119 and TGFβ1, with expression levels of SPI1 and PROS1 found to be higher 
in the iPSC-MGLC than in the microglia. Although the inclusion of this human microglial 
sample is useful for comparing expression levels of microglial markers in a range of cell 
types which are used as models of microglial to varying levels of accuracy, it is worth 
noting that there are limitations in the comparisons that can be drawn between these in 
vitro  and ex vivo samples. The monocyte, and presumably the microglial, although this 
cannot be confirmed, samples were prepared for RNA isolation immediately after 
isolation so are likely to represent in vivo expression most closely. The macrophages 
were cultured for 7 days prior to RNA extraction so are unlikely to maintain their in vivo 
expression profile, along with the in vitro iPSC-MGLC. The different culture methods 
should therefore be taken into account when comparing expression levels in these 
samples. It is also important to consider how accurately the microglia sample 
represents true, physiological microglial expression. The sample was collected from a 
“healthy” brain however this was likely to be an autopsy sample with no specific 
information provided on the time of isolation. The cause of death of the donor is also 
unknown so pre-symptomatic pathology may have existed in the brain that altered 
microglial expression. Furthermore, the process of microglial isolation reportedly 
activates microglia and alters their expression (Gosselin et al., 2017), therefore 
although this sample is useful as it gives an indication of microglial marker expression, 
it is unlikely to represent resting microglia. 
The iPSC-MGLC expressed microglial markers at levels greater than those found in the 
macrophage samples, in addition to exhibiting similar expression levels of TREM2 as 
those found in the human primary microglia sample. This demonstrates the usefulness 
of the iPSC-MGLC as a model for studying the role of TREM2 in microglia. iPSC-based 
models allow the study of disease risk factors at their correct gene dosage, avoiding 
artefacts from protein overexpression systems. Furthermore they can provide high 
numbers of relevant cell types expressing patient-specific mutations that can be 
studied at an endogenous level rather than studying loss of function via whole gene 
knockouts, as typically found in animal models. 
This study is the first model of NHD utilising iPSC-derived microglia-like cells generated 
from homozygous T66M TREM2 mutation-carrying patients and unaffected relatives 
harbouring heterozygous TREM2 mutations. It is also the first to investigate functional 
effects of homozygous TREM2 W50C mutation, initially reported by Dardiotis et al. 
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NHD is characterised by bone cysts and fractures, followed by frontal lobe syndrome 
and progressive presenile dementia (Paloneva et al., 2001). It is an autosomal 
recessive genetic disease caused by mutations in either TREM2 or in the gene 
encoding the TREM2-signalling partner, DAP12 (Paloneva et al., 2002). Patients with 
homozygous T66M TREM2 mutations have presented with frontotemporal dementia-
like syndrome-behavioural variant without bone involvement (Guerreiro et al. 2013b), 
whilst in heterozygosity, the mutation has been associated with a behavioural variant of 
frontotemporal dementia (Borroni et al., 2014) and also found in rare Alzheimer’s cases 
(Guerreiro et al. 2013a). The development of protocols to generate human microglial 
models harbouring these homozygous and heterozygous TREM2 mutations has 
therefore provided a valuable tool for studying multiple neurodegenerative diseases, 
linked by mutations in the same gene. 
The expression of microglial markers was assessed in the TREM2 mutation carrying 
iPSC-MGLC to ensure that the expression of mutations does not affect how “microglia-
like” the cells are. The expression of homozygous and heterozygous TREM2 mutations 
did not alter the expression of SPI1, PROS1 and TGFβ1, demonstrating the 
consistency of the reprogramming and differentiation of this protocol, in addition to 
confirming that TREM2 mutations do not affect the expression of several key microglial 
markers. Compared with the control lines, the TREM2 heterozygous and homozygous 
iPSC-MGLC had significantly higher levels of TMEM119, a cell surface receptor that is 
used to distinguish between CNS-resident microglia and infiltrating macrophages after 
CNS injury and inflammation (Bennett et al., 2016). In the mouse brain, TMEM119 is 
undetectable until postnatal days 3-6, but once established it remains at a constant 
level in the adult brain, with all microglia expressing TMEM119 by postnatal day 14 
(Bennett et al., 2016). Treatment of an immortalised human microglial cell line with 
‘classical’ activation stimuli LPS and IFNγ or ‘alternative’ activation stimuli IL-4 and IL-
13 did not elevate the expression levels of TMEM119 (Satoh et al., 2016), although 
mRNA was found to be increased in AD brains compared with controls (Satoh et al., 
2016). Although the function of this receptor is not yet known, these data suggest that 
expression is not associated with a particular microglial activation state but may be 
altered by disease. Once more information is known about the function of this receptor, 
the changes in expression in TREM2 mutation harbouring iSPC-MGLC could prove to 
be very interesting.  
The expression of P2YR12 was found to be highly varied between the different control 
lines and significantly lower in the T66M heterozygous and homozygous iPSC-MGLC 
lines than in the controls. This variability in expression levels may have been because 
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the Ct values obtained in the qPCR were high so differences are magnified on the 
logarithmic scale. Alternatively, P2YR12 expression has been shown to be modulated 
by microglial activation state, with alternative activation elevating expression levels 
(Moore et al., 2015), so perhaps this decreased expression is due to the cells existing 
in a more pro-inflammatory state. Increased expression of GPR34 was found in the 
T66Mhom line compared with the controls, which could be explained by the location of 
the GPR34 gene on the X chromosome. Two of the controls are from male donors so 
one would expect expression to be lower in these cells versus those from female 
donors, such as the T66Mhom patient. 
The homozygous TREM2 mutations had a significant effect on the expression levels of 
TREM2 mRNA in the iPSC-MGLC; T66M homozygous and W50C homozygous iPSC-
MGLC expressed significantly less mRNA than the control lines contrasted to the T66M 
heterozygous lines where no effect was observed. Western blot analysis indicated that, 
in control iPSC-MGLC, TREM2 protein exists in three main forms: highly glycosylated 
mature TREM2 (~37-60kDa), immature TREM2 (~28kDa) and a C-terminal fragment 
(CTF, ~14kDa). TREM2 contains a large number of N-glycosylation sites and is 
modified as it is processed through the endoplasmic reticulum (ER) and the golgi 
apparatus, before being trafficked to the cell membrane. Gene dose-dependent 
reductions in the expression of mature TREM2 protein and CTF were found in the 
T66M heterozygous, T66M homozygous and W50C homozygous iPSC-MGLC. Overall, 
decreased levels of TREM2 protein in the T66Mhet, T66Mhom and W50Chom iPSC-
MGLC were also identified by immunocytochemistry. If less mature TREM2 protein 
expressed at the cell surface, decreased levels of sTREM2 production would be 
predicted as there is less TREM2 available for cleavage by ADAM10 proteases. As 
expected, and similar to protein expression patterns, heterozygous T66M iPSC-MGLC 
generated lower concentrations of sTREM2 than control cells, with concentrations from 
homozygous mutation-harbouring cells even further reduced. The heterozygous 
TREM2 iPSC-MGLC cells displayed dramatic reductions in sTREM2 levels despite 
western blotting indicating that the cells expressed 50% of the protein levels of control 
cells suggesting that defects in TREM2 processing and trafficking to the cell membrane 
where cleavage occurs is contributing to low TREM2 shedding, in addition to overall 
lower expression levels. 
TREM2 protein from cells expressing T66M mutations has been reported to 
accumulate in the ER, resulting in a failure in trafficking to the Golgi apparatus and 
subsequent targeting to the plasma membrane (Park et al. 2015a). Furthermore, 
protein structure modelling predictions have suggested that the side chains of the T66 
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site are found within the core of the Ig fold, mutations in which are predicted to disrupt 
the stability of packing in the protein core (Kober et al., 2016). The threonine found at 
position 66 in TREM2 is fully conserved in many mammalian species (Kleinberger et 
al., 2017) and the T66M point mutation results in an amino acid shift from polar 
threonine  to  non-polar methionine, causing a polarity shift in the extracellular domain 
(Dardiotis et al., 2017). Retained T66M TREM2 protein has been found to be misfolded 
and results in increased expression of markers of the unfolded stress response (Park 
et al. 2015a). These data therefore suggest that, in addition to decreased surface 
expression of TREM2, the T66M harbouring TREM2 protein may be further contributing 
to microglial dysfunction by inducing ER stress. Indeed, preliminary 
immunohistochemical analysis of TREM2 localisation in the T66Mhom iPSC-MGLC 
indicated that TREM2 did not co-localise with the golgi, as found in the control cells, 
which indicates that the misfolded protein may not traffic to the cell membrane 
correctly. Analysis of the cellular localisation of TREM2 in W50Chom lines should also 
be performed as well as analysis of potential ER stress, for example by assessment of 
CHOP expression or PERK eIF2α kinase activity (Ubeda and Habener, 2000; Yan et 
al., 2002). 
In addition to reduced expression of mature TREM2 protein, the mutant lines generate 
significantly lower levels of TREM2 CTF. This concurs with data from HeLa cells 
transfected with human TREM2 plasmids which show that T66M mutations result in 
CTF formation deficits attributed to failures in the trafficking of misfolded TREM2 
protein to the Golgi apparatus, where CTFs are generated (Park et al. 2015a). This 
provides further evidence of TREM2 protein modification and trafficking issues arising 
from mutations. Due to the fact that the proteins were denatured during the western 
blotting process, it is unlikely that the decreased protein detection is due to antibody 
recognition failures arising from TREM2 mutant protein being misfolded. Mutations may 
affect the epitope of monoclonal antibody leading to changes in binding affinity, but the 
AF1828 is polyclonal, and the D8I4C monoclonal shows a similar expression pattern so 
the decreased TREM2 protein detection is likely not due to antibody specificity deficits. 
The TREM2 mRNA data, which does not rely on conformation specific identification, 
also demonstrates reduced levels in mutants compared with control iPSC-MGLC.  
Key findings from these experiments have been replicated in studies utilising BV2 
mouse microglia cells and human HeLa cells expressing human TREM2 with T66M 
mutations (Kleinberger et al. 2014; Park et al. 2015a) and homozygous T66M knock in 
mice (Kleinberger et al., 2017). Similarly to our iPSC-MGLC, these cells showed 
reduced levels of mature TREM2 protein and reduced sTREM2 shedding in T66M 
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mutants compared to controls. This study is the first report of sTREM2 secretion in 
human iPSC-MGLCs expressing endogenous levels of mutant TREM2 protein and  the 
decreased generation of sTREM2 mimics results found in patients carrying 
homozygous T66M mutations where sTREM2 is undetectable in plasma and CSF 
samples (Kleinberger et al., 2014; Piccio et al., 2016).  
The loss of function from protein misfolding and a lack of trafficking to the cell 
membrane may contribute to disease progression as the receptor will not be able to 
fully function if not expressed at the cell surface, although intracellular signalling may 
be able to continue without impediment. Furthermore, the role of sTREM2 is not yet 
known but this decreased availability of the TREM2 protein at the surface for cleavage 
is likely to modulate sTREM2 functionality. sTREM2 has been linked to microglia 
viability and survival (Wu et al., 2015; Zhong et al., 2017) as well as influencing 
inflammatory responses (Zhong et al., 2017) so the effect of misfolded protein on 
sTREM2 generation may explain some of the functional effects of the T66M mutation. 
Indeed, bone marrow-derived macrophages from T66M knock in mouse models had 
decreased survival, slower proliferation and increased Caspase3/7 activation 
compared to WT cells (Kleinberger et al., 2017) so the effect of T66M mutations and 
the contribution of sTREM2 secretion levels on iPSC-MGLC survival and proliferation 
should be investigated. The weekly yield from the embryoid body flasks did not vary 
between controls and mutation-carrying cells (data not shown) but differences in the 
survival of the progenitors once differentiated into iPSC-MGLC is yet to be assessed.  
The functional effects of reduced TREM2 expression levels in iPSC-MGLC carrying 
TREM2 mutations were then investigated. One of the primary activities of microglia is 
constant surveillance of their environment and the clearance by phagocytosis of any 
debris or pathogens that they encounter. TREM2 has been reported to influence 
microglial phagocytosis, however published data on the effect of TREM2 mutations on 
phagocytosis are inconsistent; microglia and macrophages from TREM2 knockout 
mouse models have exhibited both decreased phagocytosis compared to WT 
(Kleinberger et al., 2014; Xiang et al., 2016) and undetectable differences (Wang et al., 
2015). Furthermore, brain Aβ loads in AD TREM2-/- mouse models, which are used as 
a measure of phagocytic activity by microglia, are conflicting (Jay et al., 2015; Wang et 
al., 2015). However, in these studies, different AD mouse models and time points were 
investigated, which limits the usefulness of comparing these cases.  
The phagocytic activity of the iPSC-MGLC was investigated by assessing the uptake of 
fluorescent E.coli, which has been shown to bind to TREM2 resulting in phagocytosis in 
a TREM2/DAP12-dependent manner (N’Diaye et al., 2009). The T66M homozygous 
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iPSC-MGLC exhibited decreased levels of phagocytosis compared to control iPSC-
MGLC, however no effect was found in heterozygous T66M mutant cells. The 
homozygous W50C mutation resulted in a decrease in particle uptake but this was not 
statistically significant. In support of this result, T66M mutations in TREM2 have been 
previously shown to exert a negative effect on E.coli particle uptake relative to WT 
controls in HEK cells expressing mutated human TREM2 (Kleinberger et al., 2014) and 
in macrophages from T66M knock in mice (Kleinberger et al., 2017). Low sTREM2 and 
decreased surface expression of TREM2, as found in T66M iPSC-MGLC, have been 
found to correlate with reduced phagocytosis of E.coli particles (Kleinberger et al., 
2014); indeed inhibition of ADAM protease activity allowed receptor accumulation at 
the cell surface and rescued phagocytosis (Kleinberger et al., 2014). This decreased 
TREM2 expression may explain the phagocytic deficits found in the homozygous T66M 
iPSC-MGLC. The phagocytic ability of cells may be important for disease progression 
both through the clearance of debris to limit chronic inflammation and the clearance of 
Aβ in the toxic oligomeric seed formation as well as in the plaque-associated formation. 
This is the first investigation of functional effects arising from TREM2 W50C mutations 
in microglia. Compared to controls,  W50C homozygous iPSC-MGLC exhibited 
decreased TREM2 mRNA levels, reduced TREM2 protein expression including mature, 
immature and CTF formations, almost undetectable levels of sTREM2 generation and 
decreased phagocytosis (although statistical significance was not achieved). The 
phagocytic ability of monocytes and neutrophils isolated from a patient carrying a 
homozygous W50C mutation have previously been assessed and no difference was 
found compared to heterozygous relatives and controls (Dardiotis et al., 2017), 
although these cell types are not the most disease relevant for studying the effect of 
the mutation on a neurodegenerative disease. The W50C mutation is found in the 
extracellular domain of the protein and causes an amino acid substitution from 
tryptophan to cysteine. Due to the fact that the mutation is located in an evolutionary 
conserved region and results in changes in the receptor region where interaction with 
extracellular molecules for downstream signalling occurs, it has been predicted to 
result in loss of function and may be the reason for disease pathogenesis (Dardiotis et 
al., 2017). Other NHD-associated mutations, including T66M have been predicted to 
alter protein stability and folding, whilst AD-linked mutations are expected to alter 
ligand binding (Kober et al., 2016). 
It is interesting that, despite significant decreases being found in the TREM2 
expression at both protein and mRNA levels, there is no functional effect of the 
heterozygous T66M mutations on phagocytosis in the iPSC-MGLC. Kleinberger et al., 
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2014 reported only modest differences in phagocytosis between WT and TREM2-/- 
mouse microglia, however, with increased E.coli load, differences in uptake were 
greater. Therefore, differences between control and heterozygous iPSC-MGLCs, as 
well as W50C cells, may be more marked if the particle concentration was more 
saturated. It would also be important to assess phagocytic ability with more disease 
relevant substrates such as Aβ or apoptotic neurons in order to draw conclusions on 
the effect of these mutations on Alzheimer’s disease pathogenesis.  
To evaluate the effect of TREM2 mutations on cytokine release by iPSC-MGLC, the 
secretion of TNFα and IL-6 following activation with LPS was assessed by ELISA. 
TREM2 is reported to exert an anti-inflammatory influence upon TLR stimulation in 
microglia/macrophages (Turnbull et al., 2006; Ito and Hamerman, 2012). Evidence for 
this comes from studies utilising knockdown of TREM2 by siRNA in primary microglia 
(Zheng et al., 2016) or in microglia/macrophages isolated from TREM2-/- mice (Turnbull 
et al., 2006; Wang et al., 2015; Zheng et al., 2016), to demonstrate that LPS treatment 
results in increased TNFα release in the absence of TREM2. 
T66M homozygous iPSC-MGLC had an augmented TNFα response following LPS 
treatment compared to control and heterozygous cells. Microglia-derived TNFα has 
been shown to induce apoptosis of mature neurons and neuronal precursors (Talley et 
al., 1995; Combs et al., 2001; Guadagno et al., 2013), thus contributing to further cell 
death. This result has been reported previously in T66M knock in mice brain tissue 
following LPS treatment (Kleinberger et al., 2017) and LPS-stimulated TREM2-/- mouse 
macrophages and microglia (Turnbull et al., 2006; Wang et al., 2015; Zheng et al., 
2016). In models where AD relevant stimuli are utilised, such as Aβ and apoptotic cells, 
TREM2 loss of function also results in heightened pro-inflammatory responses. 
Increased TNFα secretion is found following co-culture with apoptotic neurons in 
primary mouse microglia treated with TREM2-targeting shRNAs relative to controls 
(Takahashi, Rochford and Neumann, 2005). Moreover, TREM2 expression levels also 
alter cytokine responses to Aβ, as TREM2 knockdown in primary mouse microglia 
leads to increased levels of TNFα, IL-1β, IL-6 and iNOS following stimulation with Aβ1-
42 (Jiang et al. 2014b). In mouse models of AD and aging, TREM2 knockdown results 
in augmented pro-inflammatory cytokine release (Jiang et al. 2015; Jiang et al. 2014a) 
whilst TREM2 overexpression reverses these responses (Jiang et al. 2014b; Jiang et 
al. 2015). In light of this data, it would be interesting to stimulate the iPSC-MGLC with 
apoptotic cells or Aβ to establish whether more marked effects of TREM2 mutations on 
cytokine release can be found.  
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Treatment of microglia with TNFα has been shown to reduce phagocytic uptake of Aβ 
(Hickman, Allison and El Khoury, 2008). The combination of multiple TREM2 defects in 
phagocytosis and anti-inflammatory signalling found in T66M homozygous iPSC-MGLC 
could result in the generation of a self-perpetuating cycle of microglial dysfunction. As 
T66M homozygous iPSC-MGLC have defects in phagocytosis, microglia with TREM2 
mutations may be less able to clear apoptotic cells and Aβ in the brain resulting in an 
accumulation of neurotoxic stimuli known to induce microglial expression of TNFα. 
Furthermore, as these cells also have augmented TNFα secretion following pro-
inflammatory stimulation, there may be increased secretion of TNFα into the 
extracellular space resulting in a cytotoxic, neuroinflammatory environment that further 
propagates phagocytic dysfunction and microglial over-activation, summarised in 
Figure 4.15.   
Figure 4.15 Summary of findings in T66M homozygous iPSC-MGLC and potential effects 
on pathogenesis 
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Despite reports in the literature of TREM2 loss of function causing increased IL-6 
secretion following LPS stimulation (Turnbull et al., 2006; Zhong et al., 2015), no effect 
of TREM2 mutations on IL-6 release by iPSC-MGLC was found in this study. This may 
be because the timing of sample collection for cytokine secretion analysis can 
significantly alter the results found; in the peritoneal lavage fluid of TREM2-/- mice, IL-6 
levels were increased compared to WT after 6hours of LPS treatment however, at 
20hours, IL-6 concentrations were lower vs controls (Gawish et al., 2015). Therefore, 
an effect of TREM2 mutations on IL-6 secretion, as reported in the literature (Turnbull 
et al., 2006; Jay et al., 2015; Zhong et al., 2015), may have been found if more time 
points for sample collection had been tested. 
The iPSC-MGLC were found to express similar levels of various other microglia-
expressed, neurodegenerative disease risk factors to those found in human primary 
microglia. These results indicate that this model of iPSC-derived human microglia is 
applicable for the study of other neurodegenerative diseases in which the dysfunction 
of microglia has been implicated. This protocol is currently being utilised to generate 
iPSC-MGLC from AD patients harbouring heterozygous R47H mutations, which carries 
similar odds ratio for the development of late onset AD as the APOE ε4 genotype. 
These cells will be useful for further investigation into the role of TREM2 mutations in 
AD pathogenesis.  
The expression of the neurodegenerative disease risk factors was assessed in the 
heterozygous and homozygous TREM2 mutation iPSC-MGLC to establish whether 
mutations in TREM2 alter the expression of other microglial genes linked to 
neurodegenerative disease. Considerable variation was found in APOE expression 
levels in the control lines and expression was significantly lower in the W50C 
homozygous line. The APOE ε4 status of the donors is not known and may contribute 
to the variability that was found in the different cell lines.  LPS treatment induces 
expression of APOE in monocyte cell lines but reduces expression of APOE mRNA in 
macrophage cell lines and murine peritoneal macrophages (Gafencu et al., 2007). 
Therefore the expression of APOE may also be altered by the activation state of the 
iPSC-MGLC. Interestingly, TREM2 expression has also been shown to be reduced by 
TLR4-mediated signalling (Turnbull et al., 2006; Owens et al., 2017) suggesting a link 
between TREM2 and APOE mRNA expression; both have been shown to be 
downregulated by classical microglial activation states thus the reduction of two 
protective factors in disease-associated activation conditions could contribute to AD-
associated microglial dysfunction. 
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A significant limitation of this study is the low power from only two homozygous mutant 
samples being studied, with only one line generated per patient. Work is ongoing to 
collect samples for iPSC generation from more patients carrying homozygous 
mutations and more lines are being generated from existing patient samples to 
minimise the effect of inter-individual and intra-individual variability, in the hopes of 
resolving this lack of power. Increased sample sizes will allow any subtle differences 
that may exist between the heterozygous and homozygous lines, or between the 
control and heterozygous lines, to be identified, as there is currently an unexpected 
lack of functional effect of TREM2 mutations when found in heterozygosity. 
The cells that bud from the embryoid bodies in this protocol resemble primitive tissue 
macrophages so we need to continue to make improvements in recapitulating 
endogenous environments to drive cells to differentiate into a mature, tissue-specific 
state of microglia rather than microglia-like cells or microglia progenitors. Exposure to 
neuronal factors during differentiation and maturation steps is likely to encourage the 
development of more matured, ramified, functional morphology resulting in cells that 
more accurately represent the microglia of adult brains rather than immature 
progenitors. Despite these limitations, the availability of any type of human microglia to 
study function and disease is an additional tool with advantages over the use of blood-
derived cells or rodent microglia. 
Since the commencement of this work, other protocols for the generation of iPSC-
derived microglia have been published, attempting to closely mimic the environment of 
microglia in the developing and adult brain in order to generate a more accurate model 
of this cell type. It has been shown that microglia are able to develop normally in MCSF 
deficient transgenic mice due to the fact that IL-34  and MCSF can act similarly to 
regulate CSF-1R expressing cells (Wei et al., 2010; Wang et al., 2012). New protocols 
are now utilising this alternative CSF-1R ligand by differentiating iPSC-microglia in IL-
34 and low MCSF defined medium in order to model the CNS environment more 
closely (Muffat et al., 2016; Haenseler et al., 2017). The importance of TGFβ1 in 
maintaining the microglial transcriptome signature has been recently highlighted by 
Butovsky et al, which is now being incorporated as a growth factor in differentiation 
protocols (Abud et al., 2017). Co-culturing techniques are increasingly being used 
(Haenseler et al., 2017) to try to generate more functional, ramified microglia, which 
also allows the study of the interactions between microglia and neurons, a model which 
could prove to be particularly useful if patient-derived cells for particular diseases are 
employed.  
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Gosselin et al showed that iPSC-derived microglia, despite avoiding the isolation-
associated gene transcription changes resulting from the culture of primary microglia, 
have expression patterns more similar to in vitro cultured cells than freshly isolated 
brain cells. The use of 3D cultures with multiple CNS cell types is suggested to improve 
the gene profiles of the iPSC-derived cells (Gosselin et al., 2017). Similar gene 
expression changes were identified in isolated murine microglia, in which genes 
associated with mature microglia were particularly affected, however the expression 
profile was restored upon transplantation into a mouse brain (Bohlen et al., 2017), 
demonstrating the plasticity of these cells and the importance of CNS environmental 
signals for influencing expression of mature microglia. The application of 3D co-
cultures has demonstrated the ability of iPSC-microglia to mature and function as 
predicted into highly ramified, resting cells that dynamically survey their environment 
through branch extension and retraction (Muffat et al., 2016; Abud et al., 2017). 
Combining various components of different protocols to incorporate knowledge of 
essential growth factors, co-culture conditions and microglial ontogeny would help to 
further improve iPSC-MGLC differentiation protocols to increase the likelihood of 
generating bona fide microglia that consistently express the signature microglial 
transcriptome. In addition to gene expression analysis to confirm differentiation of 
microglia-like cells, functional assays should be conducted to demonstrate that these 
iPSC-derived cells also act like microglia. Examples of these functional experiments 
include assessing appropriate cytokine release following inflammatory stimulation, 
migration in response to chemokine exposure, appropriate transient calcium responses 
and the phagocytosis of both pathogenic particles and host cell debris. 
The ability to generate cells from patient-derived iPSCs has provided a valuable 
opportunity to avoid many of the current pitfalls of isolating primary rodent microglia 
while allowing the possibility to investigate the links between genetic risk factors and 
the development of disease. Through the generation of Nasu-Hakola disease-patient 
derived iPSC-MGLC, the effect of TREM2 mutations on microglial TREM2 expression 
and the functional implications of decreased expression of this receptor have been 
assessed. The availability of a family of individuals with heterozygous and homozygous 
mutations is useful for studying the effects of specific mutations on similar genetic 
backgrounds. TREM2 in AD and Nasu-Hakola is interesting as different mutations in 
the same gene lead to the development of neurodegenerative diseases of varying 
severity. iPSC-MGLC with homozygous T66M mutations had significantly reduced 
surface and total expression of TREM2 and exhibited defects in phagocytosis and 
augmented TNFα responses following LPS stimulation, suggestive of aberrant TREM2 
anti-inflammatory signalling. In addition to modifying iPSC differentiation protocols to 
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further improve the expression of microglial markers, more disease-relevant stimuli 
should be employed that may result in the detection of functional deficits in patients 
and lines harbouring heterozygous TREM2 mutations.   
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5. CR1 and Complement in Human Microglia 
 
Since the initial identification of Complement Receptor 1 (CR1) as a genetic risk factor 
for late onset Alzheimer’s disease (Lambert et al., 2009), further studies have gone on 
to confirm the association of polymorphisms in the CR1 gene with AD. Of the 10 CR1 
SNPs found to be associated with Alzheimer’s disease in GWAS, meta-analyses and 
case-control studies, 8 are intronic (rs6656401 (Lambert et al., 2009), rs3818361 
(Carrasquillo et al., 2010; Jun et al., 2010), rs1408077 (Kok et al., 2011), rs48744610 
(Hazrati et al., 2012), rs646817 (Brouwers et al., 2012), rs12034383 (Brouwers et al., 
2012), rs6701713 (Jun et al., 2010) and rs6701710 (Wijsman et al., 2011)) and 2 are 
found in coding regions (rs116806456 and rs6691117 (Ma et al., 2014)).  Interactions 
between CR1 and C3b-opsonised Aβ and cellular debris, in addition to robust 
expression of the CR1 orthologue Crry (complement receptor 1-related gene/protein Y) 
on rodent microglia (Davoust et al., 1999), have resulted in the hypothesis that CR1 
mutations may increase the risk of AD by affecting clearance of Aβ and pro-
inflammatory debris (Crehan, Hardy and Pocock, 2012). Furthermore, CR1 regulates 
complement activation so mutations may alter the inhibitory activity of this receptor, 
resulting in neuroinflammation, which is frequently attributed to microglial activation.  
Despite mouse Crry being used to predict functions of human CR1, key differences 
exist in the structure and functions of Crry compared to hCR1. Both hCR1 and Crry act 
as C3 convertase inhibitors with decay accelerating and cofactor properties (Molina et 
al., 1992) however, only hCR1 acts as a receptor for C3b/C4b (Kim et al., 1995), which 
is key for binding and clearance of opsonised particles. Mice also express murine CR1, 
which is of similar size to hCR1, although its expression is much more limited and its 
absence from erythrocytes and platelets suggests that it may not play an important role 
in immune adherence and clearance (Miwa and Song, 2001). 
Despite confirmation of rodent microglial expression of Crry and mCR1 (Davoust et al., 
1999; Crehan, Hardy and Pocock, 2013), there is little published evidence indicating 
that CR1 is expressed by human microglia. In fact, data regarding the expression of 
CR1 in other cells of the human CNS are conflicting. Singhrao et al., have published a 
series of papers demonstrating that in vivo and in vitro samples of human neurons, 
astrocytes and microglia lack CR1 expression at the mRNA and protein level (Singhrao 
et al., 1999, 2000). It has also been reported that human oligodendrocytes do not 
express CR1 (Scolding, Morgan and Compston, 1998). However, other studies have 
published expression of CR1 in human astrocytes  (Gasque, Fontaine and Morgan, 
1995; Gasque et al., 1996; Fonseca et al., 2016) and neurons (Hazrati et al., 2012). As 
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AD is a disease of the CNS, and limitations of animal models for studying CNS 
inflammatory diseases, including AD, continue to be identified (Franco Bocanegra, 
Nicoll and Boche, 2017), it is of great importance to establish how proteins of interest 
are expressed in disease relevant tissues and cells both in health and disease. 
Multiple GWAS studies have demonstrated an association between AD and CR1, 
however little is known about the role of CR1 in Alzheimer’s pathogenesis. The 
availability of human iPSC-derived microglia-like cells (iPSC-MGLC) is an extremely 
useful tool for further investigations of this receptor’s expression and function. 
5.1 CR1 mRNA is undetectable in control human temporal lobe 
 
Due to a lack of published data confirming the expression of CR1 in the human brain, 
experiments were conducted to establish whether CR1 mRNA could be detected in 
human control brain samples. RNA was isolated from temporal lobe samples of five 
control adult brains and expression of CR1 mRNA was assessed by qPCR. The 
temporal lobe was used to investigate CR1 expression as this brain region has a dense 
microglial population, the CNS cell type where CR1 is postulated to be expressed. The 
levels of CR1 mRNA in the control human brain samples were found to be almost 
undetectable (Figure 5.1, Ct values>35), particularly when compared to the levels of 
TREM2, P2YR12 and AIF1, which are known to be expressed on human microglia. 
The detectable expression of these other microglial markers suggest that the 
indiscernible level of CR1 mRNA is not due to an absence of microglia.  
 
 
 
 
 
 
  
Figure 5.1 mRNA expression of CR1 and microglial makers in control human temporal 
lobe 
qPCR analysis of the expression of CR1, TREM2, AIF1 and P2YR12 in RNA extracted from control 
human temporal lobe samples. Graph represents expression levels of genes of interest normalised to 
GAPDH. Data plotted represents 1/Ct value so high values indicate high expression. N=5  
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5.2 RNA expression databases indicate that CR1 expression is 
undetectable in human brain 
 
The Protein Atlas database (www.proteinatlas.org) holds data on protein expression 
from antibody-based analysis of control human tissue, in addition to pooling together 
multiple online RNAseq databases, to provide expression and localisation information 
on the majority of human protein-coding genes. This tool is valuable for supporting the 
mRNA expression data generated from our small pilot study into the expression of CR1 
in the human brain.  
The HPA RNA-seq dataset (Figure 5.2a) included 3 samples of cerebral cortex in 
which an average CR1 abundance score of 0.9 TPM (transcripts per million) was 
detected. The threshold level to detect the presence of a gene transcript is set to ≥1 
TPM, therefore CR1 was undetectable in this cerebral cortex dataset.  
The Genotype-Tissue Expression project (www.gtexportal.org) dataset found that CR1 
expression was undetectable in the cerebral cortex, hypothalamus, caudate and 
cerebellum (Figure 5.2b). CR1 mRNA transcripts in the pituitary gland (n=103) and 
hippocampus (n=94) were only detected at an average of 0.1 RPKM (reads per 
kilobase per million mapped reads), however this is well below the 0.5 RPKM threshold 
set for detection. 
The Functional Annotation of Mammalian Genomes 5 (fantom.gsc.riken.jp/5/) dataset 
has a cut off for detection of ≥1 TPM. However the 0.2 TPM in the pituitary gland, 0.2 
TPM in the total brain, 0.3 TPM in the hippocampus, 0.5 TPM in the caudate and 0.1 
TPM in the cerebellum (Figure 5.2c) were all found to be below the threshold of 
confident detection of expression. 
The RNA expression data from these online datasets concur with the qPCR analysis of 
CR1 expression performed in this study; CR1 mRNA levels are found below the 
confident threshold of expression in control human brain samples. 
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5.3 Protein expression database suggests that CR1 protein is not 
detectable in human brain 
 
The Protein Atlas database provides information on the expression of CR1 protein in 
different cell types of various brain regions resulting from immunohistochemical 
analysis using 5 different antibodies. The antibody staining score describes the level of 
antibody staining observed in the cell types, which are categorised based on staining 
intensity and fraction of stained cells: not detected (n), low (l), medium (m) or high (h). 
Figure 5.2 Expression of CR1 in human brain according to RNA-seq databases 
Figures adapted from Protein Atlas Database (http://www.proteinatlas.org/ENSG00000203710-
CR1/tissue) showing expression of CR1 in human brain regions. Figures  created using data from (a) 
HPA, (b) GTex and (c) FANTOM5 datasets with RNA-seq tissue data reported as mean TPM (transcripts 
per million) or median RPKM (reads per kilobase per million mapped reads). 
a 
b 
c 
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Overall, CR1 protein expression was found to be ‘not detected’ in the cerebral cortex, 
hippocampus, caudate and cerebellum (Figure 5.3a). Further analysis of different cell 
types showed some ‘low’ CR1 expression in neuronal and epithelial cells (Figure 5.3b), 
but this was not confirmed with all of the antibodies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
5.4 CR1 mRNA is almost undetectable in microglia and iPSC-derived 
microglia-like cells 
 
Following the observation that CR1 mRNA could not be detected at the whole brain 
level, the expression of CR1 at the cellular level was investigated, with particular 
interest in whether CR1 is expressed by human microglia. RNA was extracted from 
various cell types used to model microglia including blood-derived monocytes, 
monocyte-derived macrophages and iPSC-derived microglia-like cells (iPSC-MGLCs). 
Figure 5.3 Expression of CR1 in human brain according to Protein Atlas expression 
database 
Figures adapted from Protein Atlas Database (http://www.proteinatlas.org/ENSG00000203710-
CR1/tissue) showing expression of CR1 protein in human brain regions. Expression analysis conducted 
using 5 anti-CR1 antibodies for immunohistochemistry of different tissue samples (a). Expression within 
different cell types of brain regions were assessed (b), with staining scored as not detected (n), low (l), 
medium (m) or high (h). 
a 
b 
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Commercially available human microglial cDNA (Sciencell Online), generated from 
RNA extracted from microglia isolated from a healthy brain, was also assessed. 
Neutrophils were included as a positive control for CR1 expression in addition to iPSC-
derived astrocytes (kind gift from G. Tyzack, UCL), since some studies have indicated 
that CR1 may be expressed on astrocytes (Gasque et al., 1996; Fonseca et al., 2016). 
Robust levels of CR1 mRNA expression were found in neutrophils but, in comparison, 
CR1 was found to be low in monocytes and monocyte-derived macrophages and 
almost undetectable in microglia, iPSC-MGLCs and iPSC-astrocytes (Figure 5.4).  
 
 
 
 
 
 
 
 
5.5 RNA expression database concurs with very low levels of CR1 mRNA 
in microglia 
 
The Barres Brain RNA seq database provides transcriptomic data for different cell 
types of the CNS ( http://web.stanford.edu/group/barres_lab/brain_rnaseq.html,, 
(Zhang et al., 2014)). The database showed very low levels of CR1 expression in all of 
the analysed cell types (Figure 5.5), however the highest expression was found in 
microglia/macrophages at a level of 0.15 FPKM (fragments per kilobase of exon per 
million reads mapped). Typically a cut-off of 0.5 FPKM is applied, suggesting that CR1 
is not expressed in these CNS cell types, including microglia.  
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Figure 5.4 Expression of CR1 mRNA in CNS and immune cells 
qPCR analysis to determine CR1 mRNA levels in human neutrophils, monocytes, monocyte-derived 
macrophages, microglia, iPSC-derived microglia-like cells (iPSC-MGLC) and iPSC-derived astrocytes. 
Graph represents CR1 expression normalised to GAPDH. Values relative to neutrophil expression levels 
expressed as mean ±SEM. N=1 microglia and iPSC-astrocytes, n=3 monocytes and macrophages, n=4 
neutrophils and n=6 for iPSC-MGLC. 
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5.6 CR1 mRNA expression is upregulated in pre-AD temporal lobe 
 
In addition to RNA samples from control brains, RNA samples from ‘pre-AD’ brains 
were also acquired for analysis from the Queen Square Brain Bank (UCL, London). 
These samples had been collected from donors with no apparent cognitive impairment 
who, upon post-mortem histopathological examination, were found to have Aβ deposits 
at Braak stage III or IV and thus have been described here as ‘pre-AD’ cases. The 
majority of cases also underwent ABC scoring of AD neuropathological change 
(Montine et al., 2012), which incorporates histolopathological results for Aβ plaque 
score using the Thal method (Thal et al., 2002), neurofibrillary tangle stage using the 
Braak method (Braak and Braak, 1991) and CERAD scoring of neuritic plaques (Mirra 
et al., 1991). The individual scores for each category are combined and transformed 
into one of four levels of AD neuropathological change: ‘not’, ‘low’, ‘intermediate’ or 
‘high’. All of the control cases were categorised as ‘not’ or ‘low’ neuropathological 
change whilst the pre-AD samples were all of ‘intermediate’ AD neuropathological 
change (Table 5.1). As well as the temporal lobe samples, an area of the brain which 
has high AD pathology burden and denser microglial populations, samples from the 
occipital lobe were also assessed as a control for inter-individual expression levels. 
Compared with control brains, CR1 expression was higher in pre-AD temporal and 
occipital lobe samples, although statistical significance was only achieved in the 
temporal lobe (*p<0.05, Figure 5.6c). The expression levels of the microglia specific 
marker P2YR12 were also assessed as this would provide information on changes in 
Figure 5.5 Expression of CR1 in CNS cells according to Barres Brain RNA seq database 
Figure adapted from http://web.stanford.edu/group/barres_lab/brain_rnaseq.html showing CR1 expression 
in human CNS cells in the Barres Brain RNA seq database. Expression reported as FPKM (fragments per 
kilobase of exon per million reads mapped). 
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the microglia population in these brain regions during the early stages of disease 
pathology. In both regions P2YR12 expression was found to be higher in pre-AD 
samples than controls (Figure 5.6b and d), however this was not statistically significant 
likely due to large variation in expression between the samples and the small sample 
size. 
Sample Gender Age 
Braak 
Score 
Neuropathological 
Change 
A 
Score 
B 
Score 
C 
score 
Control 1 F 86 0 Not 0 0 0 
Control 2 F 91 0 Low 1 1 1 
Control 3 M 71 0 Not 0 1 0 
Control 4 M 95 I N/A    
Control 5 F 87 I Low 1 1 1 
Pre – AD 1 F 95 IV Intermediate 3 2 2 
Pre – AD 2 F 99 IV Intermediate 2 2 2 
Pre – AD 3 F 92 III Intermediate 2 2 1 
Pre – AD 4 F 93 III Intermediate 2 2 2 
Pre – AD 5 M 89 III Intermediate 2 2 1 
AD 1 F 73 VI High 3 3 3 
AD 2 M 85 VI N/A    
AD 3 F 86 V N/A    
AD 4 M 76 V N/A    
AD 5 F 88 V N/A    
Table 5.1 Pathological details of human control, pre-AD and AD samples 
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Recently published data have suggested that neutrophils, a cell type that expresses 
high levels of CR1, infiltrate the brain during the early stages of AD and are found in 
areas with Aβ deposits (Zenaro et al., 2015). In light of this report, the expression of the 
neutrophil marker ELANE was assessed in these samples, in order to confirm the 
presence of neutrophils in the CNS parenchyma of our pre-AD samples. However, in 
the control and pre-AD samples from both the occipital and temporal lobes, the 
expression of ELANE was undetectable (Ct>40, data not shown), suggesting the 
increased expression of CR1 in pre-AD brains was not due to the presence of 
neutrophils.  
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Figure 5.6 Expression of CR1 and P2YR12 in temporal and occipital lobes of control and 
pre-AD cases 
qPCR analysis of CR1 and P2YR12 mRNA levels in the occipital lobe and temporal lobe of 
control (n=5) and pre-AD cases (n=5). Graph represents gene of interest expression normalised 
to GAPDH. Values relative to expression levels in controls expressed as mean ±SEM (* p<0.05, 
un-paired t-test). 
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5.7 Preliminary immunohistochemical analysis of CR1 expression 
indicates upregulation with AD progression 
 
A small preliminary study into the expression of CR1 protein in human temporal lobe 
tissue sections by immunohistochemistry was conducted, with 5 samples from control, 
pre-AD and AD patient groups (see Table 5.1). The ABC score of neuropathological 
scoring of all of the AD samples had not yet been performed so the groups were 
assigned according to their Braak staging of disease pathology as follows: I-II controls, 
III-IV pre AD, V-VI AD. The temporal lobe was chosen as this was shown to have 
higher expression of CR1 mRNA than the occipital lobe. Prior to staining for CR1 in 
human brain tissue samples, the antibody was tested in human kidney tissue samples. 
CR1 has been shown to be expressed in human glomerulus (Fischer et al., 1986), in 
particular the epithelial podocyte cells (Appay et al., 1990), thus kidney tissue was 
chosen as a positive control for CR1 immunohistochemistry. Clear staining of the 
glomeruli was found (Figure 5.7a and c) with little non-specific staining in the no 
primary antibody control (Figure 5.7b) therefore we were confident with the suitability of 
the antibody for probing the brain samples for CR1 expression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b 
c 
Figure 5.7 Testing of CR1 antibody in human kidney tissue 
Representative images from testing the specificity of anti-CR1 antibody in human kidney tissue. 
Positively stained glomeruli shown at 10x (a) and 40x (c) magnification. Representative images 
of no primary antibody negative control at 10x magnification shows secondary antibody 
specificity (b). Scale bars represent 500µm in 10x images and 100µm in 40x images. 
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In the control brain samples, positive staining for CR1 was present (Figure 5.8a) but 
this was at a lower level to those found in the pre-AD and AD samples (Figure 5.8b and 
c). Upon quantification, CR1 positive staining was found to be similar in pre-AD and AD 
samples, both of which were higher than in the control samples (Figure 5.8e). This 
increase in CR1 was not significant however, likely due to the small sample size of 
each group (n=5).  
CR1 is a cell surface receptor, however the morphology of the staining found did not 
indicate that a particular cell type was the source of the expression (Figure 5.9a). 
Indeed, in a few cases the staining morphology was markedly different with some 
showing long, vessel-like staining (Figure 5.9c) whereas other staining indicated dark, 
rounded cells or nuclei (Figure 5.9b). The increase in CR1 protein between control and 
pre-AD cases supports CR1 mRNA data found in the same samples. Immuno-
colocalisation studies would need to be performed to establish whether this increased 
CR1 is due to upregulation of expression in CNS resident cells, including microglia, or 
because of infiltration of cells from the periphery. Furthermore, a larger investigation 
with more samples per group should also be conducted to confirm the increase in 
expression with the onset of pathology that has been found in this preliminary study. 
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Figure 5.8 Expression of CR1 in control, pre-AD and AD temporal lobes 
Representative images from the assessment of CR1 expression in human temporal lobe samples from 
control (a), pre-AD (b) and AD (c) cases by immunohistochemistry. No primary antibody control 
representative image is also shown (d). 10x magnification, scale bar represents 500µm. CR1-positive 
staining from three randomly selected fields of view per slide (n=5 per condition) was quantified blinded (e). 
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5.8 Microglia and iPSC-MGLC express other complement factors linked to 
Alzheimer’s disease 
 
Despite the fact that microglia and iPSC-MGLC have been found to not express CR1, 
at least in the context of a healthy brain or in an unstimulated state, microglia express 
other complement factors that have been identified as playing a role in the synaptic 
loss found in the early stages of disease in AD models. The complement opsonin and 
classical pathway activator C1q, and the phagocytosis receptor CR3 have been 
recently shown to mediate oligomeric Aβ-induced dysregulation of synapse pruning by 
microglia  (Hong et al., 2016). It had been planned that the iPSC-MGLC described in 
Chapter 4 would be used to investigate the role of CR1 in human microglia however, 
since microglia and the iPSC-MGLC have been found to not express this receptor, the 
expression of C1q and CR3 by iPSC-MGLC was assessed by qPCR analysis of mRNA 
levels. The expression in three different control lines of iPSC-MGLC was compared to 
levels found in a primary human microglia sample from a healthy donor. C1QA mRNA 
was easily detectable at similar levels across the different iPSC-MGLC lines, with 
a 
b c 
Figure 5.9 Varied morphology of CR1-positive staining 
Immunohistochemical analysis of CR1 staining in AD (a, b) and pre-AD (c) temporal lobes revealed varied 
morphology of positively-stained cells. Images acquired at 40x magnification, scale bar represents 100µm. 
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expression in the microglia sample approximately 2.5 fold higher than in the iPSC-
MGLC (Figure 5.10a). The CR3 receptor is composed of CD11b and CD18, encoded 
for by ITGAM and ITGB2 respectively, which were found at twice the level found in the 
microglial sample (Figure 5.10b and c). Therefore this iPSC-derived model of human 
microglia was found to be suitable for the study of C1q and CR3, with the aim of 
investigating their role in AD.  
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Figure 5.10 Expression of AD-linked complement factors by iPSC-MGLC and microglia 
qPCR analysis of C1QA (a), ITGB2 (b) and ITGAM (c) expression in iPSC-MGLC compared with 
microglia. Graph represents gene of interest expression normalised to GAPDH. Values relative to 
expression levels in CTRL1 iPSC-MGLC line expressed as mean ±SEM (n=3 for each iPSC-MGLC line, 
n=1 for microglia sample). 
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5.9 Mutations in TREM2 alter the mRNA expression levels of AD-linked 
complement factors 
 
In addition to the Nasu-Hakola and FTD-associated T66M and W50C TREM2 
mutation-harbouring iPSC lines described in Chapter 4, two lines carrying 
heterozygous R47H TREM2 mutations were also generated (See Chapter 2 Materials 
and Methods, table 2.1). Rare missense mutations resulting in an R47H substitution in 
the TREM2 gene have been found to be associated with the development of late onset 
AD (Guerreiro et al. 2013a; Jonsson et al. 2013), with an odds ratio similar to that of 
the APOE ε4 allele. Microglia-like cells were generated from these patient-derived, 
TREM2 mutation-harbouring iPSCs and the expression of C1QA and CR3 genes was 
assessed to investigate whether any links exist between TREM2 and other AD-
associated genes. 
Both of the R47H heterozygous iPSC-MGLC were found to have significantly 
decreased expression of C1QA compared with control lines (*** p<0.001, Figure 
5.11a), with cells expressing only 20% of the mRNA found in controls. Expression of 
ITGB2, which encodes for the CD18 component of the CR3 receptor, was reduced in 
the T66M homozygous, W50C homozygous and both R47H heterozygous iPSC-MGLC 
(** p<0.01, **** p<0.0001, Figure 5.11b) versus controls. In addition to this, expression 
of ITGAM encoding the CD11b subunit of CR3 was also reduced in the W50C 
homozygous lines compared to controls, alongside the heterozygous T66M iPSC-
MGLC (*p<0.05). Expression of ITGAM was also reduced in T66M homozygous lines 
but this was not statistically significant (p=0.076, Figure 5.11c). These results suggest 
that expression of the CD18 subunit of CR3 is affected by mutations in multiple sites of 
the TREM2 gene, whilst both of the CR3 subunits are downregulated in iPSC-MGLC 
carrying homozygous W50C mutations.  
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Figure 5.11 TREM2 mutations alter complement factor expression in iPSC-MGLC 
qPCR analysis of C1QA (a), ITGB2 (b) and ITGAM (c) expression in iPSC-MGLC carrying TREM2 
mutations. Graph represents gene of interest expression normalised to GAPDH. Values relative to 
expression levels in CTRL1 expressed as mean ±SEM for 3 individual experiments (*p<0.05, **p<0.01, 
***p<0.001, ****p<0.0001; one way ANOVA with Dunnett’s multiple comparison test). 
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5.10 TREM2 R47H mutations affect the secretion of C1q by iPSC-MGLC  
  
The effect of significantly lower C1QA mRNA levels found in the R47H iPSC-MGLC on 
the generation of C1q protein was investigated by assessing the secretion of C1q from 
these cells. C1q is generated by neurons, astrocytes and microglia, and is secreted in 
order to perform its function of recognising antibodies, Aβ, pathogen-associated ligands 
or particles for clearance. This results in the activation of the classical complement 
pathway leading to C3b generation or induction of phagocytosis through gC1qR 
(calreticulin) or cC1qR (α2β1 integrin) receptor binding. The levels of C1q protein in the 
supernatants of R47H mutant and control iPSC-MGLC were determined by ELISA. 
Interestingly, despite decreased levels of C1QA mRNA being found in R47H iPSC-
MGLC, these cells secreted greater concentrations of C1q than controls (**p<0.01, 
Figure 5.12). 
 
 
 
 
 
 
 
 
 
Another line of iPSC cells carrying R47H TREM2 mutations was available to further 
investigate the effect of this AD-associated mutation on C1q. The BionCtrl iPSC line 
was generated from fibroblasts donated by a 19 year old male with no TREM2 
mutations, from which a homozygous R47H line was created using CRISPR/Cas9 
technology. Therefore, the BionCtrl and BionR47H lines are genetically identical with 
the exception of the codon at position 47 in the TREM2 gene. iPSC-MGLC were 
differentiated from these lines providing an extremely valuable tool for studying the 
effect of this point mutation in isolation on microglial expression and function.  
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Figure 5.12 ELISA analysis of C1q secretion by control and R47H TREM2 iPSC-MGLC 
Baseline C1q secretion in control and iPSC-MGLC carrying heterozygous R47H mutations determined by 
ELISA. Values relative to expression levels in CTRL1 expressed as mean ±SEM for 3 individual 
experiments (**p<0.01; unpaired t test). 
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The effect of R47H mutations in the Bion cells on C1QA expression and C1q secretion 
were therefore investigated. Quantification of C1q release by ELISA demonstrated that 
the homozygous R47H mutations had no effect on the C1q secretion by the BionR47H 
line compared with both the BionCtrl and the other control iPSC-MGLC (Figure 5.13a). 
This suggests that the R47H TREM2 mutations in the R47H heterozygous iPSC-MGLC 
are not the sole cause of the increased C1q concentrations found in the ELISA analysis 
(Figure 5.12). Preliminary analysis of C1QA mRNA expression levels in the Bion iPSC-
MGLC also suggested that there is no difference in the expression of C1q between the 
BionCTRL and BionR47H cells (Figure 5.13b). 
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Figure 5.13 Analysis of C1q mRNA expression and secretion by control, Bion control and Bion R47H 
iPSC-MGLC 
(a)Baseline C1q secretion in control and iPSC-MGLC carrying homozygous R47H mutations determined by 
ELISA. Values relative to expression levels in CTRL1 expressed as mean ± SEM for 3 individual 
experiments. (b) Preliminary results from qPCR analysis of C1QA expression relative to GAPDH for 2 
individual experiments 
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5.12 Discussion 
Polymorphisms in the gene encoding CR1 have been identified as risk factors for the 
development of late-onset Alzheimer’s disease (Lambert et al., 2009), however the 
evidence for its expression in the human CNS is unclear. Rodent cultures have been 
used to demonstrate microglial expression of the murine CR1 orthologue Crry (Davoust 
et al., 1999; Crehan, Hardy and Pocock, 2013), however, since significant differences 
exist between human and murine complement receptor expression and function, 
particularly in the case of CR1 (Jacobson and Weis, 2008), it is important the CR1 
expression  in human microglial and brain tissue is established. Analysis of RNA 
isolated from the temporal lobe, a region with relatively dense microglial population, of 
healthy human brains has shown that almost undetectable levels of CR1 expression 
are found, particularly when compared with TREM2, P2YR12 and AIF1, which are 
expressed by human microglia. This is backed up by data from various online RNA 
sequencing databases which find extremely low CR1 RNA and protein expression 
levels in the healthy human brain. 
Since CR1 could not be detected at the whole tissue level, CR1 expression was 
investigated at a cellular level using RNA that had been extracted from human 
peripheral blood mononuclear cells and microglia-like iPSC-derived cells, in addition to 
commercially available microglial cDNA. Robust CR1 expression was found in 
neutrophils but was very low in monocytes and macrophages, and levels were almost 
undetectable in the microglia and iPSC-MGLC samples. This lack of expression in 
human microglia despite high levels of CR1 orthologs in rodents highlights the 
importance of understanding the differences between rodent and human systems 
before drawing conclusions on the role of a protein or an effect of a mutation from 
studies conducted in just one species. iPSC-derived astrocytes were included in the 
analysis as CR1 protein has been reported in human control brains by western blotting 
of total brain lysates and immunohistochemical analysis that indicated expression by 
astrocytes (Hazrati et al., 2012; Fonseca et al., 2016). However, CR1 mRNA was 
undetectable in our analysis of astrocytic cells. This discrepancy could be attributed to 
different subtypes of astrocytes being analysed, the accuracy in which this iPSC model 
recapitulates human astrocytes or issues with the specificity of the antibodies used to 
detect CR1 protein expression, as the published data did not include analysis of RNA 
expression by techniques, such as qPCR or in-situ hybridisation, which have fewer 
antibody specificity-associated limitations. 
Following the observation that CR1 mRNA could hardly be detected in control brains or 
found in brain RNA seq and protein expression databases, the expression of CR1 in 
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disease was investigated in a small study of RNA and tissue samples from early 
pathology stage pre-AD and later stage AD cases. The donors of the pre-AD samples 
had not presented with any clinical symptoms of AD but were found to have 
‘intermediate’ scores of AD neuropathological change according to the ABC scoring 
system (Montine et al., 2012). This system takes into account previously used scoring 
for Aβ deposits, neurofibrillary tangles and neuritic plaques in order to report on the 
presence and extent of pathology rather than cognitive state. Minimum sampling of 
brain regions and lesions is required and results in a scoring system that provides more 
information on the full range of AD-associated pathology.  
RNA analysis found an upregulation of CR1 expression in pre-AD temporal and 
occipital lobes relative to healthy controls, although found to a lesser degree in the 
occipital lobe. Similarly, CR1 protein levels determined by immunohistochemistry were 
higher in pre-AD samples than in controls. For the immunohistochemistry, AD samples 
were also available which demonstrated increased expression relative to controls at an 
equivalent level to those found in the pre-AD tissue. This suggests that CR1 increases 
in the early stages of AD, during or following the initial deposition of Aβ plaques and 
neurofibrillary tangles. In this small, preliminary study, CR1 expression did not change 
with worsening pathology but there are currently insufficient numbers to make concrete 
conclusions. This study should be extended to include RNA samples from AD cases for 
analysis of mRNA expression levels, lysates for analysis of protein expression by 
western blotting, as well as increasing the sample size of the groups for both RNA and 
protein analysis. It should be noted that there is no way of knowing that the pre-AD 
patients, those who did not present with symptoms but upon post mortem analysis 
were found to have low levels of AD pathology, would have gone on to develop AD and 
therefore may not truly represent the early stages of disease. 
The lack of CR1 mRNA expression in control brains poses interesting questions for the 
role of CR1 in the development of AD, given that the mutation effect size and frequency 
are sufficient for it to be detected as a hit in GWAS studies of a disease of a tissue 
where it is not found in homeostasis. The fact that CR1 expression in the brain is only 
detectable after the onset of pathology suggests that increases in CR1 mRNA 
transcripts may be a consequence rather than a primary cause of disease. Whether the 
increase in CR1 expression is due to an upregulation of expression by resident cells of 
the CNS or due to infiltration through an increasingly leaky blood brain barrier by cells 
from the periphery needs to be investigated further. Immunohistochemical 
colocalisation studies need to be performed to ascertain the identity of the cells that 
express CR1 protein in the human temporal lobe samples used in this study. 
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Zenaro et al report that neutrophils, a cell type that expresses high levels of CR1, 
which I have confirmed through mRNA analysis, infiltrate the brain in the early stage of 
disease in AD models, particularly in areas with Aβ deposits. Following analysis of 
human AD brains, neutrophils were found to be present at levels up to 10x greater than 
those in controls, with cells observed in vessels and the parenchyma (Zenaro et al., 
2015). The effect of increased neutrophil numbers in AD brains is not yet known but 
inhibiting neutrophil extravasation by blocking the receptor required for neutrophil 
trafficking resulted in an amelioration of Aβ load and improvements in cognitive 
performance (Zenaro et al., 2015). As neutrophils robustly express CR1, the infiltration 
in the early stages of AD found in the mouse models could explain the increased 
expression of CR1 mRNA and protein found in the pre-AD cases. Furthermore, vessel-
like staining was found in some samples from pre-AD and AD cases, mimicking the 
presence of neutrophils in the venules found in the Zenaro study. However, the inability 
to detect the neutrophil marker ELANE in the control and pre-AD samples contradicts 
this hypothesis. Perhaps evidence of neutrophils could be found if more markers were 
investigated or expression of neutrophil elastase, encoded for by the ELANE gene, was 
assessed at the protein level by immunohistochemistry or western blotting as 
neutrophils are small and thus have low RNA levels relative to other cell types. As 
stated previously, increased sample numbers would need to be analysed with 
extensive investigations required into the cell types expressing the CR1 detected in the 
pre-AD and AD samples before conclusions can be drawn.  
Treatment of human neutrophils with TNFα and IFNγ have been shown to upregulate 
expression of CR1 (Limb et al., 1991; Arora et al., 2007). Both of these cytokines have 
been found to be increased in models of AD (Benzing et al., 1999; Abbas et al., 2002; 
Hickman, Allison and El Khoury, 2008), so perhaps the inflammatory environment 
resulting from Aβ accumulation and glial dysfunction induces augmented CR1 
expression in the brain. In order to investigate this hypothesis, iPSC-MGLC could be 
treated with these cytokines and mRNA analysis of CR1 expression could be 
undertaken. Alternatively, several studies have indicated that peripheral blood cells 
infiltrate the brain during AD, including T cells, monocytes and neutrophils (Togo et al., 
2002; Michaud et al., 2013; Baik et al., 2014), which could contribute to the expression 
of CR1 in the pre-AD and AD brain and could be investigated by immunohistochemical 
analysis. 
As CR1 is not expressed in the healthy brain, mutations in the receptor may be 
exerting an effect on AD pathogenesis from the periphery, rather than increasing risk 
due to activity in the CNS. Erythrocytes are the most abundant CR1-expressing cells 
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and CR1 surface expression binds opsonised particulate enabling trafficking to, and 
clearance within, the liver and the spleen. The peripheral sink hypothesis posits that Aβ 
in the brain can be cleared by Aβ-binding molecules in the periphery disrupting the 
equilibrium found in brain and periphery Aβ levels (Reviewed by Zhang & Lee 2011). 
Indeed, Aβ has been shown to bind erythrocyte CR1 via the complement C3b opsonin 
(Rogers et al., 2006), thus defects in CR1 immune adherence on the surface of 
erythrocytes may affect AD pathology in the CNS. Rogers et al suggest that decreased 
efficiency of Aβ binding by complement opsonisation mechanisms in plasma may be 
associated with worsened cognition, as measured by MMSE. It has also been shown 
that peripheral administration of anti-Aβ antibodies resulted in the clearance of Aβ from 
the brain in AD mouse models (DeMattos et al., 2001).  
However, analysis of the associations of CR1 polymorphisms and CSF Aβ levels has 
cast doubt over this hypothesis. A CR1 SNP that is in high linkage disequilibrium with 
CR1 polymorphisms affecting receptor density on the surface of erythrocytes was not 
associated with AD risk nor with CSF Aβ levels (Brouwers et al., 2012). The longer 
form of CR1, which has more C3b binding sites, is the most strongly associated with 
AD risk, contradicting the hypothesis that increased ability of CR1 to bind C3b-tagged 
Aβ in the periphery is protective. Furthermore, studies into enzymatic clearance of 
peripheral Aβ using neprilysin in mouse (Walker et al., 2013), rat and cynomologous 
monkey (Henderson et al., 2014) studies have cast doubt over the peripheral sink 
hypothesis, as significant decreases in plasma Aβ levels had no effect on the levels of 
Aβ in the CSF or brain. 
Following the observation that CR1 was undetectable in control human primary and 
iPSC-derived microglia, the expression of other microglial genes that link complement 
and AD was investigated. Hong et al., have recently shown that in the early stages of 
mouse models of AD, C1q and CR3 are necessary for the Aβ oligomer-induced 
synapse loss that results from dysregulated microglial pruning. The expression of 
C1QA, ITGAM and ITGB2, the genes encoding these complement cascade 
components, in human iPSC-MGLC and microglia was confirmed. iPSC lines derived 
from individuals carrying homozygous and heterozygous T66M mutations, as described 
in Chapter 4, were differentiated into microglia-like cells in order to investigate the 
effect of TREM2 mutations on C1q and CR3 expression. In addition to these Nasu-
Hakola and frontotemporal dementia-associated mutation-harbouring cells, two lines 
carrying heterozygous R47H mutations, which are associated with an increased risk for 
the development of late onset AD (Guerreiro et al. 2013a; Jonsson et al. 2013), were 
also available for analysis.  
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The iPSC-MGLC carrying the homozygous W50C mutation were found to have 
significantly lower levels of ITGB2 and ITGAM than control lines, indicating that 
expression of the mRNA encoding both components of the CR3 receptor are reduced 
in these cells. The homozygous T66M iPSC-MGLC also had a statistically significant 
reduction in the expression of ITGB2 and a trend towards decreased levels of ITGAM 
(p=0.07) suggesting that homozygous mutations in TREM2 alter the expression of the 
mRNA of the CR3 components CD11b and CD18. iPSC-MGLC with heterozygous 
T66M mutations were also found to have decreased ITGAM expression levels relative 
to controls. These data together indicate that TREM2 mutations alter the expression of 
the CR3 receptor.  
CR3, also known as Mac-1, is a heterodimeric transmembrane receptor that is 
expressed on macrophages, microglia, monocytes, dendritic cells and neutrophils and 
plays a role in phagocytosis as well as regulating cytokine secretion, leukocyte 
trafficking and synapse formation (Whitlock et al., 2000; Kinashi, 2005; Phillipson et al., 
2006). In addition to binding the complement opsonin C3b/iC3b (Beller, Springer and 
Schreiber, 1982), CR3 ligands include ICAM-1 (Diamond et al., 1990), fibrinogen 
(Wright et al., 1988) and LPS (Wright and Jong, 1986) however phagocytosis is most 
effective when particles are opsonised with C3b/iC3b (Mevorach et al., 1998). The CR3 
components CD18 and CD11b have been shown to accumulate in the phagocytic cup 
of a macrophage cell line (Jongstra-Bilen, Harrison and Grinstein, 2003) whilst 
knockout of CR3 expression in transgenic mice decreased C3b/iC3b mediated 
phagocytosis in neutrophils (Lu et al., 1997). Treatment with a CR3-blocking antibody 
has also been shown to reduce phagocytosis by macrophages (Taborda and 
Casadevall, 2002).  
Due to the importance of CR3 in phagocytosis, the decreased expression of the two 
CR3 component genes may result in a reduction in the phagocytic ability of the iPSC-
MGLC. Indeed macrophages from ITGB2-/- mice have been shown to have decreased 
levels of phagocytosis (Taborda and Casadevall, 2002). Heterozygous, lupus-
associated mutations in ITGAM result in impaired phagocytosis by mutation expressing 
T cell and monocyte lines (MacPherson et al., 2011) and in monocytes and 
macrophages from patients carrying the risk-associated mutation (Rhodes et al., 2012). 
This mutation was also found to impair the phagocytosis of C3b/iC3b coated particles 
by monocytes, macrophages and neutrophils (Fossati-Jimack et al., 2013).  
In addition to effects on phagocytosis, CR3 signalling has been shown to be anti-
inflammatory (Marth and Kelsall, 1997; Han et al., 2010). Monocytes and macrophages 
downregulate pro-inflammatory responses such as IL-12 expression and oxidative 
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bursts as phagocytosis of C3b/iC3b-opsonised particles occurs, in order to minimise 
inflammation and damage to neighbouring cells (Marth and Kelsall, 1997; Kim, Elkon 
and Ma, 2004). The use of ITGAM-/- mice has shown that CD11b functions as a 
negative regulator of TLR-mediated, pro-inflammatory cytokine and interferon release 
in macrophages (Han et al., 2010).  
As CR3 has been shown to play a role in the clearance of apoptotic cells (Mevorach et 
al., 1998) and Aβ (Choucair-Jaafar et al., 2011; Fu et al., 2012), as well as being found 
to co-localise with Aβ plaques in AD patient brains (Strohmeyer et al., 2002), 
decreased expression of ITGAM or ITGB2 due to TREM2 mutations may result in 
decreased ability of cells to clear neurotoxic Aβ and cellular debris, augmenting the 
neuroinflammatory environment and contributing to cell death. CR3-/- mice have 
decreased levels of synapse engulfment by microglia following treatment with 
oligomeric Aβ (Hong et al., 2016), suggesting CR3 is important for Aβ-induced 
microglial removal of synapses in the early stages of AD pathology. Furthermore, the 
role of CR3 in limiting pro-inflammatory responses could lead to increased cytokine 
secretion in the cells with downregulated expression of this receptor. However, results 
from studies carried out in CR3 transgenic mice should be carefully considered in the 
light of identified interspecies differences in the expression of CR1.  
In this thesis, it has been shown that iPSC-MGLC with TREM2 mutations cells have 
downregulated expression of two phagocytic receptors, CR3 and TREM2, which will 
likely affect the phagocytic capabilities of these microglia-like cells. The functional 
implications of decreased TREM2 expression on phagocytosis by these cells has 
already been assessed (see chapter 4), however the effects of decreased CR3 should 
also be investigated. CR3-mediated phagocytosis is much more effective in the 
presence of the complement factors C3b/iC3b (Mevorach et al., 1998) so the uptake of 
complement-opsonised particles by CR3 in the TREM2 mutant iPSC-MGLC should be 
assessed by incubating fluorescent particles in human serum as a source of 
complement opsonins.  
The expression of the complement opsonin and classical pathway activator C1q was 
also investigated in the TREM2 mutation harbouring iPSC-MGLC. In the CNS, C1q is 
secreted by astrocytes and microglia and released into the extracellular space, where it 
binds to immune complexes and initiates classical pathway through activation of 
various complement proteases resulting in the formation of the C3 convertase complex. 
C1q is capable of recognising and binding a range of self and non-self ligands including 
synapses, apoptotic cells, Aβ, immunoglobulin-containing complexes and PAMPs on 
the surface of viruses and bacteria (Albertí et al., 1993; Stevens et al., 2007; Fraser, 
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Pisalyaput and Tenner, 2010; Gaboriaud et al., 2011) and regulates clearance via 
phagocytosis both with and without complement activation. C1QA mRNA levels were 
found to be significantly lower in both heterozygous R47H mutation iPSC-MGLC lines 
compared with controls. The R47H mutation is found in the extracellular domain of the 
TREM2 receptor and is thought to affect TREM2 ligand binding efficiencies (Atagi et 
al., 2015; Bailey, DeVaux and Farzan, 2015; Poliani et al., 2015).  Interestingly, when 
the secretion of C1q protein was investigated by ELISA, supernatants from R47H 
iPSC-MGLC were found to contain greater concentrations of C1q versus control iPSC-
MGLC, contradicting the typical view that decreased mRNA levels result in lower levels 
of protein generation.  
There are various reasons for this unexpected discrepancy in mRNA and protein 
levels; a study conducted showed that only 40% of variation in protein expression 
levels is due to variation in the abundance of the respective mRNA (Vogel and 
Marcotte, 2012). The remaining 60% is due to post-transcriptional variation consisting 
of a balance of transcript stability, translational regulation (RNA processing, RNA 
stability and regulatory elements) and protein degradation. Low C1QA mRNA levels 
may be found in R47H iPSC-MGLC due to decreased stability of the RNA leading to 
faster degradation and reduced half-life. Intracellular signalling and activity can alter 
regulation of translation (Sonenberg and Hinnebusch, 2009; Roux and Topisirovic, 
2012), generating greater protein despite low levels of mRNA, as single mRNA 
transcripts can be translated multiple times. In the future, western blotting and 
immunocytochemistry should be performed to establish whether TREM2 mutations 
alter the size of the intracellular pool of C1q protein because, if a protein product is 
designed to be release from the cell, the correlation between intracellular protein levels 
and mRNA levels can be lost. Alternatively, R47H mutations may alter the mechanisms 
and signalling pathways regulating the release of C1q from iPSC-MGLC resulting in 
augmented release despite low mRNA levels relative to controls. Alterations in C1q 
expression could lead to effects via classical complement activation, such as 
phagocyte recruitment, synapse removal, immune regulation and cell lysis or via non-
classical pathways including phagocytosis, immune regulation, neuroprotection and 
cognitive aging (Stephan et al., 2013). Baseline expression of C1q mRNA and protein 
is different between R47H mutant iPSC-MGLC and controls, however expression 
following activation of iPSC-MGLC should be assessed to establish whether 
differences between R47H and control iPSC-MGLC are also found in these conditions. 
Links between TREM2 and C1q have been identified previously. Alveolar macrophages 
from TREM2-/- mice had increased levels of C1q protein, although this was also 
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associated with increased C1qa mRNA levels (Sharif et al., 2014), unlike the 
expression found in these TREM2 mutant iPSC-MGLC. The C1Q  gene, as well as the 
gene encoding C3, have been identified as a ‘core’ TREM2-related hub gene within the 
‘Fc-gamma R-mediated phagocytosis’ pathway of human and mouse brains 
(Forabosco et al., 2013; Matarin et al., 2015), which could explain why altered C1q 
expression is found in iPSC-MGLC carrying TREM2 mutations.  
Analysis of the C1q secretion by BionCtrl and BionR47H iPSC-MGLC suggest that 
R47H TREM2 mutations alone do not in fact alter the secretion of C1q. This is backed 
up by preliminary data from qPCR analysis of C1QA mRNA levels (n=2), which 
currently suggest that there is no difference in expression of C1QA between BionCtrl 
and BionR47H.The Bion cell lines were generated from fibroblasts from a healthy 19 
year old donor who does not harbour TREM2 mutations, in contrast to the R47H 
heterozygous lines which were donated by a 75 year old and a 54 year old presenting 
with symptoms of AD. Homozygous R47H mutations were inserted into the TREM2 
gene of the BionCtrl line using CRISPR/Cas9 technology in order to generate a tool for 
unravelling the specific effects of this AD-associated mutation on cells of identical 
genetic backgrounds. No significant difference in the secretion of C1q was found 
between BionCtrl iPSC-MGLC and BionR47H iPSC-MGLC suggesting that the 
augmented C1q secretion identified in AD patient-derived R47H heterozygous iPSC-
MGLC compared to controls is not due to the R47H mutation in TREM2. Both 
heterozygous R47H iPSC-MGLC were found to have increased secretion, which 
reduces the likelihood of unrelated C1q mutations being the cause of the augmented 
secretion. The epigenetic memory of the fibroblasts from which the iPSC were 
generated could therefore be the cause of this altered C1q expression. Epigenetic 
modifications accumulate with age (Li et al., 2009; Mahmoudi and Brunet, 2012; 
Fernández-Santiago and Ezquerra, 2016) and can be modified by disease (Wang, 
Oelze and Schumacher, 2008), potentially altering the expression of genes associated 
with AD. 
Indeed, expression of C1q increases in the aging brain of humans and mice 
(Reichwald et al., 2009; Stephan et al., 2013), with reports of up to 300 fold increases 
in transcript levels (Stephan et al., 2013). Perhaps environmental cues related to age 
alter the epigenetic regulation of the transcription of C1q, which is expressed by 
fibroblasts (Al-Adnani and O’D McGee, 1976), or the stability of C1q mRNA resulting in 
increased secretion of C1q in the older, AD patient-derived R4H heterozygous iPSC-
MGLC. C1q is upregulated in response to various CNS insults and injuries, including 
viral infection, ischemia/reperfusion, kainic acid treatment, stroke and Aβ treatment of 
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organotypic brain slices (Dietzschold et al., 1995; Goldsmith et al., 1997; Huang et al., 
1999; Fan and Tenner, 2004) resulting in improved neuronal viability and neurite 
outgrowth (Pisalyaput and Tenner, 2008), suggesting that it may act as a protective 
response to injury (Benoit and Tenner, 2011). Of particular importance to the role of 
C1q in AD, C1q found in the absence of complement activation has been shown to 
interact with and prevent toxicity from fibrillary and oligomeric Aβ (Pisalyaput and 
Tenner, 2008; Benoit et al., 2013) and induce neuronal expression of neuroprotective 
factors including nerve growth factor and neurotrophin-3 (Benoit and Tenner, 2011). 
C1q enhances microglial phagocytosis of Aβ (Webster et al., 2000) and binds to 
phosphatidylserines exposed by apoptotic cells for early and efficient removal of these 
cells via ‘eat me’ signals (Païdassi et al., 2008). Therefore, C1q may be upregulated in 
the R47H iPSC-MGLC as a response to both age and disease-associated conditions in 
order to protect surrounding neurons.  
Classical complement activation via C1q and C3b has been shown to be essential 
during development, as a lack of C1q results in defective anatomic refinement of 
synaptic connections causing excessive innervation, enhanced synaptic connectivity 
and epileptogensis (Stevens et al., 2007; Chu et al., 2010). The expression of C3 and 
its products including the opsonin C3b/iC3b is high during development but decreases 
and remains low during adult life and normal aging (Stephan et al., 2013). Indeed, 
despite high levels of C1q found in healthy aged mice brains, C3 was found to be low 
and no particular synapse loss was detected despite C1q colocalising with synapses 
(Stephan et al., 2013). Interestingly, C1q was found to negatively affect synaptic 
plasticity and contribute to cognitive decline in aged animals that were otherwise 
healthy (Stephan et al., 2013). However, in the models of AD where aged brains are 
put under additional stresses from the generation and accumulation of Aβ, C1q and C3 
levels were augmented and found to be involved in synapse loss arising from Aβ-
induced microglial dysfunction (Hong et al., 2016). In this study, Hong and colleagues 
showed that microglia and complement pathways become inappropriately activated in 
AD leading to synaptic loss through microglial priming. Following treatment with Aβ or 
in mouse models of AD, microglial generation of C1q is induced by Aβ oligomers 
resulting in deposition on synapses. Downstream of C1q deposition and activation, 
increases in C3 product generation are found which result in tagging of synapses for 
phagocytosis by CR3 causing subsequent LTP impairment (Hong et al., 2016). 
Inhibition of C1q and the use of C1QA-/- mice showed that C1q is a key mediator of 
oligomeric Aβ-induced synaptic loss and LTP dysfunction (Hong et al., 2016). 
Therefore, in the healthy aging brain, increased levels of C1q may act to be 
neuroprotective and important for homeostasis. However, in the presence of Aβ-
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induced microglial dysfunction, C1q can contribute to disease progression through 
aberrant induction of complement activation and synaptic damage. In the case of the 
AD patient-derived iPSC-MGLC, increased C1q secretion may be a result of 
neuroprotective efforts or due to epigenetic modification of expression in response to 
microglial activation by Aβ, which could have detrimental effects on synapse function. 
C1q has also been implicated in the synaptic alterations found in the hippocampus of 
multiple sclerosis patients (Michailidou et al., 2015) indicating that C1q dysfunction is 
not solely an AD-associated phenomenon and other cell stresses found in the 
neuroinflammatory diseases may also result in unregulated synapse disruption. The 
studies into the various protective and neurotoxic effects of C1q activity suggest that a 
fine balance must be found between effective removal of potential sources of injury, 
such as apoptotic cells and Aβ, and excessive synapse removal following injury 
induced activation of microglia and complement signalling. In order to study the effect 
of the R47H heterozygous iPSC-MGLC on this equilibrium, co-culture experiments 
utilising iPSC-derived neurons could be performed to investigate the effect of increased 
microglial C1q on neurons; whether increased C1q induces the expression of 
neuroprotective factors or results in excessive and detrimental synapse stripping 
should be investigated.  
The availability of the Bion cell line from a young donor for analysis of the effect of 
R47H mutations in TREM2 on gene expression, receptor function and cellular 
phenotypes has been extremely valuable in highlighting the importance of cell donor 
age and disease background in the generation of iPSC lines from AD cases and 
controls. In theory, transcription factor reprogramming using the Yamanaka factors 
should reset the methylation and epigenetic regulation of the genome of the 
reprogrammed cell type although some epigenetic memory of the somatic tissue of 
origin has been found to exist in iPSC lines (Kim et al., 2010). Epigenetics are heritable 
changes in gene expression that occur independently of nucleotide sequence changes, 
resulting in alterations in the accessibility of the DNA for transcription through DNA 
methylation or alter expression post translationally through histone acetylation and 
methylation or via non-coding RNAs (Fernández-Santiago and Ezquerra, 2016). 
Changes in epigenetic signatures or ‘epigenetic drift’ from the original epigenome has 
been reported during aging (Hannum et al., 2013) and also in sporadic diseases, 
including AD (Wang, Oelze and Schumacher, 2008) which could be contributing to 
disease development. Interestingly, fibroblasts from sporadic AD cases have been 
reported to have alterations in oxidative stress responses (Ramamoorthy et al., 2012) 
which, upon reprogramming and differentiation into a more disease-relevant cell type 
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such as microglia, may have an even more marked effect on disease-associated 
phenotypes. Therefore, differences in C1q expression between AD patient-derived 
iPSC-MGLC and iPSC-MGLC from a 19 year old donor with the disease mutations 
inserted could be explained by age and disease-associated changes to gene 
expression levels.  
The age of sources of fibroblasts for reprogramming should also be considered due to 
variations in the reprogramming efficiency of young and aged cells. Age-dependent 
declines in reprogramming efficiencies have been identified in murine fibroblasts, with 
strong effects of age even seen in ‘middle aged’ donors (Mahmoudi and Brunet, 2012). 
These differences in aged cells could be attributed to higher densities of senescent and 
pre-dysfunctional cells present in cell populations obtained from older donors. Aged 
cells have increased expression levels of Ink4 and Arf, two anti-proliferative genes 
which have been shown to decrease the efficiency and fidelity of reprogramming (Li et 
al., 2009). Furthermore, the tissue source of material for reprogramming has also been 
found to affect efficiency, with keratinocytes found to be more readily reprogrammed 
than fibroblasts (Maherali et al., 2008).  
Serial reprogramming has been shown to be effective in reducing the epigenetic 
memory of cells (Kim et al., 2010), particularly related to biases in lineage 
differentiation propensities based on the lineage of the original cell type. However, 
one’s area of research interest may alter one’s opinion on whether epigenetic memory 
is a disadvantageous artefact of reprogramming or a useful source of information on 
disease pathogenesis, particularly in the case of a disease where the greatest risk 
factor is age. If one is focussed on the effects of specific point mutations on defined 
cells for the development of disease, it may be more useful to use CRISPR/Cas9 
technology to generate the desired point mutations in control cell lines or to repair 
disease associated mutations in patient-derived cells. This would generate the 
necessary controls for establishing whether altered phenotypes and genotypes are due 
to the mutation of interest. Conversely, incomplete eradication of epigenetic signatures 
may be a valuable opportunity for investigating epigenetic changes to chromatin during 
disease providing information on pathogenesis, particularly in the case of sporadic 
rather than monogenic diseases. The fact that the epigenetic memory is not completely 
wiped during reprogramming reinforces the importance of utilising aged matched 
controls, considering the effect of age on the epigenome. In order to overcome this 
issue to establish the effect of R47H mutations in the TREM2 gene on C1q expression 
and secretion, the point mutation should be repaired to generate controls with identical 
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genetic background. Any variations found in C1q in the R47Hhet iPSC-MGLC could 
therefore be confidently attributed to the mutation in TREM2. 
In summary, I have shown using RNA analysis and an investigation of online 
databases that under physiological conditions CR1 is not detectable in human 
microglia and is found at extremely low levels in the human brain. Expression is 
upregulated in the early stages of AD pathology although the source of this RNA and 
protein expression needs to be established. Other complement components linked to 
AD, C1q and CR3, are expressed by microglia and have been shown to be modulated 
by the expression of TREM2 mutations in human iPSC-MGLC. The functional 
implications of altered expression of multiple components of the innate immune 
response system in the brain should be assessed as predicted effects upon the 
phagocytic ability of microglia could have significant implications for development as 
well as the response to AD pathogenesis and other CNS insults and infections. 
  
 
 179 
 
6. Conclusions 
 
Since their initial identification by Franz Nissl in 1899, opinions on the functions of 
microglia in the CNS have evolved. Once viewed as merely support cells, the use of 
transgenic animal models have demonstrated that microglia are essential for fully 
functional development and maintenance of neuronal networks, whilst the use of  
GWAS and gene expression network analyses have identified roles of microglia-
expressed genes in many neurodegenerative diseases, including AD. The ability to 
accurately model these low frequency but highly active cells has also progressed, 
allowing us to further understand their role in physiology and pathogenesis. GWAS and 
exome sequencing studies have identified AD-associated genes that would never have 
been discovered by genetic linkage analysis alone, such as TREM2 and CR1, as well 
as identifying core pathways that appear to play roles in AD pathogenesis. Two 
consistently identified pathways are those involved in the immune system and 
inflammatory responses, which in the brain, primarily point to the involvement of 
microglia.  
In this thesis, models have been characterised that have been generated using two 
techniques, iPSC and CRISPR/Cas9 technologies, that, in the decade since their 
conception, have had ground-breaking effects on basic biological research as well as 
translational medicine and biotechnology.  Gene and protein expression dynamics and 
phenotypic changes in CRISPR/Cas9-generated TREM2 null BV2 microglia, and iPSC-
derived microglial-like cells from patients harbouring TREM2 mutations were 
investigated. Both models showed that these predicted loss of function mutations 
resulted in aberrant TREM2 protein expression and localisation, a lack of sTREM2 
generation and decreased phagocytosis. This consistency between models and the 
generation of results concurs with published data and suggests that these models are 
reliable for the study of the effects of mutations in this receptor.  
The generation of a microglial model harbouring TREM2 T66M mutations has value 
beyond the study of Nasu-Hakola disease alone. T66M mutations have also been 
identified in FTD-like syndrome-behavioural variant, FTD, and AD cases, indicating the 
range of contexts in which this model could be useful. Also, although T66M 
heterozygous mutations are only found in a few rare cases of AD (Guerreiro et al. 
2013a), an R47H mutation in TREM2 is one of the largest genetic risk factors for the 
development of late onset AD, second only to APOE genotype. Therefore this tool for 
studying TREM2 dysfunction could provide valuable information for the investigation of 
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all pathologies in which altered TREM2 activity may contribute, regardless of the 
mutations associated. 
Although the characterised iPSC-derived microglia-like cells already express many of 
the genes identified as key features of the microglial transcriptome signature identified 
by Butovsky et al, 2014 which currently acts as the gold standard for microglial models, 
our model of microglia-like cells is still in its infancy. As CNS environmental factors 
continue to be identified as important for directing microglial differentiation and 
homeostasis, the culture conditions used in our model will continue to evolve in order to 
more accurately recapitulate those found physiologically, with the aim of creating the 
most microglia-like phenotype. Microglial differentiation in the presence of neuronal- 
and astrocytic-derived factors is becoming more commonplace and should be 
incorporated into our protocol. This could be achieved through supplementing media 
with factors produced endogenously by these cell types, the use of neuron/astrocyte-
conditioned medium or through 3D co-culture with iPSC-derived astrocytes and 
neurons.  
The ability to generate microglia-like cells from patient-derived fibroblasts has the 
potential to revolutionise therapies for the multitude of neurodegenerative diseases in 
which microglia have been implicated. Through the combination of iPSC technology 
and CRISPR/Cas9, disease-modifying mutations could be repaired in patient-derived 
fibroblasts prior to differentiation into microglia. Once the safety of the transplantation 
process has been confirmed, the ‘repaired’ microglia could be used as a cell therapy to 
populate the brain, with the aim that ‘repaired’ microglia are less vulnerable to 
pathology-associated dysfunction and act in a more neuroprotective manner than the 
existing pool of microglia. Proof of concept for the use of iPSC-derived cells as a cell 
therapy for neurodegenerative diseases has been recently published; it was 
demonstrated that iPSC-derived dopaminergic neuron progenitors could be safely 
transplanted into non-human primates, resulting in successful engraftment and 
improved motor function in the absence of rejection or tumour formation (Kikuchi et al., 
2017).  
The need to apply the use of iPSC technology to generate co-cultures for studying the 
interactions between dysfunctional microglia and neurons has been emphasised by 
results suggesting a link between TREM2 mutations and alterations in expression of 
C1q and CR3. These complement components have been shown to be essential for 
optimising neuronal networks during development but also implicated in the synapse 
loss found in the early stages of AD. Investigating the functional effects of the identified 
alterations in expression in a more disease relevant context would provide valuable 
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information on the contributions of TREM2 mutations to neurodegenerative disease 
pathogenesis.  
In the case of all findings identified using the patient-derived iPSC-MGLC, a lack of 
power from the use of only one line from one or two patients puts considerable 
limitations on the conclusions that can be drawn. Therefore, in order to improve the 
statistical power of these results and allow more confident suggestions to be made 
regarding the effects of TREM2 mutations, extra lines should be generated from 
existing donor samples and ongoing work to recruit and generate iPSCs from additional 
carriers of TREM2 mutations should continue.  The investigation into complement 
expression in microglia and the brain highlighted two significant caveats to further 
consider when modelling disease: the implications of species specific differences in 
gene expression and the importance of using aged matched controls.  
The identification of a lack of expression of CR1, an AD-risk associated gene, in control 
brains and in unstimulated human microglia has significant implications for the current 
working hypothesis that CR1 contributes to AD through altered complement regulation 
and Aβ clearance by microglia. With our preliminary study, we have shown that 
expression of CR1 is found in the brains of AD patients and in donors without cognitive 
deficits but with early stages of pathology identified post mortem. Whether the 
increased expression is due to upregulation of CR1 expression by microglia activated 
by Aβ or from infiltration of CR1 expressing cells into the brain parenchyma is not yet 
known. This result was identified in disease relevant tissue samples, rather than in an 
AD model, and thus would be a priority to investigate further to elucidate the effect of 
AD-associated SNPs in the CR1 gene on pathogenesis.  
In conclusion, data have been presented demonstrating the suitability of iPSC-derived 
microglia like cells for the study of microglia in the context of neurodegeneration. These 
studies have also highlighted some weaknesses of current modelling techniques that 
need to be overcome. Due to small sample sizes, concrete conclusions regarding the 
effect of TREM2 mutations on microglial dysfunction and the expression of CR1 in 
control and AD human brains cannot yet be drawn, but the results presented herein 
have interesting implications for the understanding of these recently identified AD-
associated mutations in  pathogenesis, which should be investigated further. 
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